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Bladder cancer (BC) is the 7th most common cancer worldwide. Although BC is not 
usually fatal, it is characterized by frequent recurrences that can progress to more 
invasive disease. The recurrence rates of BC are as high as 50-70%, therefore, life-
long close surveillance is needed. This renders BC a very expensive cancer to treat. 
Cystoscopy is considered the gold standard for the clinical diagnosis of human BC. 
As cystoscopy is expensive and invasive, it may compromise patients’ compliance 
and account for the failure in detecting recurrent BC in some patients. Urinary 
cytology is commonly used for the noninvasive detection of BC. While it has a good 
sensitivity for poorly differentiated tumors, especially for carcinoma in situ, the 
sensitivity for low grade papillary urothelial carcinoma is low. Moreover cytology 
results are not available immediately and are interpreter dependent. Large panels of 
markers have been investigated to achieve an improvement in noninvasive 
diagnostics. However, the markers do not have the specificity and sensitivity of 
cystoscopy. As such, alternative noninvasive diagnostic methods for BC such as the 
use of biomarkers become important. Metabonomics is a burgeoning science bringing 
together analytic technology, metabolite evaluation, and computation. The integration 
of this tool into current biomarker research programs gives us an opportunity to 
screen for biomarkers related to BC. 
 
In this thesis, we investigated the role of urinary metabonomics in the diagnosis of 
human BC using multianalytical platforms. In addition, in vitro molecular changes in 
BC were characterized using nontumorigenic and tumorigenic human urothelial cells. 
Urine samples collected from BC patients and non-BC subjects were subjected to 
GC/TOFMS, NMR and GC×GC/TOFMS analysis. The acquired data were subjected 
xviii 
 
to chemometric data analysis such as principal component analysis and orthogonal 
partial least squares discriminant analysis. Furthermore, feasibility of distinguishing 
different stages or grades of the BC using urinary profiles was also investigated.  
Advantages and drawbacks of each analytical platform in urinary metabonomic 
analysis were examined. 
 
BC patients were clearly distinguished from non-BC subjects based on their global 
urinary metabolic profiles. Significantly higher sensitivity in detecting BC was 
observed using urinary metabonomics compared to urinary cytology. Additionally, 
urinary metabonomics exhibited early potential in the staging and grading of bladder 
tumors. Although the relationship between these results and the physiological or 
biochemical mechanisms involved remains unclear, this thesis confirmed that there 
exist endogenous metabolites in the patients’ urine, which could be promising 
markers for BC detection. The findings were further supported by metabonomic 
analysis of BC cell culture media samples. The use of multiple analytical methods 
aided the identification of a broader spectrum of important metabolites associated 
with BC. In addition, GC×GC/TOFMS was demonstrated as a powerful tool for 
analyzing both in vitro metabolic footprinting cell medium and complex urine 
samples. Application of GC×GC offered several advantages including enhanced 
chromatographic resolution (without increase in analytical run time), improved 
identification of metabolites and also separation of reagent artifacts from the 
metabolite peaks. In summary, urinary metabonomics is amenable for the noninvasive 
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CHAPTER 1 : Introduction  
 
1.1 Overview of bladder cancer 
Bladder cancer (BC) is the second most common genitourinary malignant disease in 
the United States  with estimated 70,980 newly diagnosed cases and 14,330 deaths in 
2009 [1]. The incidence rate of BC is about four times greater among men than that of 
women [1]. The increased incidence of BC in males has been mainly attributed to 
environmental and dietary exposures [2]. The risk of developing BC increases with 
advancing age, and most cases are diagnosed in individuals with age above 60 years 
[1]. Several risk factors have been attributed for BC, of which exposure to tobacco 
smoke and occupational exposure to aromatic amines are the two major 
environmental risk factors associated with BC [3]. The relative risk of BC 
development in smokers is two to four times that of nonsmokers and it increases with 
the number of cigarettes smoked and the duration of smoking [4,5]. It was also 
observed that former smokers generally have a lower risk of developing BC compared 
to current smokers. Many of the carcinogens such as aromatic amines present in the 
tobacco smoke are also found in the chemical industry work environment, making 
occupuational exposure the second major risk factor for BC [6]. Most notably, β-
naphthylamine, 4-aminobiphenyl and benzidines are frequently associated with BC 
[7]. These aromatic amines have many industrial uses, but primarily used in textile, 
rubber and aluminum manufacturing industries [8].  Other risk factors for BC include 
high levels of arsenic in drinking water [9], heavy consumption of phenacetin 





1.1.1 Staging and grading of BC 
Pathologic staging of BC is most important regarding risk management and in 
dictating patient management [12]. Staging of BC is based on the degree to which the 
tumor invaded into or through the bladder walls and adjacent organs (Figure 1). The 
most widely accepted staging system is Tumor-Node-Metastases (TNM) system 
adopted by Union Internationale Contre le Cancer (UICC). The use of TNM system is 
encouraged, as it corresponds best with the clinical outcome of the tumors [12]. TNM 
classification describes Ta tumors as noninvasive papillary tumors confined to the 
mucosa, Tis tumors as flat carcinoma-in-situ (CIS) confined to mucosa, T1 tumors as 
invasive tumors that invade the submucosa (lamina propria). T2 and higher lesions, by 
definition, are muscle-invasive tumors.  
 
Figure 1. TNM staging of bladder cancer. Tumors Ta and T1 are considered 





There has been a long-standing lack of agreement among pathologists concerning the 
ideal system for grading these tumors [13]. Recently, World Health Organization 
(WHO) and the International Society of Urological Pathology (ISUP) published a new 
classification system for grading urothelial neoplasms that employs specific 
cytological and architectural criteria [14]. The new classification system is commonly 
referred as WHO/ISUP 2004 classification system. The new system was proposed to 
overcome the concerns on the lack of reproducibility and subjectivity in assigning 
tumor grades. The WHO/ISUP 2004 classification system separates noninvasive 
papillary urothelial neoplasms into four categories, designated papilloma, papillary 
urothelial neoplasm of low malignant potential (PUNLMP), low-grade carcinoma, 
and high-grade carcinoma. There are mainly two striking changes in the new system.  
Firstly, the introduction of a newly designated category called PUNLMP, to 
circumvent use of the term carcinoma for tumors with a low probability of 
progression, but yet not entirely benign [14]. Secondly, the WHO/ISUP 2004 
classifies grades of tumors into only two categories: low or high. Although, WHO 
classification is a positive initiative in attempting to standardize grading of bladder 
tumors, its ability to ensure reproducibility in grading tumors is still questionable. 
Recently, it was observed that reproducibility is particularly low for the PUNLMP 
classification (50%). However, differentiation between low-grade and high-grade 




1.1.2 Noninvasive and invasive BC 
BC has been traditionally classified into two groups: superficial tumors and muscle-
invasive tumors. More than 75% of patients with BC are diagnosed as having 
superficial disease that is confined to the mucosal and submucosal layers of the 
bladder at the time of the initial evaluation. These tumors encompasses a wide range 
of disease from noninvasive low-grade papillary cancer (Ta) with almost no 
progression to muscle-invasive disease to superficially invasive (T1) high-grade 
papillary or solid cancer [16]. Despite the indolent nature of the superficial bladder 
tumors, the recurrence rate is as high as 70%. This, necessitating long term follow up 
for BC [17]. Additionally, one third of the recurrent superficial bladder tumors can 
eventually progress to a higher grade or stage of BC [18]. These superficial bladder 
tumors are considered to be originated from simple and nodular urothelial hyperplasia 
and, if they are treated early, the 5-year survival rate of the patients approaches 90% 
[19]. 
 
The second main variant, which accounts for about 25% of BC, presents as an 
invasive tumor and the patient usually has no previous history of low-grade 
noninvasive papillary tumor. These tumors seem to arise de novo or derive from flat, 
high-grade CIS lesions [19]. Despite radical cystectomy and debilitating systemic 
therapy, at least 50% of patients with CIS die from metastases within 2 years of 
diagnosis. The 5 year survival rate of metastatic BC is as low as 6% [20].  
 
It is becoming increasingly clear that the pathogenesis of low grade Ta tumors follows 
a molecular pathway that is usually distinct from CIS and invasive tumors.  Low 
grade noninvasive Ta tumors are characterized by activating mutations in the Harvey 
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rat sarcoma viral oncogene homolog (HRAS) and fibroblast growth factor receptor 3 
gene (FGFR3) [21,22]. Approximately, 70% of low grade Ta tumors harbor FGFR3 
mutations compared with 10 to 20% of invasive tumors [21].  High-grade invasive 
tumors are often characterized by structural and functional defects in the p53 and 
retinoblastoma protein (RB) tumor suppressor pathways [23]. In addition to distinct 
differences in molecular alterations between noninvasive and invasive BC, marked 
contrasts in epidemiology, chromosomal alterations, clinical outcome, and therapeutic 
management between these two clinical phenotypes have been noted [23]. The low-
grade Ta could benefit tremendously from receptor tyrosine kinase (RTK)–Ras 
pathway inhibition mediated by small molecule inhibitors, monoclonal antibodies, 
farnesyl and geranyl inhibitors, and RAF and mitogen-activated protein kinase (MEK) 
inhibitors. The invasive tumors, on the other hand, could benefit from replacement 
therapies that restore the functions of p53 and RB [19]. In clinical management of BC, 
transurethral tumor resection and intravesical Bacille Calmette-Guerin (BCG) are 
generally recommended in superficial BC [24], and radical cystectomy is generally 
advocated in invasive tumors [25]. 
 
1.1.3 Detection and surveillance of BC 
BC may be diagnosed incidentally or through the presentation of symptoms such as 
haematuria, bladder irritation, dysuria, or urgency [26]. Microhematuria testing and 
urine cytology are the most basic and widely used tools for the detection of BC. 
Cystoscopic examination and histopathologic evaluation of the biopsied tissue is the 
gold standard for diagnosis of the disease [27]. Cystoscopy is invasive and may be 
associated with a small but definite risk of morbidity. Because of the frequency of 
recurrence, cystoscopic surveillance is essential after tumor resection. The schedule 
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recommended by the European Organization for Research and Treatment of Cancer 
(EORTC) for patients with low- to intermediate-risk disease is cystoscopy at 3-month 
intervals for the first 2 years, at 4-month intervals for the next 2 years and yearly 
thereafter [28]. Due to the need for the life-long surveillance, the per-patient cost of 
BC management is highest among all other cancers. Just in USA, the total financial 
burden exceeds $3.7 billion per year [29]. In recent years, numerous urine-based 
bladder tumor markers (UBBTMs) have been evaluated to determine whether less 
invasive follow-up of patients with BC is feasible [30]. Among the assays evaluated 
in the past years are the bladder tumor antigen (BTA) test,  urinary nuclear matrix 
protein 22 (NMP22), fibrin degradation product (FDP), autocrine motility factor 
receptor, bladder cancer nuclear matrix protein (BCLA-4), cytokeratin 20 (CK20), 
telomerase, hyaluronic acid, hyaluronidase, Immunocyt, urinary bladder cancer 
(UBC) test, CYFRA 21-1, chemiluminescent hemoglobin, hemoglobin dipstick, 
urinary tissue polypeptidespecific (TPS) antigen, bladder cancer antigen (BCA), beta-
human chorionic gonadotropin, tissue polypeptide antigen (TPA), and microsatellite 
analysis [23,27,31]. Sensitivity and specificity of various molecular markers for 
diagnosis of BC are collated from recently published review articles [16,21,27] and 
shown in Table 1. In the following section, a brief overview of the most widely used 
bladder tumor markers in clinical management of BC is presented.  
 
1.1.3.1 Microhematuria testing 
Detection of hematuria is the most basic screening test for BC. Almost 85% of BC 
present with gross or microscopic hematuria [32]. Detection of microhematuria is 
simple and inexpensive and can be easily detected using commercially available 
hemoglobin dipsticks such as Hemstix®. Presence of intact red blood cells is not 
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essential; the test can detect trace amount of hemoglobin accurately. However, 
microhematuria testing for detection of BC has low positive predictive value of 8% 
[33] as hematuria is a feature of many urological conditions, including urinary tract 
infection (UTI), calculi, inflammation and benign prostatic hyperplasia (BPH) [27]. 
Moreover, the test sensitivity is extremely variable (47-95%) [27].  
 
1.1.3.2 Urine cytology 
Examination of voided urine or bladder washing specimen for exfoliated cancer cells 
is the most established noninvasive diagnosis of BC. Often called urine cytology, it 
has high specificity but relatively low sensitivity, particularly in well differentiated 
BC [34].  Moreover cytology results are not available immediately and are interpreter 
dependent. Cytology is not a point-of-care test and is costly compared with most 
commonly available tumor markers [35]. The cytology evaluation can be hampered 
by low cellular yield, urinary tract infection, urinary stones, or intravesical instillation. 
Sensitivity and specificity of urine cytology are 34 and 99%, respectively [35] . 
 
1.1.3.3 BTA test 
BTA assay detects human complement factor-H related protein (hCFHrp) which is a 
bladder tumor associated antigen [36]. The antigen is found in vitro being produced 
only by human bladder cancer cells and not by any other epithelial cells. Two 
versions of BTA assays, BTA stat® and BTA TRAK® detect hCFHrp by qualitative 
immunoassay and quantitative ELISA, respectively [36]. Both the tests are approved 
by FDA for the management of BC in combination with cystoscopy. The median 
sensitivities of BTA stat® and BTA TRAK® are 67 and 63%, respectively [27].  
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Although, both tests show high specificity (above 90%) among healthy individuals, 
the specificity among patients with UTI and calculi is as low as 50% [37]. 
 
1.1.3.4 NMP22 test 
NMP22 test is an immunoassay that detects complex and fragmented forms of the 
nuclear mitotic apparatus protein in urine. It has been demonstrated that BC patients 
have 25-fold greater NMP22 levels in urine compared to healthy subjects [28]. 
NMP22® BladderChek® test kit is a qualitative point-of-care immunoassay that 
detects urine NMP22. Reported sensitivity of the NMP22 test kit is variable with 
median sensitivity and specificity of 57 and 86%, respectively [27]. The sensitivity of 
NMP22 increases with tumor size, grade, and stage. The positive predictive value of 
this test is low, rendering it less useful for initial diagnosis or screening. Because of 
its high negative predictive value, it would be more useful in monitoring patients for 
recurrence [38]. Since NMP22 is present in each cell in the body, it is elevated when 
there is increased cell death. Therefore, much benign urological pathology such as 
inflammation, urolithiasis, and bowel interposition can cause a false positive reading 
[39]. As all other FDA approved urinary markers for BC, the NMP22 test is only 
approved for use as an adjunct to current diagnostic methods, such as cystoscopy. 
 
1.1.3.5 UroVysion® test 
The UroVysion® test is a multitarget, multicolor fluorescent in situ hybridization 
(FISH) assay that uses pericentromeric enumeration probes to detect aneuploidy for 
chromosomes 3, 7, and17; it additionally uses a locus specific identifier to detect loss 
of the 9p21 locus. One key advantage of this assay is its ability to detect occult tumors 
that are not visible by cystoscopy [27]. However, the use of FISH is limited as it is 
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expensive, labor-intensive and has low sensitivity for detecting low grade tumors (36-
57%) [27,30]. 
 
All the molecular tests discussed above have significantly higher sensitivity than 
cytology. Among these, BTA, NMP22, ImmunoCyt, FDP test, and the UroVysion 
assay have achieved FDA approval for diagnostic purposes. However, cytology 
remains superior in terms of specificity. For the diagnosis of BC, few studies have 
examined combining multiple molecular tests to enhance detection capability [40,41]. 
It has been noted that combinations of a panel of molecular markers yielded higher 
sensitivity as compared to the use of single marker. For example, Soyuer et al. noted 
that the simultaneous use of three markers (ImmunoCyt test, cytology and CK20) 
could achieve a diagnostic sensitivity of 92.5% compared to individual sensitivities of 
75.9, 83.3 and 70.4% for urine cytology, ImmunoCyt and CK20, respectively [41]. 
Increased sensitivity, may, however, come at the cost of specificity, resulting in more 
false-positive results [40]. Based on the review of existing markers for BC, it is clear 
that the current molecular tests are far from being ideal for the diagnosis or 





Table 1. Sensitivity and specificity of urinary markers in the detection of BC  
 




Advantages False positives 
 
Drawbacks 
Cytology  Microscopy  16–100 
 
62–100 High specificity. 
Most established 
noninvasive method 
for diagnosis of BC. 
None Low sensitivity for 
low grade tumors. 
Background cells 
such as leukocytes 
confound the 
analysis. 
BTA stat  Qualitative immunoassay; 
detects hCFHrp 






















sandwich ELISA; detects 
NMP22 
48–100 70–91 Requires urine 
stabilization before 
transportation 
ImmunoCyt  Immunocytofluorescence; 
detects a glycosylated form 
of carcinoembryonic antigen 
and mucin glycoproteins 
70–80 60–70 Increased sensitivity 
with cytology without 





cannot be used; urine 
fixation required 
UroVysion  Multitarget, multicolor 
fluorescent in situ 
hybridization assay 
69–87 89–96 Sensitive in detecting 
CIS, high-grade, and 
occult tumors 
 None Lower sensitivity for 
low-grade/-stage 
tumors 
Accu-Dxa Qualitative immunoassay; 
detects fibrin and FDP 







Test spot may darken 
upon drying, giving a 
false positive result 
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HA-HAase  Quantitative ELISA; detects 
HA and HAase 
91–100 70–89 Sensitive in detecting 
both low- and high-
grade/-stage tumors 
    
TRAP Telomerase PCR ELISA kit 
or real-time PCR; involves 
PCR amplification of a 
telomeric template by 
telomerase 
70–100 60–70   UTI, severe 
urinary tract 
inflammation 
Needs at least 50 
telomerase-
expressing cells to 
yield a positive result. 
Sensitivity affected 
by TRAP degradation 
in urine and sample 
collection and 
processing errors 
Microsatellites  PCR 72–97 80–100   UTI, BPH Requires highly 
trained personnel and 
sophisticated 
equipment 
Lewis X Immunocytochemistry; 
detects Lewis X antigen 






expressed by benign 
umbrella cells of 
urothelium 
Abbreviations: BTA, bladder tumor antigen; NMP, nuclear matrix protein; ELISA, enzyme-linked immunosorbent assay; FDP, 
fibrinogen degenerative protein; FISH, fluorescence in situ hybridization; HA, hyaluronic acid; TRAP, telomeric repeat amplification 
protocol; RT-PCR, reverse transcriptase polymerase chain reaction; UTI, urinary tract infection; BPH, benign prostatic hyperplasia
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1.1.3.6 Systems biology strategies for biomarker discovery 
Recently, a number of biomarkers of BC have been identified through genomic, 
proteomic and epigenetic studies. However, the markers were only identified through 
small case-control and single institution studies which require further validation through 
multicenter trials [42]. Both genomics and proteomics hold great promise for the study of 
complex biological systems with potential applications to biomarker discovery. There is 
no doubt that the massive amount of information generated by gene expression 
microarray studies has had a major impact in the discovery and understanding of disease-
associated patterns of gene-expression for major diseases including cancer [43]. 
Nevertheless, one needs to be mindful that gene or protein expression profiling provides a 
partial characterization of the pathophysiological status of a patient. The complementary 
measurement of metabolites (such as sugars, fats, amino acids, vitamins and so forth) 
provides a direct and hence dynamic snapshot of the current physiological status of an 
individual. The analysis of the metabolome is an especially useful approach for 
identifying pathways that are perturbed in a given pathology. As there is not necessarily a 
good quantitative correlation between mRNA concentrations and enzyme function, 
endogenous metabolites, downstream of both transcription and translation, are potentially 
better indicator of enzyme activity [44,45]. The integration of metabonomics into current 
biomarker research program may provide us an opportunity to screen for biomarkers 




1.2 Hypothesis and objectives  
The current standard for tumor detection and monitoring of recurrence or progression of 
BC is cystoscopy and urinary cytology. Cystoscopy is invasive and may be associated 
with a small but definite risk of morbidity. On the other hand, sensitivity of cytology for 
low grade tumors is poor. Although, numerous UBBTMs (Table 1) have been evaluated 
for less invasive follow-up of patients with BC, none of the UBBTMs were as accurate as 
cystoscopy. As such, the development of an alternative noninvasive and less expensive 
method to accurately detect BC at high sensitivity and accuracy becomes important.  
 
One recent study demonstrated that well-trained dogs can fairly accurately identify 
patients with BC based on urine odor [46].  This indicated that some compounds in the 
BC patients’ urine samples could be promising markers for bladder cancer. As the 
olfactory acumen of dogs is relatively strong, it is possible that some of the urinary 
markers are mildly volatile or non-volatile in nature. Therefore, we hypothesize that there 
are unique endogenous urinary metabolites that are promising markers of BC. 
 
To date, no studies have evaluated the feasibility of metabolic profiling for the 
characterization of human BC. Application of urinary metabolic profiling for diagnosis of 
BC is theoretically plausible since pathogenesis of BC may result in dynamic but 
discernible changes in the molecular environment of the urinary tract and these changes 
can be reflected in the composition of the urine. Therefore, metabolic profiling of urine 
samples for BC diagnosis is a logical scientific approach. The information gap embodies 
three important research questions: Does human BC generate a signature urinary 
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metabolic phenotype that is discernable using metabonomic analysis? Secondly, is 
urinary metabonomics more sensitive compared to urinary cytology? Thirdly, can human 
BC urinary profiles distinguish the different stages or grades of the carcinoma? Before 
applying metabonomics for the diagnosis of BC, a number of important research gaps 
related to urinary metabolic profiling needs to be addressed. Firstly, a systematic review 
on multiple analytical platforms, metabolic markers reported in various cancers and 
trends in metabonomic research is warranted. Secondly, little research has been directed 
towards understanding influences of sample preparation on urinary metabolic profiles. 
Thirdly, although, nuclear magnetic resonance (NMR) spectroscopy-based metabonomic 
platform is relatively established, there is no generic method for global profiling of 
urinary metabolites using gas chromatography/mass spectrometry (GC/MS). Lastly, only 
a fraction of the metabolic space is currently captured by various analytical platforms and 
an expansion of the metabolic coverage is desired. Recent advances in analytical 
platforms, particularly two dimensional GC shows potential to analyze large number of 
analytes simultaneously. Therefore, it is desirable to increase the metabolic space 





The overarching aim of the thesis was to determine whether urinary metabonomics would 
allow prediction of some aspect of cancer development in the bladder and thereby, 
provide a proof-of-principle for its application in the clinical diagnosis of human BC. The 
specific objectives of this research are listed as follow. 
 
• To conduct systematic literature survey to understand trends, analytical 
strategies commonly employed, biofluids used and marker metabolites 
identified in various types of cancers using metabonomic research (Chapter 
2). 
• To study potential influences of sample preparation and analytical variations 
on the profiles of metabolites present in healthy human urine followed by the 
development and validation of a GC/MS metabonomic platform for the global 
profiling of urinary metabolites (Chapter 3).  
• To perform urinary metabolic profiling of BC patients using multianalytical 
platforms namely, gas chromatography/time-of-flight mass spectrometry 
(GC/TOFMS) and NMR spectroscopy (Chapter 4).   
• To investigate application of two dimensional gas chromatography time-of-
flight mass spectrometry (GC×GC/TOFMS) for the in vitro and urinary 
metabolic profiling of BC (Chapter 5). 
• To compare and contrast advantages and drawbacks of various analytical 




CHAPTER 2 : Trend analysis of metabonomics and systematic review of 
metabonomics-derived cancer marker metabolites  
 
2.1 Introduction 
Metabonomics is an emerging ‘omics’ discipline that measures the dynamic 
multiparametric response of a living system’s metabolome to genetic modifications or 
pathophysiological stimuli [47,48]. Several terms have been used to describe the study of 
the metabolome, which include metabolomics, metabonomics, metabolic profiling, 
metabolic footprinting and metabolic fingerprinting. Definitions of these terms and the 
context in which they are used have been discussed in several reviews previously [49-51]. 
In contrast to classical biochemical approaches which usually focus on single metabolites 
or metabolic reactions [52], metabonomics allows one to survey global changes in 
metabolic pathways and gain a holistic understanding of the changes in a biological 
system [53,54], since fluctuations in the metabolome is a result of a complex interaction 
between the genome, transcriptome, proteome, and the environment [52,53].  
 
One big challenge faced by metabonomics is the chemical diversity of the metabolome, 
which consists of a vast number of components that belong to a wide variety of chemical 
classes, such as amino acids, lipids, organic acids and nucleotides [49]. These compounds 
not only have diverse physical and chemical properties, but also occur in differing 
concentration ranges. This is in contrast to genomics and proteomics, where the analytes 
of interest have relatively well defined chemistries [55]. Hence, analysis is particularly 
challenging as there is no one analytical platform that can capture all metabonomic 
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information in a sample [52,56]. Commonly employed analytical platforms include 
NMR, GC/MS and liquid chromatography/mass spectrometry (LC/MS). The choice of 
metabonomic analytical instrumentation is often goal specific as each analytical platform 
has its own advantages and limitations [56]. To overcome this limitation, researchers 
have been improving on current technologies [55,57], and also employing a multi-
platform approach [58-61]. Despite the above challenges, metabonomics is still fast 
becoming an important platform in biomarker research, drug development and diagnosis 
of various pathologies [52,62,63]. Several different disease states are currently being 
studied using metabonomics, including cancer [64-68], central nervous system (CNS) 
disorders like schizophrenia [69,70], alzheimer disease [71] and parkinson’s disease [72], 
cardiovascular diseases [73-75] and diabetes [76-79]. These studies not only aimed to 
understand the pathogenesis of the disease, but also investigate possibility of disease 
diagnosis, prognosis and treatment. 
 
While numerous research articles are being published in the area of metabonomics, little 
effort has been directed to estimate trends in publications related to different ‘omic’ 
platforms and comparison of trends between them. Similarly, systematic literature survey 
on analytical platforms and biological matrices commonly exploited in metabonomic 
studies is currently lacking. Such a comparison will allow us to gain an understanding of 
trends in metabonomics research. Although Kind [80] highlighted some general statistics 
in  metabonomic research, the trends in the applications of different analytical platforms 
and biological matrices in metabonomics have not been investigated. Our primary aim in 
this section was to examine the overall trend in terms of the number of metabonomic 
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publications (for the past 14 years), the metabolic spaces covered by NMR, GC/MS and 
LC/MS analytical platforms and the utilization of different biological matrices in 
metabonomic research.  
 
While common and differential marker metabolites had been identified using various 
analytical platforms across different disease states [52], consolidation of marker 
metabolites in each disease state has not been carried out so far. A systematic review of 
commonly reported marker metabolites in cancers could aid our understanding of 
pathogenesis of diseases. Most cancers including BC have a long asymptomatic period 
and are difficult to detect in early stages. Moreover, there is currently a lack of highly 
sensitive and specific diagnostic tools. Since cancer cells have a unique metabolic 
phenotype [63], metabonomics could possibly be the ideal tool for cancer diagnosis in the 
future.  
 
Recently, metabonomic studies pertaining to oncology have been reviewed by Spratlin et 
al. [63] and Griffin et al. [81]. Both the reviews provided a general overview of 
methodology employed in metabonomics, such as analytical platforms and statistical 
analysis. In addition, Spratlin et al. discussed a few clinical biomarkers in oncology, such 
as choline, glucose and citrate while Griffin et al. highlighted several metabolic 
biomarkers of tumors, such as alanine, glycine, lactate, taurine, myo-inositol and 
nucleotides. The discovery of a wide array of cancer marker metabolites embodies one 
important research question. Are these cancer marker metabolites common for all cancer 
types or does some of them belong to specific metabolic phenotypes of selected cancers? 
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An in-depth analysis and integration of the numerous cancer marker metabolites that have 
been identified is essential for translational oncology research such as the profiling of 
BC. While some of the previously identified marker metabolites could not be developed 
into clinical oncology biomarkers, they can provide researchers with a more in-depth 
understanding of the cancer cell metabolome. Therefore, our secondary aim in this 
section was to conduct a systematic review to consolidate metabonomics-derived marker 
metabolites in oncology so as to provide integrated background information for our 
subsequent BC metabonomic study. 
 
2.2 Methodology 
PubMed and Web of Science (WOS) databases were employed for literature review. To 
profile publications related to specific research areas, multiple key words and filters were 
used. Research articles from 1995 to 2009 were included in all reviews, except for the 
comparison of metabonomics against genomics, proteomics and transcriptomics, where 
research articles from 1985 to 2009 were included. Publications such as conference 
proceedings, meeting abstracts, reprints, corrections and additions were excluded. Since 
the focus of our current review was preclinical and clinical metabonomics, publications 
involving metabolic profiling of plants, non-mammalian system, microorganisms, 




2.2.1 Trend analyses 
2.2.1.1 Analysis of genomics, metabonomics, proteomics and transcriptomics  
Various keywords were used to identify publications in different ‘omics’ fields, namely 
genomics, metabonomics, proteomics and transcriptomics (Table 1, Appendix I). After 
exclusion of publications based on defined criteria, the number of publications from 1985 
to 2009 was charted according to a pre-designed workflow (Figure 1, Appendix I). 
Additionally, the percentage increase in publications related to each ‘omic’ platform, 
from 2004 to 2009, was also calculated to observe recent publication trends in each 
systems biology platforms. Percentage increase was calculated by taking the ratio of total 
number of publications in each year to that of total number of publication in the previous 
year related to each ‘omic’ technology.  
 
2.2.1.2 Preclinical & clinical metabonomics  
Relevant keywords describing metabonomics were used to identify preclinical and 
clinical metabonomics publications (Table 1, Appendix I). After considering the 
exclusion criteria, the number of publications from 1995 to 2009 was profiled according 
to a pre-defined workflow (Figure 1, Appendix I). 
 
2.2.1.3 Regional metabonomic research 
Preclinical and clinical metabonomics studies published from 1995 to 2009 were collated 
using various keywords (Table 1, Appendix I). Flowchart illustrating methodology 
employed to determine regional and yearly trend in metabonomic is shown in Figure 2, 
Appendix I. For this review, only WOS was utilized as it offers the option to analyze 
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publications according to countries of the authors. Subsequent to the exclusion of 
publications based on the exclusion criteria, publications were grouped and charted 
according to geographical regions, namely, the United States of America (USA) and 
Canada, Europe, Asia Pacific, Middle East and South America. For papers with authors 
related to multiple research institutions located in different geographical regions, all 
addresses were considered. The key research institutions spearheading metabonomic 
research in each geographical region were also collated. 
 
2.2.1.4 Analytical platforms used in metabonomic studies 
Keywords describing metabonomics research (Table 1, Appendix I) were used to identify 
preclinical and clinical metabonomics publications from 1995 to 2009. Subsequently, 
another set of keywords (Table 1, Appendix I) were used to categorize publications that 
utilized the respective analytical platforms, such as NMR, GC/MS, LC/MS, capillary 
electrophoresis mass spectrometry (CE/MS), direct infusion mass spectrometry (direct 
infusion MS) and fourier transform infrared spectroscopy (FT-IR). The number of 
publications per year for each analytical platform was profiled subsequently (Figure 3, 
Appendix I).  
 
2.2.1.5 Biofluids used in metabonomic research 
Subsequent to appropriate exclusion, publications were sieved and binned according to 
the sample matrices adopted in the respective studies namely, blood, urine, cerebrospinal 




2.2.1.6 In vitro versus in vivo metabonomics 
Metabonomics studies were filtered and classified into in vitro, preclinical (in vivo 
animal) and clinical (human) studies using appropriate keywords (Figure 3, Appendix I). 
 
2.2.2 Collation of marker metabolites in oncology 
Preclinical and clinical metabonomics studies pertaining to oncology published from 
1995 to 2009 were profiled. Targeted metabolic profiling studies reporting less than thirty 
metabolites were excluded in the current study. Once the relevant publications were 
collated, the cancer marker metabolites were further separated into common and specific 
marker metabolites reported for the different cancers. Subsequently, the biological 
pathways involving the reported marker metabolites and their relationship to the 
pathology of cancers were examined. For metabolic pathway interpretation, only cancers 
with more than three reported publications in metabonomics investigations were 
considered, and each metabolite must be present in at least two types of cancers or 
reported at least three times in each cancer type. The pathways were analyzed using the 
Human Metabolome Database (HMDB) [82] and Kyoto Encyclopedia of Genes and 
Genomes (KEGG) databases [83].  
 
2.3 Results & Discussion 
2.3.1 Trend analyses 
2.3.1.1 Analysis of genomics, metabonomics, proteomics and transcriptomics 
Overall, there were higher number of publications in genomics and proteomics each year 
compared to metabonomics and transcriptomics (Figure 2A and B). The observed trend 
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was possibly related to the earlier establishment of genomics and proteomics 
technologies in the “-omics” field. Nevertheless, the publications in genomics and 
proteomics appeared to be reaching a plateau in recent years (Figure 2B). This was also 
evident from the decline in the percentage increase of the number of genomic-and 
proteomic-based publications each year over the past five years especially during the 
2008/2009 period where decrements were observed (Figure 2C and D). There was a clear 
discrepancy in terms of the absolute number of genomics-based publications documented 
by PubMed compared to WOS (Figure 2A versus B). This observation underscored that 
publications collated in these databases are different and literature research should 
encompass multiple databases. In comparison, the number of publications in 
metabonomics continued to increase over the years (Figure 2A-D). Being a relatively 
new research area compared to genomics and proteomics, metabonomics appeared to be 
in the ‘exponential growth’ phase. However, it was noted that the percentage increase per 
year in metabonomic publications in past five years was not significant, particularly for 
literatures reported in WOS (Figure 2C and D). Although the percentage increase in 
transcriptomic-based publications per year appeared to be comparable or even higher 
than those of metabonomics, the absolute increase in terms of the number of publications 




Figure 2. Comparison between different ‘omic’ technologies, in terms of number of publications per year (A: Web of Science (WOS); 
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2.3.1.2 Preclinical & clinical metabonomics 
Increasing trend in the number of publications in preclinical and clinical metabonomic 
over the years was similarly observed (Figure 4A, Appendix I). This exponential increase 
was evident in linear trend of the semi-logarithmic plot of the number of publications 
against the publication years (Figure 4B, Appendix I). Thus, it was clear that 
metabonomic research is fast expanding, particularly in the area of preclinical and 
clinical applications. This finding was consistent with our expectation as systems biology 
research is generally translational in nature, aiming to generate knowledge and tools for 
clinical applications. Hence, similar to other “-omics” platforms, the growing trend in 
preclinical and clinical metabonomic research is expected to continue.  
 
2.3.1.3 Regional metabonomic research  
A large number of preclinical and clinical metabonomic-based research articles were 
published by various research institutions in Europe followed by USA and Canada 
(Figure 4C, Appendix I). This trend could be explained by the presence of world-leading 
metabonomic laboratories in these regions such as the Imperial College London in United 
Kingdom and the University of California, Davis, in the USA (Table 2, Appendix I). 
However, it was worth noting that recently, the number of metabonomic studies reported 
by institutions in the Asia Pacific region is increasing, with China and Japan publishing 




2.3.1.4 Analytical platforms used in metabonomic studies 
For preclinical and clinical metabonomics, NMR and LC/MS were clearly more 
extensively reported compared to GC/MS (Figure 3A and B). Nevertheless, the 
increasing trend in the usage of GC/MS in metabonomics was similar to NMR and 
LC/MS from 2005 onwards. The popularity of NMR is related to its ability to provide 
detailed structural information of small organic molecules and profile a large number of 
biofluid constituents [53,56,84]. Moreover, it is non-discriminating and nondestructive, 
and requires little or no sample preparation such as high-resolution magic-angle spinning 
NMR where analysis of ex-vivo intact tissue is possible [84-86]. While NMR may not be 
sensitive compared to techniques like mass spectrometry, it remains as the most robust 
and reliable workhorse in metabonomics. LC/MS is becoming increasingly popular, 
leading to the most number of metabonomic-based publications in 2008 and 2009. Its 
increasing popularity is related to its minimal sample preparation compared to GC/MS, 
good sensitivity and dynamic range [51,84,87]. While the use of GC/MS is potentially 
limited by the need for sample derivatization, its high resolution, good sensitivity and 
robustness render the increasing recognition of GC/MS in metabonomics [51,84]. In 
reality, the choice of these key analytical platforms is also defined by the availability of 
the instruments in the respective research institutions. Utilization of other analytical 
platforms such as CE/MS, FT-IR & direct infusion MS was comparatively lower. This 
might be due to various reasons, such as the difficulty of sample deconvolution in direct 
infusion MS, and the reduced sensitivity and lack of structural information presented by 
FT-IR spectrum for biomarker identification [51,84]. Further discussion on the various 




Figure 3C and D illustrate the utilization of single- and multi-platform approaches in 
metabonomic-based publications. The combinatorial utilization of GC/MS and LC/MS 
was the most commonly employed multi-platform approach, followed by LC/MS and 
NMR. A multi-platform approach is strategic in expanding the coverage of metabolic 
space of the investigated biological system. This was evident from a study of the human 
CSF where each analytical platform (NMR, LC/MS and GC/MS) detected various unique 
metabolites which were not detected by the parallel platforms [88]. However, there were 
clearly more reports using single analytical platform. This observation was possibly 
related to the lack of multiple platform technologies in each metabonomic-based 
laboratory. However, with the increasing trend in research collaboration, one can expect 
an increase in metabonomic-based publications utilizing multiple analytical platforms to 




Figure 3. Comparison between different analytical platforms, in terms of number of metabonomic-based publications per year (A: 
Web of Science (WOS); B: PubMed), and Venn diagrams illustrating the utilization of nuclear magnetic resonance (NMR), gas 
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2.3.1.5 Biofluids used in metabonomic research 
The most frequently profiled biological matrices in metabonomics are blood, urine and 
tissue (Figure 4). Choice of sample matrices often depends on the disease studied and the 
ease of obtaining the sample. For instance, blood is relatively easy to obtain from 
patients, and its constituents are affected by many diseases. Therefore, blood is 
commonly used in metabonomic studies [89,90]. However, its composition can be 
affected by many organ systems and changes detected in the blood may not be specific to 
a particular disease. Thus, the use of blood as a matrix has limitations in some instances. 
Urine, being closely related to the renal system, is commonly used to study diseases of 
the renal system, such as bladder and kidney cancer [64,91-93], and a host of other non-
renal related studies. While the collection of urine is noninvasive, collection of first-void 
urine might be plagued with compliance problems. Moreover, urine has been reported to 
be more sensitive in reflecting the effect of acute dietary intake, compared to blood and 
saliva [94]. Storage conditions can also affect the stability of urine metabolites [55]. 
Thus, urine has its advantages and limitations in metabonomic studies. Tissue is 
commonly utilized in clinical oncology studies [65,68,95-97], since it provides the direct 
and accurate representation of the cell metabolome. However, harvesting tissue is an 
invasive process, often requiring biopsy. Since tissue samples can be subjected to 
histological examination, there is also less incentive to develop metabonomics for clinical 
disease diagnosis utilizing tissue. However, metabonomic studies utilizing tissue are 







Figure 4. Comparison of commonly utilized biofluids in metabonomic studies. 
 
 
The composition of CSF is dependent on the metabolite production rates in the brain, 
thus it is a reflection of changes in the brain extracellular and interstitial environments 
[98-100]. However, even though CSF is a good representative sample to study 
biochemical changes in CNS disorders [70,88,101,102], its utilization rate was low, 
probably due to the difficulty in collecting CSF clinically. Saliva is easily accessible and 
samples can be obtained noninvasively with minimal pain or stress [103,104]. Moreover, 
no special or expensive instrument is required, and its collection is also associated with 
fewer compliance problems [104]. Thus, saliva has been proposed to be a useful 
diagnostic biofluid for endocrine disorders and various diseases, such as the detection of 







































despite the advantages, there were limited studies that utilize saliva as a matrix for 
metabonomic studies [94,103,107-109]. This might be related to potential limitations, 
such as a relatively high level of inter- and intra-individual variation, diurnal variation, 
and influence of collection method and degree of stimulation on saliva composition 
[94,104]. Amniotic fluid, being closely related to both the mother’s health and fetal status 
and development, has the potential to reveal disorders in the mother or fetus [110,111]. 
Nevertheless, studies reporting the use of amniotic fluid as a matrix were limited.   
 
2.3.1.6 In vitro versus in vivo animal and human metabonomics  
Similar numbers of clinical and preclinical studies were reported in metabonomic-based 
publications (Figure 5A and B). There was an exponential increase in clinical and animal 
metabonomic studies from the year 2000 onwards. In comparison, there were fewer in 
vitro studies. Most clinical studies were directed towards diagnosis of diseases such as 
cancer, diabetes and ocular diseases [76,112-116], investigation of dietary effects 
[94,117-119] and epidemiologic research [120]. Animal studies were directed towards 
drug profiling and toxicology research [121-126] and investigation of disease models 
[127-131], while in vitro studies were mainly directed towards elucidation of toxicity and 
metabolic pathways [132-137]. Given the large number of clinical studies, it could be 
predicted that metabonomics would be translated from the laboratory-based biomarker 






Figure 5.Comparison of trends in clinical, preclinical and in vitro metabonomics studies 
(A: Web of Science (WOS); B: PubMed) 
 
 
2.3.2 Collation of marker metabolites in oncology  
Many studies were performed to identify the metabolic differences between normal and 
cancer cells using different analytical platforms and matrices. From 1995 to 2009, 117 
oncology-related papers, including studies utilizing magnetic resonance spectrometry 
(MRS), were published in WOS and PubMed. The distribution of these publications 
according to the type of cancers is shown in Figure 6A. Majority of these publications 
were related to brain and breast cancers, and utilized MRS as their analytical platform.  
 
An overview of the reported cancer marker metabolites and their perturbations in cancers 
is illustrated in Figure 6B. From the heat map (Figure 6B), the number of studies 
reporting a particular metabolite identified as cancer biomarker can be visualized. 
























































different cancer phenotypes to determine metabolites that are commonly perturbed across 
various cancers and biomarkers that were specific to a particular cancer type. The 
pathways identified to be perturbed in cancers are listed in Table 4 of Appendix I. It was 
noted in this study that not all the metabolites identified were documented in HMDB, 
such as marganic acid, oxamate, xylonic acid and sphingomyelin. Additionally, some 
metabolites are not associated with any specific biological pathways (Table 4, Appendix 
I). The cancer marker metabolites and their associated biochemical pathways are 







Figure 6. (A) Distribution of oncology-related metabonomic studies based on type of 
cancers studied and (B) heat mapa illustrating the number of studies reporting various 
marker metabolites in different cancers. 
 
aNames of metabolites and the direction of change in concentration of marker metabolites shown in Table 







2.3.2.1 Common pathways involved in cancer 
Glycolysis. Perturbations in metabolites involved in glycolysis, such as glucose and 
pyruvate, were observed in various cancers (Table 4, Appendix I). The down regulation 
of glucose [65,96,138,139], together with the elevation in pyruvate [115,139-141] and 
lactate [65,115,139,142-145], confirmed that cancers have a unique glucose metabolic 
phenotype. Otto Warburg observed that glycolytic production of adenosine triphosphate 
(ATP), rather than oxidative phosphorylation via tricarboxylic acid (TCA) cycle, was 
characteristic of most cancer cells, even under aerobic conditions [146-148]. The 
increased expression of Na+ dependent glucose transporters (GLUT) [146], together with 
the up regulation of enzymes involved in the glycolytic pathway, such as 
phosphoglycerate kinase 1 and alpha-enolase [149,150], also reflects a possible increase 
in glycolytic activity in cancer cells.  
 
While ATP production via glycolysis is less efficient compared to TCA cycle, cancer 
cells still rely largely on glycolysis to meet their energy requirements [151]. Several 
explanations have been postulated. Firstly, though oxidative phosphorylation generates 
more ATP per mole of glucose, it is rate-limited by the shuttling of reduced nicotinamide 
adenine dinucleotide (NADH) from the cytosol into the mitochondria [146,152]. Thus, 
cancer cells utilize a rapid influx of glucose to facilitate rapid ATP production via 
glycolysis to meet its energy demand [148,153,154]. Secondly, rapidly proliferating 
cancer cells have a large requirement for amino acids, lipids and nucleotides. Thus, 
cancer cells cannot utilize bulk of their glucose intake for ATP production via oxidative 





macromolecule synthesis and cell proliferation, such as ribose for nucleotides, glycolytic 
intermediates for non-essential amino acids and acetyl coenzyme A (acetyl-CoA) for 
fatty acids [146,148,153]. Lastly, under hypoxic conditions, reactive oxygen species 
(ROS) accumulates as a by-product during oxidative phosphorylation. Thus, by 
generating ATP via glycolysis, cancer cells reduce the amount of oxidative stress they are 
exposed to and protect themselves from damage [155-158].  
 
However, elevated glucose levels and lowered lactate levels were found in the serum of 
oral cancer patients [141]. Tiziani et al. have postulated that this may be due to the unique 
behavior of oral cancer, where the ability of insulin to regulate glucose uptake was 
affected [141], thus favoring ketogenesis and carbohydrate accumulation [159-162]. 
However, they were unable to pinpoint any specific pathway, since serum metabolic 
composition can be affected by many different exogenous and endogenous factors. 
Further studies are required to verify the differences observed in oral cancer metabolome 
compared to the other cancer metabolomes. 
 
TCA cycle. Perturbations in the TCA cycle were observed consistently in various cancers 
(Table 4, Appendix I), and TCA cycle was suggested to be impaired in cancer cells in 
several studies [65,95,140]. Citrate was found to be at lower levels in cancer cells, while 
the levels of fumarate, malate, succinate were generally found to be elevated. However, 
tumor cells generally have a functional TCA cycle as impairment of TCA cycle due to 
enzyme mutations has been observed in some rare cases of cancer, such as the mutation 






During cell proliferation, most of the carbon that enter TCA cycle is utilized for 
generation of precursors for macromolecule synthesis rather than for ATP production 
[154]. Though citrate can be used for ATP production, a bulk of it is transported out of 
the mitochondria, converted to oxaloacetate and acetyl-CoA, and subsequently utilized 
for de novo fatty acid and sterol synthesis [165]. Thus, the decrease in citrate levels could 
be possibly due to the increased utilization of citrate as a precursor for biosynthesis. 
Moreover, the inhibition of ATP citrate lyase has been shown to limit tumor growth 
[153,166]. This export of citrate to the cytosol results in a reduction of the fraction of 
mitochondrial citrate oxidized, thus some authors term it as a “truncated” cycle [154]. 
Other TCA cycle intermediates can also be utilized for biosynthesis, such as malate 
[164]. Moreover, glutamine, a major respiratory source in cancer cells, can enter TCA 
cycle through alpha-ketoglutarate (glutaminolysis), serving as a substrate to fuel the TCA 
cycle for the generation of necessary building blocks for cell proliferation [153,154,167-
170]. Thus, the anaplerotic flux of glutamine into TCA cycle allows rapidly proliferating 
cancer cells to utilize TCA cycle intermediates for biosynthesis [170].  
 
Pyruvate metabolism & glucose-alanine cycle. Studies have shown that reduced 
pyruvate oxidation and increased glycolysis results in the elevation in lactate and alanine 
levels in cancer cells [168,169,171]. Indeed, many clinical metabonomics studies have 
identified significant elevations in pyruvate, lactate and alanine in various cancers such as 
colorectal, liver and kidney cancers [65,139,140,143] (Table 4, Appendix I). The 





perturbations to pyruvate metabolism may contribute to tumor growth, progression and 
resistance to anticancer therapy, especially in hypoxic conditions [169]. In addition to 
enhanced glycolysis and effects on TCA cycle, the elevation in alanine levels has also 
been associated with increased protein synthesis [172]. Elevated alanine level has been 
observed in prominently in meningioma, and reported to be comparatively higher than 
other types of brain tumors [173-176]. However, no clear explanation was provided to 
account for the difference in meningiomas. 
 
Glutathione (GSH) metabolism. GSH metabolism was found to be perturbed in cancers, 
with elevated levels of GSH found in brain, head and neck, and colorectal cancers (Table 
4, Appendix I). [142,172,177,178]. However, its role in cancer is still not clear, as its 
protective and pathogenic roles are contradicting. GSH plays an important role in 
removal of carcinogens and provides a certain degree of protection from free radicals 
[179,180]. It has been postulated the increase in GSH levels to be a response to increased 
oxidative stress [179]. However, elevated GSH levels has also been associated with 
resistance of tumor cells to anticancer therapies, such as chemotherapy and radiotherapy 
[178] suggesting that cancer cells avoid the action of anticancer agents by conjugating the 
drug with GSH and excreting it [181,182]. In addition, with elevated cysteine levels in 
cancer cells, GSH synthesis is not limited by the availability of cysteine [179,183]. Some 
studies have also demonstrated that cancer cells which were exposed to buthionine 
sulfoximine (an inhibitor of GSH biosynthesis enzyme) pretreatment were more sensitive 
to anticancer therapy [179,182,184], further supporting the role of GSH in chemotherapy 






Purine and pyrimidine metabolism. Both purine and pyrimidine metabolism have been 
found to be perturbed in cancer cells [185-188]. Uracil and hypoxanthine were observed 
to be increased in tissue samples in colorectal, cervical and ovarian cancers [68,97,138]. 
The increase in nucleoside levels in cancer cells has been postulated to be due to the 
increased capacity for deoxyribonucleic acid (DNA) synthetic capacity and higher 
propagation rate of cancer cells [97,188,189]. 
 
Modified nucleosides such as pseudouridine, 2,2-dimethylguanosine and 1-
methyladenosine have also been found to be elevated in urine of cancer patients [190-
193]. The concentration of modified nucleosides in urine is a good indication of oxidative 
DNA damage and ribonucleic acid (RNA) turnover in the body [194-199]. Thus, the 
increase in urinary modified nucleosides in cancer patients indicates increased oxidative 
DNA damage, increased cell turnover and RNA metabolism [200], possibly due to the 
effects of high cell turnover rate and RNA/DNA modification in cancer [112]. 
Furthermore, modified nucleosides have been found to offer better sensitivity and 
specificity than routine clinical tumor markers [190,195], demonstrating the possible 
application of metabonomics in cancer diagnostics. 
 
Urea cycle. The urea cycle, which takes place primarily in the liver in mammals, has 
been reported to be perturbed in cancer (Table 4, Appendix I).  While arginase in the liver 
is known to catalyze the breakdown of arginine to ornithine and urea, its function in 





synthesis [201,202]. In cancer, polyamine biosynthesis has been found to be perturbed 
[203,204], and high arginase activity in cancer cells has been reported [205,206]. 
Arginase is believed to provide ornithine for polyamine synthesis [201], and ornithine has 
also been reported to be increased in tissue samples, and down regulated in serum in 
colorectal cancer [97,115]. While arginine has been reported to be involved in 
immunological function [115,207,208], its role is still not clearly established [201]. The 
increase in urea cycle intermediates has also been associated with increased turnover of 
amino acids [97]. Thus, the role of urea cycle and its intermediates in cancer needs to be 
further studied, since many of them are also involved in the other biochemical pathways 
which can also cause their levels to be perturbed.  
 
Ammonia recycling. Ammonia recycling, whereby glutamine and glutamate are the main 
amino acids involved, has been found to be perturbed in various cancers (Table 4, 
Appendix I). Researchers have suggested a reduced role of aminotransferase reactions 
that utilize glutamine or a decreased need for nitrogen transport across cells, based on the 
perturbed glutamate/glutamine ratio observed [97]. However, the effect of cancer on 
nitrogen/ammonia metabolism is not clear, since little research has been carried out. In 
addition, many of the metabolites involved in ammonia recycling are also involved in 
other pathways. Therefore, further studies need to be carried out to identify the exact 
ammonia recycling pathways that are perturbed in cancers.  
 
Transcription/translation and amino acid metabolism. Most amino acids were found to 





Appendix I). This has been associated with over-utilization of amino acids and a higher 
turnover of structural proteins in cancer cells [97,115,172], due to its rapid proliferation. 
Up regulation of amino acid transport systems and activation of accessory pathways of 
protein synthesis have been reported [172], reflecting the increase in demand for amino 
acids in cancer cells.  
 
In addition, the pertubations in the levels of amino acids could also be related to their 
metabolism (Table 4, Appendix I). However, the effect of perturbations of amino acid 
metabolism in cancer cells is not clearly established. Elevated levels of valine, isoleucine 
and leucine were observed in tissue samples [65,95,97,143,172], and their down 
regulation was observed in serum of cancer patients [115,140,141]. These observations 
have been associated with reduced utilization from succinyl-CoA due to truncated TCA 
cycle and increased glycolysis [65,95,140]. Glycine was also commonly reported to be 
elevated in cancer [65,68,97,138,143,173,189,209-212], which has been associated to 
enhanced glycolysis in tumor cells, since glycine can be produced from the glycolytic 
intermediate 3-phosphoglycerate [65,189,209,210]. Other postulations include enhanced 
nucleotide synthesis in colorectal cancer, and increased collagen synthesis in ductal 
carcinomas [210]. Glycine has also been associated with hepatic protective functions 
[189]. However, it is difficult to pinpoint the exact pathways that are perturbed since 
glycine is involved in several biochemical pathways. 
 
In addition to its role in the urea cycle, arginine can also be channeled to produce nitric 





in the defense against cancer cells, and the regulation of the immune system [115,207]. 
However, endogenously produced NO has not been shown to have any effect on cancer 
cell growth in vitro [213]. Thus, it was postulated that the effect of arginine on cancer 
could vary depending the activity of the different enzyme pathways involved [214]. More 
research needs to be carried out to determine the effect of perturbations in arginine 
metabolism on cancer cells. Elevated levels of proline [68,97,143,215] has been 
associated with perturbed mucin production [215], and disturbed expression of proline 
dehydrogenase, which has been reported to modulate tumor growth and apoptosis 
[115,126]. Similarly, elevated levels of cysteine [97,143,215] observed was associated 
with altered function and production of mucins in colorectal cancer, and increased protein 
synthesis [68]. However, it was interesting to note that in kidney cancer, many amino 
acids, such as isoleucine, leucine, arginine and glycine, were found to be down regulated 
in tissue samples, and up regulated in serum [96,139]. This has been attributed to a 
perturbed TCA cycle and increased protein degradation from cell necrosis [139]. 
However, observed differences could be due to several reasons, such as differing 
experimental methods, sample collection, or the inherent pathology of kidney cancer 
being distinct from other types of cancers. Thus, more studies need to be performed to 
investigate and confirm this difference in amino acid perturbation between kidney cancer 
and other cancers.  
 
2.3.2.2 Specific marker metabolites in cancers 
In our review, several marker metabolites have been found to be perturbed only in 





metabolites in the central nervous system was predominantly detected as marker in brain 
tumors [173,174,211,212,216-221], thus it could possibly be a biomarker for brain 
cancer. Reductions in NAA level have been associated with neuronal loss or dysfunction 
[211,212,219,221]. However, NAA may not be specific to cancer, as there are other 
diseases that can cause neuronal loss and lead to a decrease in NAA levels, such as 
Alzheimer's disease [222-224] and Parkinson’s disease [225]. Thus, more research is 
needed to differentiate the metabolome of brain cancer from those belonging to other 
types of neurodegenerative diseases, in order for metabonomics to be explored as a 
complementary brain cancer diagnostic tool. 
 
Sarcosine levels was found to be elevated in prostate cancer, and correlated with its 
invasiveness [226]. Sarcosine is thus a potential biomarker for diagnosis and monitoring 
of prostate cancer progression. Further studies are warrented to validate its clinical 
usefulness through multi-center clinical trials. It is interesting to note that glycine, a 
precursor for sarcosine, was not identified to be perturbed in prostate cancer, though its 
level was found to be increased in other cancer types [65,97,138,143,189,209].  
 
2.4 Conclusions 
To summarize, our literature review provided useful insights on the progression of 
metabonomics in comparison to other ‘omic’ technologies the utilization trends of 
various analytical platforms and biological matrices in metabonomics. Genomics and 
proteomics are leading in terms of the number of publications per year although their 





and LC/MS are the most popular analytical platforms utilized in preclinical and clinical 
metabonomics while the single-platform approach is currently more popular than the 
multi-platform approach. In addition, it was observed that blood, urine and tissue are the 
most commonly studied biological matrices. In the second part of our review, it was 
confirmed that different cancers possess both common and specific metabolic 
phenotypes. Many biochemical pathways were found to be perturbed, with glycolysis 
being one of the most-documented pathways perturbed in cancers. Many of the metabolic 
disturbances observed are due to the need to support cell growth and proliferation, such 
as glycolysis, TCA cycle, transcription and translation, and purine and pyrimidine 
metabolism. In addition, some of these metabolic disturbances serve to facilitate cancer 
cell survival, such as glutathione metabolism, pyruvate metabolism and arginine 
metabolism. Specific cancer marker metabolites related to brain and prostate cancers, 
such as NAA and sarcosine, were also identified respectively. In terms of the cancer 
metabolome, the current research is possibly profiling the “tip of the iceberg”. More 
fundamental research and biomarker validation studies are needed to elucidate and 
establish the role of the human metabolome in cancer pathology.  
 
Our review reinforced the potential of metabonomics in biomarker discovery and 
elucidation of the pathogenesis of cancers. Therefore, the application of metabonomics 
would provide us an opportunity to screen for metabolic biomarkers related to BC. To 
identify marker metabolites reliably it is important to develop and validate analytical 





CHAPTER 3 : Validation of GC/MS platform for global profiling of urinary 




Metabolites are the end products and by-products of the many complex biosynthetic and 
catabolism pathways that exist in humans and other living systems. In genomics and 
proteomics, the analytes of interest are biological macromolecules, which are polymeric 
in nature, and the chemistries of the building blocks are relatively well defined. On the 
other hand, in metabonomics, the chemical space associated with the endogenous 
metabolites is large and highly diversified. This great diversity in chemical properties of 
the metabolites and their wide concentration ranges pose a significant challenge in 
developing a robust and reproducible global profiling assay [227]. As these small 
molecular metabolites vary greatly in terms of their physicochemical properties and acid 
or base characteristics, several separation techniques have been investigated to resolve 
these analytes prior to MS detection. Among the tandem techniques investigated, the 
coupling of capillary GC to MS (GC/MS) proved to be a potentially useful method based 
on its high sensitivity, peak resolution and reproducibility. Availability of GC/MS EI 
spectral library further facilitates the identification of diagnostic biomarkers and aids the 
subsequent mechanistic elucidation of the biological or pathological variations [228].  
 
Blood and urine are the most frequently used biological matrices for exploring the 





samples, advantages of urinalysis are numerous especially sample collection is 
noninvasive. Legido-Quigley et al. conducted a systematic study on effect of analytical 
variation on metabonomics analysis and suggested that before any differences in urinary 
metabolites are correlated to a pathological response, it is important to address the cause 
of analytical variations [233]. Broadly, the analytical variations can be classified into 
variations related to sample preparation, data acquisition and data preprocessing [233]. If 
analytical variations are not thoroughly investigated, there is a strong possibility that 
some of the marker metabolites identified could be a result of chance correlation to 
analytical variations. Therefore, in this study, the development and validation of a 
GC/MS metabonomic platform is first performed. Subsequently, various RT alignment 
software in GC/MS data preprocessing are investigated. Rationales for the development 
of GC/MS-based metabonomic platform and evaluation of RT alignment software are 
presented in the following sections independently.  
 
3.1.1 GC/MS method development for urinary metabolic profiling 
Several GC/MS-based analytical methods have been developed for the metabolic 
profiling of compounds belonging to different chemical classes in urine [230,234-236]. 
Sample preparation typically involves incubating urine with urease enzyme, followed by 
protein precipitation using ethanol or methanol. The mixture is then vortex-mixed, 
centrifuged, supernatant is collected, dried and derivatized using silylation reagent. In 
some cases, derivatization with oximation reagent is carried out prior to silylation [236]. 
Pretreatment of urine with urease enzyme was first proposed by Shoemaker et al. to 





many of the low intensity metabolite peaks [237]. The pretreatment of urine with urease 
has enabled the simultaneous analysis of several categories of compounds in a single 
analytical run. Many derivatizing agents were explored in metabolic profiling including 
BSTFA (N,O-bis-(trimethylsilyl)trifluoroacetamide) [230,238] and MSTFA (N-methyl-
N-(trimethylsilyl)trifluoroacetamide) [239], which are being used predominantly in 
metabonomic investigations [239-242]. However, none of the methods cited above were 
validated based on their assay precision. Recently, Zhang et al. evaluated linearity, 
precision, and sensitivity of a GC/MS method for 26 known metabolites in rat urine as 
MSTFA derivatives [236]. Similarly, Qiu et al. evaluated repeatability and stability of 25 
urinary metabolites in rat urine as ethyl chloroformate derivatives [234]. To the best of 
our knowledge, no thoroughly optimized method for the global profiling of human 
urinary metabolites as BSTFA derivatives has been presented thus far. 
 
3.1.2 Data pre-processing in GC/MS analysis 
In metabonomic studies, spectral data generated from GC/MS has to be pre-processed 
prior to multivariate data analysis [243,244]. Multivariate data analysis generally 
involves interpretation of chemical variation among samples in the magnitude of detector 
signal at corresponding variables such as RT. Up to date, RT alignment during data pre-
processing still poses a challenge for the efficient and accurate identification of 
biomarkers, since chemometric techniques are inherently sensitive to RT precision [245]. 
In global metabonomic studies, whereby all metabolites in the samples are analyzed and 
quantified, RT of the metabolites should be reproducible to a high degree for correct 





separate measurements, especially when a large number of samples are incorporated. In 
metabonomic experiments, RT drifts may be induced by column performance changes, 
column saturation, column temperature or gas flow rate fluctuations [247-250]. Hence, 
RT alignment during data pre-processing is important to align peaks originating from the 
same metabolite in multiple samples to an identical RT. Several algorithms were 
proposed based on linear and non-linear corrections for RT alignment [244,249,251]. 
Recently, few studies evaluated RT alignment accuracy for LC/MS data [248,252]. It was 
noted that despite detailed documentation on the different algorithms, little information 
has been reported on the comparative performance of these algorithms for GC/MS data. 
Hence evaluation of RT alignment software for using GC/MS data becomes pertinent. 
 
3.1.3 Aims of current study 
Our overall aim of the study was to investigate the potential influences of sample 
preparation and RT shifts on the profiles of metabolites present in the healthy human 
urine samples. In the first part of this chapter, the development and validation of a 
GC/MS metabonomic platform suitable for the global profiling of urinary metabolites is 
described. The method was applied to investigate gender based metabolic differences in 
urine samples. Development and validation was performed on single quadrupole GC/MS. 
However, subsequent analyses were performed on GC coupled to TOFMS due to 







In the second part, performance of various RT alignment software commonly used in 
GC/MS analysis were evaluated. Three freely available software and two commercially 
available data alignment applications were evaluated in this study. The freely available 
software include MetAlign [253], MZmine [254,255] and TagFinder [256] and the 
commercially available software applications include the Calibration feature and 
Statistical Compare of the ChromaTOF software (version 4.21, LecoCorp). MetAlign and 
MZmine, which were initially designed for processing LC/MS data, had been validated 
using GC/MS data as well [257,258]. The applications of MET-IDEA [259], 
MetaboliteDetector [260], MetaboAnalyst [261], MeltDB [262], ChromA [263] , XCMS 
[264] and AnalyzerPro [265] were also attempted, but not selected for evaluation in this 
study due to difficulties in using them to process the GC/TOFMS data. Unlike previous 
studies [253,255,256] that evaluated the algorithms individually, our study evaluated for 




3.2.1 Chemicals and reagents 
BSTFA and MSTFA with 1% TMCS were purchased from Pierce (Rockford, IL,USA). 
MBTFA (methyl-bis(trifluoracetamide)), urease of Sigma type III, alkane standard 
mixture (C10 to C40), standard compounds and sodium sulfate (anhydrous) were obtained 
from Sigma-Aldrich (St. Louis, MO, USA). Milli Q water (Millipore, Bedford, MA, 






3.2.2 Preparation for GC/MS method development and validation 
3.2.2.1 Sample collection  
Spot urine samples were collected from 53 healthy human volunteers. The subjects 
consisted of 31 males and 22 females. All the subjects were non-smokers and were not 
consuming any medication at least one week before sample collection. All the volunteers 
completed confidential health and lifestyle related questionnaires, reported gender, age, 
and signed informed consent forms to be participants in the study. The average ages for 
male and female subjects are 23.5 ± 3.1 years and 25.9 ± 3.3 years, respectively. All urine 
samples were stored in 1.2 mL aliquots at -80oC until further sample processing. A 5 mL 
each of randomly selected 5 male and 5 female urine samples was pooled and the mixture 
was used as quality control (QC) samples. Individual urine samples were designated as 
metabonomic study urine samples.  
 
3.2.2.2 Sample preparation  
Both pooled urine QC samples and metabonomic study urine samples were prepared 
using the same method. Briefly, urine samples were thawed at room temperature (25 ± 3 
°C). A 100 U of urease was added to 200 µL of urine and incubated at 37°C for 1 h, to 
decompose and remove excess urea. To precipitate urease and other proteins, 1.8 mL of 
ice cold ethanol was added to the mixture. The mixture was vortex-mixed at high speed 
for 2 min, centrifuged subsequently for 10 min at 10000 × g at 4oC.  Then 1700 µL of 
supernatant was carefully separated and evaporated to dryness at 50oC under a gentle 
stream of nitrogen using TurboVap LV (Caliper Life Science, Hopkinton, MA, USA).  





sodium sulfate) was added to the dry residue, mixed for 1 min and dried again at 50oC 
under nitrogen. The dried metabolic extract was derivatized subsequently by adding 100 
µL of either mixture of BSTFA with 1% TCMS or MSTFA with 1% TCMS and heating 
at 70oC for 30 min to form trimethylsilyl (TMS) derivatives. TMS derivatives were 
cooled and 80 μL of supernatant was transferred into GC vial. For the trifuoroacyl (TFA) 
derivative of the amino functional group, 100 μL of MBTFA was added to BSTFA 
derivatized metabolic extract and then reacted at 70oC for 30 min. The completed TMS-
TFA derivatives of metabolic extract were cooled and 100 μL of supernatant was 
transferred into GC vial. For all the samples, 1.0 µL of derivatized extract was injected 
for GC/MS analysis.  
 
3.2.2.3 GC/MS analysis 
Analyses were performed on a Shimadzu QP2010 GC/MS system (Shimadzu, Kyoto, 
Japan). A HP-5MS 30 m × 250 µm (i.d) fused silica capillary column (Agilent J&W 
Scientific, Folsom, CA), chemically bonded with a 5% diphenyl  95% 
dimethylpolysiloxane cross-linked stationary phase (0.25 µm film thickness), was used 
with open split interface. Helium was used as the carrier gas at 1.2 mL/min and the 
injector split ratio was set to 1:10. The injector and source temperatures were 250oC and 
200oC, respectively. Oven temperature was kept at 60oC for 3 min, increased at 7oC/min 
to 140oC where it was held for 4 min and further increased at 5oC/min to 300oC where it 
remained for 3 min. The MS was operated in EI mode (70eV). Data acquisition was 
performed in the full scan mode from m/z 50 to 650 with a scan time of 0.5 sec. Data 






3.2.2.4 Validation experiments using pooled urine QC samples 
All the pooled urine QC samples and spiked standards were processed and analyzed 
using the procedures described in the sample preparation and GC/MS analysis sections, 
respectively. Validation experiments are summarized in Error! Reference source not 
found.. 
 
3.2.2.4.1 Linearity of response  
26 standard compounds (Table 3) were used to evaluate the linear response of the GC/MS 
method. These compounds which belong to different chemical classes were chosen based 
on their varied physicochemical and GC retention properties. Stock solutions of each 
standard compound were prepared at 10 mg/mL in Milli-Q water, except organic acid 
standard compounds that were initially dissolved in 100 µL of DMSO and diluted using 
Milli-Q water to obtain 10 mg/mL stock solution. The mixture stock solution was 
prepared subsequently in water containing 200 ng/µL of each standard compound except 
for the amino acids which were prepared at 500 ng/µL. Each calibration standard was 
then prepared by spiking different volumes of the mixture stock solution into 200 µL of 
Milli-Q water. Calibration standards ranging from 0.5 to 50 ng/µL were prepared for 
amino acids and 0.2 to 50 ng/µL for other classes of compounds. The calibration 
standards were then processed in the same way as the pooled urine QC samples. 
Calibration curves were acquired by plotting the peak areas against the nominal 































Freeze thaw  
stability 
Up to 3 cycles Up to 60 days 0.2 to 50 ng/µL Up to 24 hrs 





3.2.2.4.2 Intra-day and inter-day precision  
 The intra-day precision was estimated by analyzing five replicates of the pooled urine 
QC samples that were processed independently. The inter-day precision was determined 
by analyzing the QC samples on four different days (day 0, 7, 14 and 60 respectively). 
The criteria for acceptability of the precision data were within 15% relative standard 
deviation (RSD).  
 
3.2.2.4.3 Autosampler stability 
The stability of BSTFA derivatized metabolites, kept in autosampler at ambient 
temperature (25 ± 3°C) was determined periodically by injecting replicate preparations of 
the processed samples consecutively for up to 24 h. The peak areas of the analytes 
obtained at the initial cycle were used as the reference to determine the relative stability 
of the analytes at subsequent sampling points.  
 
3.2.2.4.4 Freezer stability 
Freezer stability of the metabolites in urine samples was assessed by processing and 
analyzing the pooled urine QC samples stored at -80°C for up to 60 days. These QC 
samples were analyzed on days 0, 7, 14 and 60.  
 
3.2.2.4.5 Freeze–thaw stability 
The stability of the metabolites in urine samples following repeated freeze–thaw cycles 
was assessed using the optimized GC/MS assay. The urine samples were stored at -80°C 





room temperature (25 ± 3°C) for approximately 2 h. After drawing out the required 
volume (200 µL), the samples were then returned to the freezer. The stability of analytes 
was assessed after three freeze–thaw cycles.  
 
3.2.2.5 Data preprocessing and chemometric data analysis  
Metabonomic study urine samples were analyzed using the optimized GC/MS assay. RT 
correction of peaks was performed using the AART (Automatic Adjustment of Retention 
Time) function of the Shimadzu GCMSsolution software with respect to RTs of alkene 
standards injected on each day of validation analysis. Identity of the GC/MS peaks was 
established by comparing the mass spectra and the retention index of the peaks with those 
available in the NIST mass spectral library (Wiley registry) and internally compiled 
spectral libraries. Peaks with similarity index more than 70% were assigned compound 
names while other peaks were listed as unknown (UN) compounds. To obtain accurate 
peak areas, one mass was specified for the quantitation of each compound. Additionally, 
two reference ions were used along with the quantifying mass to cross-validate the peak 
identity of each compound. Integrated peak areas of multiple derivative peaks belonging 
to the same compound were summed and considered as single compound. The total ion 
intensity for each detected peak was normalized against the sum of the peak intensities 
within that sample chromatogram using custom scripts developed within Microsoft Excel 
2003. The resulting data comprising peak number (RT-m/z pair), sample name, and ion 
intensity were analyzed using principal component analysis (PCA) and orthogonal partial 
least squares (OPLS) applications of the SIMCA software (version P11, Umetrics, Umeå, 





chemometric data analysis. PCA was used initially to detect severe and moderate outliers 
and visualize grouping trends. OPLS was then applied using gender as classifier.  
 
3.2.3 Preparation for evaluation of RT alignment software 
To investigate the performances of RT alignment software, two independent datasets 
were utilized. The first data set included a mixture of eighteen standard metabolites 
(Table 2). The second data set was obtained from the urinary metabonomic study of 
human BC comprising 24 BC and 51 non-BC urine samples. Evaluation of RT alignment 
software using GC-based urinary metabonomic dataset is presented in CHAPTER 4 
(Section 4.2.6) 
 
3.2.3.1 Sample preparation  
Totally, 18 standard compounds as shown in Table 2 were selected to cover a wide RT 
range. Primary stock solution of each compound was prepared at 10 mg/mL in methanol. 
Subsequently, 200 µL of each compound was aliquoted, mixed and diluted to obtain a 
secondary stock solution with the resulting concentration of 200 µg/mL of each 
metabolite in the mixture. Aliquots of secondary stock solution were evaporated to 
dryness at 50°C under a gentle stream of nitrogen. 100 µL of toluene (dried over 
anhydrous sodium sulfate) was added to each dry residue, mixed for 1 min and dried 
again at 50°C under nitrogen. The dried metabolic extract was derivatized first with 50 
µL of methoxyamine (20 mg/mL) for 2 h at 60°C. Subsequently, 150 µL of MSTFA with 
1 % TCMS was added to the mixture and heated for 1 h at 60°C to form the trimethylsilyl 
(TMS) derivatives. Final concentrations obtained for the derivatized products were 5 and 






Table 2.  List of standard compounds with respective retention times (RT) 
Peak Standard Compound RT range RT (sec)# 
1 Malonic acid Early 500 
2 Benzoic acid   Early 530.8 
3 Glycerol  Early 573 
4 Succinate  Early 584.9 
5 Glycine  Early 596.7 
6 Uracil Early 604.3 
7 Malic Acid Mid 728.2 
8 Adipic acid Mid 728.4 
9 Tartaric acid Mid 838.5 
10 Ribose  Mid 875.6 
11 Xylitol Mid 901 
12 Ribitol Mid 914.6 
13 Isocitric acid Late 952.3 
14 Citric acid Late 953.7 
15 Glucose Late 1019.4 
16 Manitol Late 1047 
17 Fructose Peak 1 Late 1002.7 
18 Fructose Peak 2 Late 1008 
19 Uridine  Late 1283.9 
#RT corresponds to control samples at high concentration. 
 
3.2.3.2 GC/TOFMS analysis 
A Pegasus 4D GC×GC/TOFMS (LecoCorp., St. Joseph, MI, USA) was utilized in the 
single dimension gas chromatography/time-of-flight mass spectrometry (GC/TOFMS) 
mode for all analyses. The GC/TOFMS instrument was equipped with an Agilent 7890 
gas chromatograph. A DB-1 20 m × 250 µm fused silica capillary column (Agilent J&W 
Scientific, Folsom, CA),  with 0.25 µm film thickness, was used with open split interface. 
Helium was used as the carrier gas at 1.5 mL/min and the injector split ratio was set to 
1:20. The mass spectrometry was operated in EI mode at 70 eV. Data acquisition was 






3.2.3.2.1 Retention time shifts induction.  
By altering programmed temperature gradient, RT shifts equivalent to one and two peak 
widths were induced in the positive or negative RT direction for each compound at both 
low and high concentration. Induction of approximately one and two peak width RT shift 
in positive RT direction is referred as pos1 and pos2 in this chapter. Similarly, RT shifts 
in negative direction will be referred as neg1 and neg2 shifts. In all the RT induction 
experiments, initial temperature of the oven was set to 70oC and held for 0.2 min. For the 
controls, the temperature was programmed to increase at 10oC/min to 270oC where it was 
held for 10 min. For induction of pos1, temperature was programmed to increase at 
9.95oC/min to 170oC and subsequently at 10oC/min to 270oC where it was held for 10 
min. To induce pos2 shift, temperature was increased at 9.90oC/min to 150oC, followed 
by 10oC/min increase to 270oC where it was held for 10 min. Peak shifts for neg1 was 
induced by changing the temperature gradient to 10.05oC/min until it reached 170oC, 
followed by 10oC/min to 270oC and held for 10 min. Whereas for neg2, temperature 
gradient was set at 10.10oC/min until 150oC and subsequently changed to 10oC/min until 
270oC and maintained for 10 min. The secondary oven was always maintained at 10oC 
higher relative to the primary oven temperature for all the analyses.  
 
3.2.3.3 Data processing  
Each chromatogram obtained from GC/TOFMS analysis was processed for baseline 
correction, noise reduction, deconvolution using the ChromaTOF software (version 4.21, 





imported into each software independently and processed. Alignment accuracy of each 
software was calculated based on the percentage of peaks that were correctly aligned at 
both low and high concentrations. A number of independent experiments were performed 
to find the optimal set of parameters to maximize the accuracy and performance of 
individual software.  
 
3.2.3.4 Calibration feature  
All the chromatograms were individually processed for library matching and peak area 
calculation using a data processing method created in the ChromaTOF software. The area 
of each peak was calculated using the unique mass of each derivatized metabolite. Only 
peaks with signal to noise ratio (S/N) greater than 100 were utilized for further analysis. 
A calibration method was created in ChromaTOF software to align peak information 
from multiple chromatograms. One of the control samples (where no RT shift has been 
induced) at high concentration was utilized as a reference. Analyte peaks identified from 
the reference chromatogram corresponding to each standard compounds were registered 
into the calibration method.  In the calibration method, 3 peaks (glycerol, malic acid and 
ribitol) corresponding to early, mid and late RT were specified as RT markers. 
Subsequently, relative retention times (RRT) of the remaining analytes were calculated 
with respect to the marker compound peaks. A similarity match criteria of 70% and RRT 
deviation of 2 sec were utilized in the calibration method. All the chromatograms were 
then imported into the calibration method as standards and processed to match and 





all the chromatograms listed in the calibration table were copied and pasted in to an excel 
sheet manually.  
 
3.2.3.5 Statistical Compare  
Statistical Compare is a recently introduced feature in the ChromaTOF (Version 4.21) 
software to align peak information obtained from multiple chromatograms. All the 
chromatograms were individually processed to generate analyte peak area values in each 
chromatogram in the same way as for calibration feature. Statistical Compare utilized a 
mass spectral match criterion of 60% when aligning the multi-dimensional peak data 
comprising sample name, metabolite, RT, mass and integrated peak area. Quantitation 
mass for each peak in the data table was selected from the unique mass that was most 
common to all the matching peaks within the retention window (2 times of peak width). 
Subsequently, this unique mass was used to calculate the peak areas from each 
chromatogram. Similarly, the best quality peak from matching peaks was then selected 
whereby the assigned name was used as the analyte name in the data table. The resulting 
data table comprised of observations where each of them was in turn described by 
variables (peak intensities) aligned according to their RT and unique mass pairs as 
identifiers. The data table is exported as a .csv file. 
 
3.2.3.6 MetAlign 
MetAlign interface is broadly divided in to three sections, part A, part B and part C 
corresponding to data import, alignment and statistical analysis, respectively. All the files 
were imported as a single group and processed together (part A). Under part B, rough 





time dimension and mass peaks were grouped based on the amplitudes [253].  For the 
scaling and alignment, the maximum shift per 100 scans was set at 15 and the minimum 
number of data files was set at 70% of total processing files. Maximum shift at the 
beginning and end values for the ‘first region’ parameters were set to 100 and 200 
respectively. Options in part C of MetAlign software on statistical analysis were not 
utilized as they were not relevant to this study. A snap shot of MetAlign software 
interface with optimized parameters used for our analysis are shown in Figure 1, 
Appendix II. 
 
3.2.3.7 MZmine2  
MZmine 2 is new version of MZmine software that offers additional features and 
extensions such as support for mzXML data format, capability to perform batch 
processing and data visualization option [266]. MZmine implements an alignment 
method which uses a master peak list generated from the sample files. Every peak from a 
sample file is mapped against the master peak list and assigned to the best matching 
existing row. If the m/z and RT difference beyond the tolerance limit specified, the 
software appends a new row to the master peak list. The following processing services 
were utilized for the alignment of analyte peaks: chromatogram builder, ransac alignment 
and gap-filling. Among the two alignment algorithms available, ransac alignment method 
was utilized with m/z tolerance of 0.1, RT tolerance of 10 sec and minimum number of 
points of  0.2% with a threshold value of 10 sec. Figure 2 (Appendix II) shows the 






3.2.3.8 TagFinder  
TagFinder is relatively new software but it is specifically designed for the alignment of 
GC/MS data [267]. In the workspace with the imported sample files, the mass fragments 
are sorted by mass and RT. Mass fragments of equal mass across all the sample files are 
binned and aligned into mass tags. Each mass tag has its own specified RT window. In 
the present study, all the three processing steps including time scanning, clustering and 
correlation, were incorporated to generate the final data matrix. The time scan width was 
set at 1.0 sec, tag time width 0-10 sec, sample count being 70% of total files and pearson 
correlation method was adopted with minimum 6 pairs clustering. In each workspace 
created, TagFinder generated unique mass spectral tags based on the RT, mass and 
arbitrary abundance. Subsequently, the mass spectral tags were aligned in to a peak table 
and were exported in .csv format. Finalized parameters utilized for the analysis are shown 
in the Figure 3, Appendix II. 
 
3.3 Results and discussion 
3.3.1 GC/MS method development and validation 
In urine metabonomic study, it is paramount to profile and analyze as many urinary 
metabolites as possible so that subtle but clinically significant differences in metabolic 
fluxes due to pathological processes can be detected. Therefore, our target in this Chapter 
was to develop and validate a simple GC/MS method that could detect as many chemical 







As most of the metabolites in the urine are nonvolatile, metabolic profiling via GC/MS 
usually requires chemical derivatization at the polar functional groups to reduce the 
polarity, increase the thermal stability and volatility of the analytes. BSTFA is one of the 
most commonly used derivatizing agents to render polar compounds volatile by adding 
TMS moiety to polar functional groups [230,238]. While TMS ethers of mono- and 
disaccharides are easily prepared, TMS derivatization of monosaccharides often results in 
the formation of multiple GC peaks since the reducing sugars are present in the sample as 
mixtures of different anomers. In addition, problems of steric hindrance might lead to 
mixtures of fully and partially derivatized analytes. One way to overcome this 
phenomenon is to convert the aldehyde and keto groups of sugars into oximes using 
methoxylamine prior to TMS derivatization. Oximation can reduce the number of 
tautomeric forms and reduce multiple peak formation. But oximation must be performed 
over a relatively long period of time (up to17 h) and/or at high temperature to ensure 
complete derivatization [268,269]. In view of this long sample processing time, the 
oximation step was avoided in our study and integrated peak areas of multiple peaks 
obtained from monosaccharides were summed prior to data processing (assuming equal 
response) [242]. Moreover, precision of individual peaks from monosaccharides was 
observed to be within the acceptance criteria. This might be due to the fact that peaks 
from monosaccharides eluted at longer RTs, where chromatographic interference with 
metabolites belonging to other chemical classes was minimal. It was observed that the 





and sugars) was minimal. In the view of above reasons, the oximation step was not 
adopted in our study.  
 
In the present study, we also investigated different derivatizing agents (BSTFA, MSTFA 
and MBTFA) to explore the detection of a maximum number of urinary metabolites with 
good chromatographic precision. BSTFA and MSTFA demonstrated similar 
derivatization efficiencies in terms of number of detected peaks, peak intensity and peak 
area variations. MBTFA which is more efficient in derivatizing secondary and tertiary 
amine groups [270] was investigated in combination with BSTFA. Although more amino 
acids were detected when BSTFA derivatization was followed by MBTFA derivatization, 
the integrated peak areas had higher variation (data not shown). Hence, only BSTFA was 
used as the derivatizing agent in our optimized GC/MS assay.   
 
3.3.1.2 Metabolite identification 
Identities of all the GC/MS peaks were investigated by comparing the mass spectra of the 
compounds with those available in the NIST mass spectral library (Wiley registry). 
Although the NIST library is extensive, one has to be mindful that it may not contain a 
large number of endogenous metabolites that are found in the biological metabolic 
pathway. Therefore, the identities of some of the compounds were putative until they 
were confirmed using standards. Hence, standard compounds (Table 3) belonging to 
different chemical classes were also utilized in our study to check the identities of some 
of the metabolites. Both RT and mass spectra of the detected peaks were compared to 





detected using the GC/MS assay. After the subsequent combination of multiple 
derivatized peaks for selected compounds, 150 endogenous compounds with low 
percentage peak area variations were detected using the GC/MS assay (Table 1-5, 
Appendix II). Of the 150 endogenous compounds, 144 compounds were assigned a 
compound name and the remaining 6 compounds were not assigned any compound name 
as similarity index of these peaks were less than 70% when compared with the NIST 
mass spectral library. It was clear from our results that the developed GC/MS method 
was able to detect endogenous metabolites belonging to different chemical classes 
(Figure 8). This is important in metabonomic research where a wide coverage of the 
metabolome is desirable.  
 
Figure 8. Percentage distribution of 150 putative urinary metabolites profiled by the 
GC/MS metabonomic platform. 
 
Although the separation of peaks has been optimized to a great extent in our method, one 





solution to identify all the peaks in the chromatogram is to use a deconvolution software 
like AMDIS [271] prior to library searching. However, it was reported that the poor 
repeatability of most of the deconvolution software is likely to generate number of false 
positive and false negative results [272]. If deconvolution of peaks had been carried out 
in our study, it might become difficult to differentiate analytical variation and variation 
due to deconvolution errors. Therefore, deconvolution was avoided despite the low 
chromatographic resolution between some of the peaks. As a result, the application of the 
GC/MS method is limited to detect only the major components in the GC/MS 
chromatograms.  
 
3.3.1.3 Validation studies 
An overlay of five GC/MS chromatograms obtained from intra-day and inter-day QC 
samples is shown in Figure 9. As shown in the insert of Figure 9, the variation of peak 
intensities and RT was low even for low intensity peaks. This high RT precision is 
important in urine metabonomic study as RT fluctuations pose challenge to data 
processing and may result in erroneous peak assignment. Correlation matrix was built to 
access the pair-wise linear correlation between GC/MS analysis of QC replicates. The 
correlation map revealed that the replicates were highly correlated (pairwise correlation 
coefficient >0.96). The high correlation between the QC replicates further confirmed that 
the overall variations in GC/MS method was low and it could be utilized for our 







Figure 9. Overlay of five QC urine GC/MS chromatograms (insert: expanded 






















3.3.1.3.1 Linearity of response 
The calibration curves for most of the test compounds were satisfactory with regression 
coefficients greater than 0.999 (Table 3). Amino acids showed linear increase in response 
from 0.5 to 50 ng/µL and compounds belonging to other chemical classes showed a linear 
increase in response from 0.2 to 50 ng/µL. Some of the compounds, such as L-serine and 
L-phenylalanine had nonlinear response at lower concentrations. Therefore, calibration 
curve was plotted using higher concentrations of these analytes.    
  























Table 3. Linearity of the GC/MS method for determination of standard compounds  
 




Amino acids     
 L-Alanine 6 0.5 0.9994 
 L-4-
Hydroxyproline 
6 0.5 0.9997 
 L-Isoleucine 6 0.5 0.9990 
 L-Serine 5 1 0.9903 
 L-Valine 6 0.5 0.9995 
 L-Phenylalanine 4 2 0.9918 
 Glycine 6 0.5 0.9988 
Organic acids     
 Adipic acid 6 0.5 0.9995 
 Citric acid 4 2 0.9824 
 Isocitric acid 6 0.2 0.9990 
 Malic acid 6 0.2 0.9999 
 Malonic acid 6 0.2 0.9990 
 Oxalic acid 6 0.2 0.9991 
 Succinic acid 6 0.2 0.9962 
 Shikimic acid 6 0.2 0.9993 
 Tartaric acid 6 0.2 0.9998 
Sugars and 
sugar alcohols 
    
 D-Arabinose 6 0.2 0.9994 
 D-Galactose 6 0.2 0.9992 
 D-Glucose 6 0.2 0.9990 
 D-Xylose 6 0.2 0.9997 
 Fructose 5 0.5 0.9969 
 Galactitol 6 0.5 0.9999 
 Glycerol 6 0.2 0.9999 
 Iso-Erythritol 6 0.5 0.9992 
 Ribitol 6 0.2 0.9998 
 Xylitol 6 0.5 0.9996 
     
#Regression coefficient is calculated from calibration curve starting at the given 






3.3.1.3.2 Freezer stability study 
Collection of human urine samples for metabonomic studies usually occurs at the clinic 
or hospital, so it is important to determine the proper storage conditions to ensure that 
composition of metabolites does not change during the period of analysis. The storage of 
human urine samples at room temperature (22oC) or 4oC with or without preservative 
(sodium azide) was shown to have significant effect on the changes in urine metabolites 
over time (4 weeks), as detected by 1H-NMR [273]. Urine samples stored at -80oC, on the 
other hand, showed metabolite profile that best reflected the original metabolite 
concentrations [273]. Hence, we further evaluated and confirmed the stability of 
endogenous metabolites by GC/MS analysis of urine samples stored at -80oC. The intra- 
and inter-day variation of the GC/MS assay of selected urinary metabolites stored at 
−80oC are summarized in Table 4. Precision data from pooled urine, as judged from RSD 
of less than 15%, were satisfactory. However, 5-hydroxyhexanoic acid, methylsuccinic 
acid (Table 2, Appendix II), alpha-L-galactofuranoside (Table 3, Appendix II) and 2,3,4-
tri-O-acetyl-D-xylono-1,5-lactone (Table 5, Appendix II) showed slightly higher inter-
day variations than our acceptable limits (>15% but below 16%). 1,4-dioxane (Table 5, 
Appendix II) showed high inter-day variation of 66%. However, this compound was 
suspected to arise from the column bleeding. More than 95% of the endogenous 
metabolites were stable for 60 days at -80oC. Therefore, metabonomic study urine 
samples were stored at -80oC and were analyzed within 60 days from their respective 







Table 4. Percentage variations and stability of endogenous compounds in human urine 
(analyzed as TMS derivatives) 
  Variation (%RSD) 












      
Amino acids      
 L-Alanine 5.90 3.04 0.72 0.96 
 L-4-Hydroxyproline 14.11 12.49 1.73 2.54 
 L-Isoleucine# 10.12 4.59 8.19 52.04 
 L-Serine 4.42 2.29 0.35 1.80 
 L-Valine 5.58 4.03 2.84 1.44 
 Phenylalanine# 4.37 4.48 3.24 16.30 
 Glycine 4.32 4.86 1.11 4.41 
Organic acids      
 Adipic acid 8.05 5.97 10.10 1.24 
 Citric acid 6.14 4.18 0.52 0.25 
 Isocitric acid 8.59 4.86 1.40 1.25 
 Malic acid 3.02 4.87 1.26 1.90 
 Malonic acid 11.57 4.65 2.05 13.17 
 Oxalic acid 6.67 10.91 11.90 13.71 
 Succinic acid 5.48 6.59 5.93 4.67 
 Shikimic acid 3.88 2.86 1.63 5.03 
 Tartaric acid 6.69 3.08 1.08 0.03 
Sugars and 
sugar alcohols 
     
 D-Arabinose 14.65 4.24 1.44 4.26 
 D-Galactose 6.79 3.19 2.14 1.12 
 D-Glucose 2.90 2.06 1.82 2.88 
 D-Xylose 12.04 5.29 0.96 1.96 
 Fructose 14.81 10.76 0.47 4.90 
 Galactitol 7.68 3.11 3.88 0.84 
 Glycerol 10.58 3.04 0.79 1.50 
 Iso-Erythritol 3.64 2.10 0.01 2.21 
 Ribitol 4.77 1.34 0.49 1.60 
 Xylitol 5.33 2.27 0.16 3.48 






3.3.1.3.3 Autosampler stability study 
Stability of derivatized urine samples kept in autosampler at 25 ± 3°C was also 
investigated over a period of 24 h. Variation in normalized peak areas of most of the 
identified endogenous metabolites was within the acceptable limits (RSD < 15%) (Table 
4). 2-Pentenoic acid (Table 4, Appendix II) and UN-3 (unknown compound) (Table 5, 
Appendix II) were suspected to be unstable metabolites as their RSDs were higher than 
15%. Therefore, each batch analysis was performed within 24 h of derivatization of 
samples.  
 
3.3.1.3.4 Freeze–thaw stability 
All the identified 150 endogenous compounds were also used to evaluate their stability in 
urine samples after three freeze–thaw cycles. Except L-isoleucine (Table 4), 
phenylalanine (Table 4) and 2,3,4-tri-O-acetyl-D-xylono-1,5-lactone (Table 5, Appendix 
II), all other compounds were found to be stable in the frozen urine at -80°C for at least 
three freeze–thaw cycles. Hence, more than three cycles of sample freeze-thaw should be 
avoided as far as possible.   
 
3.3.1.4 Metabonomics of male and female human urine samples 
The optimized GC/MS method was applied for the metabonomic profiling of urine 
samples obtained from healthy volunteers in an attempt to distinguish gender-based urine 
metabolic profiles. Male and female derivatized samples were injected randomly for 
GC/MS analysis. We used normalized data set with 53 observations (male and female 





mean-centred and pareto-scaled. Two samples were identified as outliers from the PCA 
scores plot and DModX plot and were excluded from further data analysis. PCA scores 
plot revealed grouping of male and female observations with some overlap. Although, 
PCA gives a simplified representation of the information contained in the spectra, PCA 
cannot generally utilize additional information related to the data, such as class 
information (male or female). Therefore, PCA is often followed by a supervised analysis 
technique such as partial least squares analysis (PLS) or orthogonal-PLS (OPLS) that aids 
in obtaining a list of potential biomarkers which are statistically significant and which 
separate one class from another [274,275]. The objective of OPLS is to divide the 
systematic variation in the X-block into two model parts, one part which models the co-
variation between X and Y, and another part which expresses the X-variation that is 
orthogonal (not related) to Y. This may lead to better class-resolution in a discriminant 
problem. The main benefit in the interpretation of data using OPLS compared to PLS lies 
in the ability of OPLS to separate predictive from non-predictive (orthogonal) variation 
[276]. In this study, our OPLS model contained four latent variables, showing the 
performance statistics of R2X = 0.452, R2Y = 0.972 and Q2Y (cumulative) = 0.539. The 
X-score plot of t1 and t2 of the OPLS model is displayed in the Figure 10. Evidently, the 
data indicated a clear discrimination between the male and female groups. It was mainly 
the first latent variable that was responsible for separating the two groups. The second 






Figure 10. OPLS scores plot obtained from the urine analysis of healthy male and female 
volunteers.  
 
3.3.1.4.1 Differentiating metabolites between male and female  
Analysis of OPLS loadings and variable importance plots (VIP) indicated several 
metabolites that were different in male and female urine samples. These spectral variable 
were further confirmed using the variable line plot. As a first approach, variable line plot 
was inspected for any visual differences in metabolite levels for each variable listed in 
VIP. Welch t-test was then employed to detect metabolites that were significantly 
different between the male and female groups. Using a threshold value of p < 0.05, six 
metabolites were detected differentiated both groups. Alterations in the mean metabolite 
concentration expressed as fold change of each marker metabolite is shown in Table 5. 





to be in higher in female compared to male subjects. On the other hand, the levels of 2,4-
dihydroxybutanoic acid and 2,3-butanediol were found to be at lower in female compared 
to the male gender. Figure 11 shows a comparison of the normalized area values of 
succinic acid and 2,3-butanediol in box and whisker plot. 
 
Table 5. Metabolic differences in male and female urine sample 





1 Succinic acid Organic acids 92% 2.10 <0.0001 
2 2,3-butanediol Alcohols 94% -1.43 0.008 
3 2,4-dihydroxybutanoic 
acid 
Organic acids 97% -1.74 0.014 
4 Fucose Sugars 94% 1.42 0.019 
5 3-hydroxyhippuric acid  - 93% 2.28 0.031 
6 Fumaric acid Organic acids  75% 1.60 0.033 
 *Similarity index (SI) shows percentage match between the mass spectrum of identified 
compounds compared to the standard library spectrum. ##Positive value indicates higher 
concentrations in females compared to males and negative values indicate higher 
concentrations in males compared to females. 
 
Figure 11. Box and whisker plots of (A) succinate and (B) 2,3-butanediol normalized 


































Our results, showing higher levels of succinic acid, hippuric acid and fumaric acid in 
female compared to male subjects, were in close agreement with the findings from other 
metabonomic studies which investigated gender specific urinary metabolism using NMR 
[277,278]. Gender-related differences in the elimination of citrate in the urine are 
commonly observed and its level is generally greater in females [278,279]. Although we 
observed higher concentration of citrate in females compared to males, the difference in 
mean concentration between the genders was not statistically significant (p=0.092). Lack 
of statistical significance could be attributed to the high variability in the levels of urinary 
citrate in each group. It had been reported that citrate could be highly variable in human 
urine as a result of various individual metabolic processes [280]. Other endogenous 
compounds like urinary steroids can also be expected to be different in male and female 
urine samples as sex differences in steroid metabolism have been clearly demonstrated in 
clinical studies [281]. However, the basal concentrations of many urinary steroids are too 
low to be detected by our current GC/MS assay. In summary, it was confirmed that it is 
possible to differentiate urine samples according to gender using our GC/MS-based 
metabonomics platform. This would reduce the potential of misinterpreting the clinical 
data by detecting biomarkers due to gender difference rather than disease such as BC.  
 
3.3.2 Transfer of analytical parameters from GC/MS to GC/TOFMS 
In this chapter, GC/TOFMS was used for the evaluation of RT alignment software. 
Coupling of GC to the TOF analyzer offers several advantages compared to the coupling 
to quadrupole MS. Fast spectral acquisition rate of TOFMS (up to 500 Hz) enhances the 





if their spectra are sufficiently distinct [282]. Therefore, complete chromatographic 
resolution of the analytes is not mandatory to extract MS spectra of coeluting peaks 
[283]. Deconvolution capability is highly advantageous in analysis of complex samples 
such as biological matrices where coelution of metabolites is prevalent. The ability of 
peak deconvolution provides an opportunity to reduce the analytical run time since 
chromatography resolution can be compromised to a certain extent. In the same context, 
spectral purity and sensitivity are significantly enhanced in GC/TOFMS compared to 
GC/MS analysis [282]. In view of the above mentioned advantages, GC/TOFMS was 
utilized for our subsequent analyses. There were two fundamental changes between 
GC/MS and GC/TOFMS analytical parameters. Firstly, the GC/MS analytical run time 
was reduced from 55 to 30 min by utilizing GC/TOFMS analysis. Secondly, 
methoximation was utilized prior to TMS derivatization in GC/TOFMS analysis since 
multiple peaks from derivatized sugars were more evident when deconvolution was used. 
Since, several sugars are present in urine samples; generation of multiple peaks increases 
complexity in chromatographic separations and data analysis. Furthermore, as EI spectra 
of most of the sugars are similar, probability of misalignment of sugar peaks is higher 
when retention time shifts are encountered. Multiple peak formation of sugars can be 
overcome by introducing an oximation step prior to silylation, which inhibit cyclization, 
resulting in fewer peaks (up to 2) per sugar. Moreover, α-ketoacids are protected against 
decarboxylation, and enolizable keto groups are fixed by oximation. Thirdly, BSTFA was 
used instead of MSTFA. Previously, we have shown that BSTFA and MSTFA have 
similar derivatizing efficiency (section 3.3.1.1). However, MSTFA derivatives were more 





conditions were comparable between GC/MS and GC/TOFMS analyses. GC/MS data 
should be subjected to number of data preprocessing steps such as RT alignment prior to 
chemometric analysis. Therefore, evaluation of RT alignment software was undertaken.  
 
3.3.3 Evaluation of RT alignment software 
We evaluated the comparative performance of five software packages for RT alignment 
at two different concentration levels of metabolites and four levels of RT shift induction 
(pos1, pos2, neg1 and neg2). A representative GC/TOFMS chromatogram obtained from 
analysis of a mixture of standard compounds is shown in Figure 12. Standard compounds 
were selected mainly based on the following three criteria. Firstly, metabolites having 
physiological relevance and typically found in biological matrices were selected. 
Secondly, the metabolites should cover a wide range of RT. Finally, two pairs of 
structurally similar metabolites that were observed commonly misaligned in 
metabonomic studies were selected. The two pairs of compounds were include malic, 
adipic acid, and isocitric, citric acid. In addition, sugars such as glucose and fructose were 
included since they are structurally similar, have comparable RT and form multiple peaks 





Figure 12. (a) Total ion chromatogram inclusive of nineteen derivatized metabolic peaks 
at high concentration. (b) Chromatogram of succinate peak at dual levels of positive and 
negative RT shift induction. 
 
 
3.3.3.1 Calibration feature 
The calibration feature of ChromaTOF software demonstrated relatively high alignment 
accuracy compared to the other software, as shown in the heatmap in Figure 13. The 
calibration feature gave an overall alignment accuracy of 93%. Although, alignment of 





not integrated at low concentration due to S/N criteria. Calibration feature efficiently 
aligned peaks related to both positive and negative shifts. Misalignment of peaks was 
observed to be mainly compound dependant. However, utilizing calibration feature for 
RT alignment required considerable amount of manual intervention at various steps. 
 
Figure 13. Heatmap showing percentage RT alignment accuracies across 5 data 
processing methods at two concentration levels (low and high ), two directions (positive 
and negative) and two levels (one and two peak width) of RT shifts. Bright green and 



























3.3.3.2 Statistical Compare 
Statistical Compare is a fully automated feature integrated into ChromaTOF software to 
align peak information from multiple chromatograms. Therefore, exporting to NetCDF 
format was not required for processing of data. The aligned peak table contained sample 
information, peak identity (based on library match) and unique mass used for peak 
integration. Statistical Compare obtained an overall alignment accuracy of 73%. The 
relatively low accuracy value was attributed by six analyte peaks which were poorly 
aligned. All the standard compound peaks demonstrated accuracy percentages of over 
80%, except for the six metabolites, namely adipic acid, xylitol, ribitol, glucose, mannitol 
and fructose peak 2. Without the negative effect of these outliers, the average RT 
alignment accuracy percentage increased from 73 to 93%. The same metabolites outliers 
showed poor alignment accuracy at low concentration when calibration feature was used. 
One drawback of Statistical Compare feature is that it does not provide options to set 
similarity match criteria, RT window or calculated relative retention time.  
 
3.3.3.3 MetAlign  
MetAlign is the RT alignment software developed by Wageningen UR for LC/MS-based 
plant metabolomic data. The popularity of this software has recently resulted in its 
application to preprocess GC/MS data [253]. MetAlign exported amplitudes of each mass 
at each scan number. In our study, MetAlign demonstrated RT alignment accuracy of 
82% for high concentration samples and when RT of compounds was subjected to 
positive shifts. However, significantly lower alignment accuracy (58%) was observed 





phenomenon was observed in low concentration samples, whereby negative shifts yielded 
88% while positive shifts yielded only 73% RT alignment accuracy. It is important note 
that MetAlign requires additional tools to convert amplitude values into corresponding 
peak area values and does not provide library matching to confirm peak identity. 
 
3.3.3.4 MZmine 
MZmine (version 1.96) is implemented as a stand-alone open-source Java application 
toolbox, initially catered for LC/MS data [266]. Therefore the default parameters were 
not suitable for GC/MS data and modification of default parameter settings was 
necessary. Although MZmine has peak deconvolution function, this function was not 
performed to enable a fair comparison of RT alignment results with other software which 
do not have the deconvolution option. The alignment accuracies obtained for individual 
metabolites were illustrated by the line graph in Figure 14. It was observed that 
metabolites which showed lower RT alignment accuracy belonged to the middle RT 
range. MZmine showed promising alignment results at both high and low concentration 





Figure 14. RT alignment accuracy demonstrated by MZmine for standard compounds. 
The metabolites on the axis are arranged from left to right in ascending order of RT.  
 
3.3.3.5 TagFinder 
TagFinder is a single user application that was developed to generate data matrices that 
contain aligned mass spectral tags and samples of an experiment [267]. In our study, 
TagFinder generated the lowest RT alignment accuracy. Other than a consistently poor 
alignment, five metabolites were not detected at each concentration level. Specifically, 
isocitric acid and uridine were not detected at both concentration levels. Of the nineteen 
peaks, thirteen peaks generated alignment RT accuracy of approximately 50%. Extensive 
optimization of parameters was carried out to improve the alignment accuracy. However, 
changing different parameters did not result in significant improvement. Despite our 
efforts to optimize the parameters, the low RT alignment accuracy of TagFinder could 
still be attributed to inappropriate parameter settings. TagFinder is a relatively new 
software designed specifically for GC/MS data. There is little information provided in the 
literature on the software. One of the challenges in managing TagFinder was the lack of 


























































effect of parameters such as force_min_tag_width, gliding_median_count and 
core_adjency_option, on the RT alignment results was unclear. Although 73 or 147 was 
recognized by other software as the highest intensity mass for more than ten peaks, 
TagFinder recognized 73 or 147 as highest intensity mass ion for only four peaks. Its 
lower RT alignment accuracy might also be due to the high dependency of the alignment 
algorithm on retention index (RI) calculation. The RI calculation step was omitted in this 
study so that the software will align data based on RT values. The omission of RI 
calculation might also have significant effect on the RT alignment accuracy of 
TagFinder.  
 
3.3.3.6 Comparison of software 
Each software evaluated in this study presented varying performance and ease of use. All 
the three external software supported the import of NetCDF files, which can be generated 
by most GC/MS instruments, hence reducing the need for additional tools for file 
conversion. The overall RT alignment accuracy across all thirty metabolites was highest 
for calibration feature (93%), followed by MZmine (92%), MetAlign (74%), Statistical 
Compare (73%) and TagFinder (42%). Due to the fact that the calibration feature and 
Statistical Compare software are integral parts of the ChromaTOF package, two main 
advantages were derived. Firstly, data conversion to NetCDF format was not necessary. 
Secondly, both the features retained metabolite names in the peak tables thus, reducing 
the need for additional library matching to know the metabolite identities. Across all the 
software, RT alignment was found to be less accurate when 2 peak width shift was 





different levels of RT shift induction, this study served to analyze the relationship 
between the tmetabolite concentrations and alignment accuracy. Although a clear 
relationship between concentration of metabolites and RT alignment accuracy could not 
be determined, a few observations were made. Both MetAlign and TagFinder showed 
higher RT alignment accuracy in low concentration samples, while calibration feature, 
Statistical Compare and MZmine displayed higher RT alignment accuracy in high 
concentration samples. Specifically for MetAlign, alignment accuracy was compromised 
when the metabolites that were present at the high concentration range was shifted in the 
negative direction. In contrast, an opposite trend was observed for the low concentration 
metabolites. 
 





MetAlign MZmine TagFinder 
1 peak width shift 94 76 81 93 45 
2 peak width shift 93 70 66 92 38 
 
Calibration feature and MZmine presented consistently higher accuracy across all the 
samples, except for a few metabolites. In contrast, TagFinder showed a relatively lower 
accuracy across various RT shift conditions. Apart from high RT alignment accuracy and 
integration within the ChromaTOF software, calibration feature offered several 
advantages including visualization tools, flexibility in setting RT window, RRT 
calculation and spectral match criteria according to user requirements. However, it is 
important to note that it required significant manual intervention and amount of manual 





built based on reference chromatogram, some of the metabolites may not be included in 
the peak table if they are not present in the reference chromatograms. On the contrary, 
MZmine could perform untargeted profiling of data with minimal manual intervention. 
Similar to calibration feature, MZmine provided methods for deconvolution and 
visualization of data. Additionally it included support to perform parallel processing. 
However as shown in Figure 14, MZmine demonstrated its own limitations in aligning 
metabolites in the mid RT region and its efficiency in aligning closely-eluting 
metabolites, such as adipic acid and malic acid, or isocitric acid and citric acid was poor.   
 
Statistical Compare demonstrated similar accuracy compared to MetAlign. Therefore, it 
would be more efficient to utilize Statistical Compare as data conversion to NetCDF 
format could be omitted assuming the users are using the ChromaTOF package. Although 
Statistical Compare is a convenient platform, its RT alignment efficiency for other 
batches of samples is questionable as it does not offer the flexibility to optimize 
alignment-related parameters such as RT window and MS spectral match criteria. 
Moreover, RT alignment accuracy is compound-dependent. Therefore, counter checking 
the data manually becomes necessary to confirm RT alignment of important marker 
metabolites.  
 
Although, most of the software showed considerably good RT alignment accuracy, it is 
important to note that RT shifts in GC/TOFMS metabonomic studies will be much more 
complex due to bi-directional RT shift, co-elution of multiple analytes, broader analyte 





above-mentioned factors can significantly affect RT alignment accuracy and the 
subsequent chemometric data analysis. 
 
3.4 Conclusions 
In this chapter, two main prerequisites for metabolic profiling using GC/MS were 
addressed namely, (1) robust and precise analytical method and (2) reliable method for 
preprocessing chromatograms. An optimized protocol of extraction and derivatization 
was established and validated for metabonomic profiling of human urine using GC/MS. 
Approximately, 150 compounds were detected and identified, most of which showed low 
analytical variation and good stability. Metabolic profiling of male and female urine 
samples clearly demonstrated that GC/MS-based profiling combined with pattern 
recognition techniques facilitated the discrimination of urine samples due to gender. 
Evaluation of data alignment accuracy of software packages showed that they still require 
further improvements before they can be routinely utilized in GC/TOFMS metabonomic 
studies. Calibration feature and MZmine offered several advantages and achieved highest 
alignment accuracy among all other software. While the inclusion of RT alignment 
software is still essential for data processing, users have to hold reservations and be 
mindful about the possible misalignment that may occur intrinsically. For biomarker 
discovery studies, manually counter-checking the important biomarkers is warranted. 
Findings presented in this chapter clearly indicate that GC/MS metabonomic platform is 
suitable for the global profiling of urinary metabolites to screen markers for BC 





CHAPTER 4 : Urinary metabonomic analysis of BC using GC/TOFMS and NMR. 
 
4.1 Introduction 
As noted previously (CHAPTER 2, Section 2.3.1.4), NMR and GC/MS are the most 
commonly used analytical platforms in metabonomic investigations [51,84-86]. Both the 
techniques generate high-density, diverse chemical data sets with specific strengths and 
drawbacks. NMR has the advantages of being rapid, non-destructive to samples, 
applicable to intact biomaterials and rich in chemical structural information. Moreover, 
sample preparation is minimal especially in urinary metabolic profiling. Finally, NMR is 
a quantitative technique that can report a number of metabolites in a single measurement 
[84-86,284]. Despite these advantages, sensitivity of NMR is lower compared to mass 
spectrometry techniques such as GC/MS [284,285]. In addition, low abundant 
metabolites may not be detected due to the overlapping signals from high concentration 
metabolites [285]. GC/TOFMS has been proven to be a potentially useful metabolic 
profiling platform based on its high sensitivity, peak resolution and reproducibility 
[282,286,287]. Availability of GC/MS EI spectral library further facilitates the 
identification of diagnostic biomarkers and aids the subsequent mechanistic elucidation 
of the pathological phenotypes [228]. Unlike electrospray ionization (ESI) which is used 
in LC/MS, EI ionization used in GC/MS is less prone to matrix effects [288]. Moreover, 
we have demonstrated previously (CHAPTER 3) that GC/MS-based urinary metabolic 
profiling shows high inter- and intra-day precision [289]. However, extensive sample 
preparation and long chromatographic analysis render GC/MS a relatively low 






Although, the two platforms offer unique advantages in metabonomic analysis, very few 
studies utilized NMR and GC/MS for metabolic profiling [290]. In general, given that 
each analytical platform only probe subsets of the total metabolome, the combined use of 
two or more analytical technologies provides a more robust strategy for classifying 
disease and for identifying and validating candidate biomarkers than the use of a single 
platform [291]. Therefore, application of NMR and GC/TOFMS for urinary metabolic 
profiling of BC is investigated in this Chapter. A recent study reported the feasibility of 
using LC/MS to analyze urinary metabolites to discriminate between controls and BC 
patients [292]. However, potential marker metabolites responsible for the separation of 
BC patients from controls were not identified. More importantly, the predictability and 
robustness of the orthogonal partial least squares discriminant analysis (OPLS-DA) 
model were not evaluated and cross-validated. It is also important to note that one key 
challenge of using LC/MS for the metabolic profiling of complex urine samples is the 
varied results related to matrix effects [284,285]. Since, feasibility of LC/MS in 
metabonomics profiling of BC was investigated previously, it was not utilized for urinary 
metabolic profiling in our study.  
 
To date, no studies have evaluated the feasibility of GC/TOFMS-and NMR-based 
metabolic profiling for the characterization of human BC. This information gap embodies 
three important research questions: Does human BC generate a signature urinary 





metabonomics more sensitive compared to urinary cytology? Thirdly, can human BC 
urinary profiles distinguish the different stages or grades of the carcinoma?  
 
4.1.1 Aims of current study 
The overall aim of the present study was to determine whether urinary metabonomics 
would allow prediction of some aspect of cancer development in the bladder and thereby, 
provide a proof-of-principle for its application in the clinical diagnosis of human BC. The 
secondary objectives include: (1) comparison of GC/TOFMS and NMR in urinary 
metabolic profiling of BC, (2) evaluation of RT alignment software in clinical 
GC/TOFMS metabonomic data, and (3) investigation of metabonomic platform to 
distinguish different stages or grades of BC. 
 
4.2 Materials and methods 
4.2.1 Chemicals  
MSTFA with 1% TMCS (trimethylchlorosilane) and MOX reagent (2% 
Methoxyamine.HCl in pyridine) were purchased from Pierce (Rockford, IL,USA), urease 
of Sigma type III, alkane standard mixture (C10 to C40), and sodium sulfate (anhydrous) 
were obtained from Sigma-Aldrich (St. Louis MO, USA). Na2HPO4 (99%, anhydrous), 
NaH2PO4 (99%, anhydrous), 3-(trimethylsilyl) propionic-2,2,3,3,d4 acid sodium salt 
(TSP) and sodium azide (NaN3) were obtained from Sigma-Aldrich. D2O was obtained 
from Goss Scientific Instruments, UK. Milli Q water (Millipore, Bedford, MA, USA) 






4.2.2 Clinical population 
The overall workflow of metabolic profiling approach utilized in this study is 
summarized in Figure 15. The presence of tumors in bladder was initially visualized 
using cystoscopy. Subsequently, histopathology examination of transurethrally resected 
specimens was used to diagnose BC and determine stage and grade of these tumors. 
Tumors were classified according to WHO/ISUP classification criteria [12]. Patients 
whose histology did not show any malignancy were considered in the non-BC group. The 
clinicopathological data of BC and non-BC groups are summarized in Table 7. All the 
volunteers completed confidential health and lifestyle related questionnaires, reported 
gender and age, and signed informed consent forms to be participants in the study (IRB 
No. DSRB-B/07/192). Urine samples collection and interview of the participants was 
performed by Dr. Lata Raman Nee Mani and Dr. Revathi Kamaraj at National University 
Hospital (NUH), Singapore. All the urine samples were stored in aliquots at -80°C until 
further sample processing. GC/TOFMS analysis was performed at later date subsequent 
to NMR analysis. Therefore, sample set utilized for NMR analysis is subset for 
GC/TOFMS analysis. However, one of the BC patient samples was excluded from 







Figure 15. An overview of workflow utilized in urinary metabolic profiling of bladder 






Table 7. Summary of clinicopathogical characteristics of bladder cancer (BC) patients 
and non-BC subjects. 
 
Characteristics GC/TOFMS NMR 
 BC Patients Non-BC  BC Patients Non-BC  
No. of subjects 24 51 19 33 
Age (mean ± SD) 67.2 ± 12.3 61.3 ± 12.4 65.27 ± 15.08 63.2 ±14.2 
Gender     
Male 
 
20 (83.3 %) 28 (54.9 %) 18 (94.5 %) 18 (54.5 %) 
Female 4 (16.7 %) 23 (45.1 %) 1 (5.3 %) 15 (45.5 %) 
Cancer stage and 
gradea 
 
    
PUNLMP 4 (16.7 %)  4 (21.1%)  
Ta-LG 6 (25.0 %)  1 (5.3%)  
Ta-HG 3 (12.5 %)  3 (15.8%)  
T1-LG 1 (4.2 %)  1 (5.3%)  
T1-HG 5 (20.8 %)  5 (26.3%)  
CIS 2 (8.3 %) 
 
 1 (5.3%)  
Others 3 (12.5 %)  4 (21.1%)  
Citizenship     
Chinese 19 (79.2 %) 39 (76.5 %) 15 (78.9%) 31 (93.9%) 
Indian 4 (16.7 %) 10 (19.6 %) 3 (15.8%) 1 (3.0%) 
Othersb 1 (4.2 %) 2 (3.9 %) 1 (5.3%) 1 (3.0%) 
Smoking habit     
Non smokers 
 
9 (37.5%) 24 (47.1%) 3 (15.8%) 10 (30.3%) 
Ex-smokers 9 (37.5%) 3 (5.9%) 9 (47.4%) 2 (6.1%) 
Smokers 4 (16.7 %) 4 (7.8%) 4 (21.1%) 1 (3.0%) 
Information not 
available 
2 (8.3 %) 20 (39.2 %) 3 (15.8%) 20 (60.6%) 
aTumors were classified according World Health Organization (WHO)/International 
Society of Urological Pathology (ISUP) classification criteria. Low grade and high grade 






4.2.3 Urine preparation for GC/TOFMS analysis.  
Prior to sample preparation and GC/TOFMS analysis, all the urine samples were 
randomized along with 10 QC urine samples. QC samples were prepared by mixing equal 
amounts of urine samples from 5 BC patients and 5 non-BC subjects. The urine samples 
were thawed at room temperature (23 ± 3°C). A 100 U of urease was added to 200 µL of 
urine sample and incubated at 37oC for 1 h, to decompose and remove excess urea. To 
precipitate urease and other proteins, 1.7 mL of methanol was added to the mixture. The 
mixture was vortex-mixed at high speed for 5 min, centrifuged subsequently for 10 min 
at 10000 × g at 4oC.  A 1.5 mL of supernatant was then carefully separated and 
evaporated to dryness at 40oC under a gentle stream of nitrogen gas using TurboVap LV 
(Caliper Life Science, Hopkinton, MA, USA). A 100 µL of toluene (dried over 
anhydrous sodium sulfate) was added to the dry residue, mixed for 1 min and dried again 
at 50oC under nitrogen gas. The dried metabolic extract was derivatized first with 50 µL 
of MOX reagent (20 mg/mL) for 2 h at 60oC. Subsequently, 100 µL of MSTFA with 1% 
TCMS was added to the mixture and heated for 1 h at 60oC to form TMS derivatives. 
TMS derivatives were cooled and 100 μL of supernatant was transferred into GC vial and 
subjected to GC/TOFMS analysis. 
 
4.2.4 GC/TOFMS analysis 
A Pegasus 4D GC×GC/TOFMS (LecoCorp., St. Joseph, MI, USA) was utilized in 
GC/TOFMS mode for the analysis. The GC/TOFMS instrument was equipped with an 
Agilent 7890 gas chromatograph. A DB-1 30 m × 250 µm (i.d.) fused silica capillary 





with open split interface. Helium was used as the carrier gas at 1.5 mL/min and the 
injector split ratio was set to 1:20. The injector, transfer line and ion source temperatures 
were maintained at 220, 200 and 250oC, respectively, throughout each analysis. Oven 
temperature was programmed at 70oC for 0.2 min, increased at 10oC/min to 270oC where 
it was held for 10 min. The MS was operated in EI mode (70 eV). Data acquisition was 
performed in the full scan mode from m/z 40 to 600 with an acquisition rate of 20 Hz. 
 
4.2.5 GC/TOFMS data preprocessing 
Each chromatogram obtained from GC/TOFMS analysis was processed for baseline 
correction, noise reduction, smoothing, deconvolution, library matching and area 
calculation using an identical data processing method created using ChromaTOF software 
(version 4.21, LecoCorp.). Data preprocessing steps utilized in GC/TOFMS analysis is 
shown in Figure 16. Only peaks with S/N greater than 100 were utilized for further 
analysis. Area of each peak was calculated using unique mass. All GC/TOFMS detected 
peaks were identified by comparing both the MS spectra and the retention index (RI) with 
those available in the NIST mass spectral library (Wiley registry) and internally compiled 
spectral libraries. Resulting data table subsequent to data preprocessing was then 
exported as a .csv file. MetaboAnalyst [293] was utilized to replace missing values in the 













4.2.6 Evaluation of RT alignment software 
The standard mixture contained fewer metabolites and might not adequately represent 
complex peak-shift artifacts commonly encountered in the clinical metabonomic data 
[246]. Hence, in this study, results from the standard metabolites were supplemented with 
findings generated using human urine samples, in order to comprehensively assess the 
RT alignment efficiency in relation to biomarker discovery application. The urine data 
were processed using the same set of software parameters used for the standard mixtures 
(CHAPTER 3, Section 3.2.3.3). Aligned sample data were normalized using total area 
normalization. The normalized data matrix consisting of a random training set of twenty 
BC and forty-one non-BC samples was used to construct the OPLS-DA models using 
SIMCA-P+ software. Independent OPLS-DA model was constructed for each alignment 
software package using the same training set data. The alignment accuracy performance 
of the software was assessed by comparing the overall cross-validation coefficient, Q2, 
and the prediction accuracy of external prediction set. Each external prediction set 
constituted four BC and ten non-BC samples. Prediction accuracy was defined as the 
percentage of external samples in the prediction set that were predicted correctly when 
cross-validated using the corresponding OPLS-DA model.  
 
4.2.7 Urine preparation for NMR spectroscopy 
Prior to sample preparation and NMR analysis, all the urine samples were randomized 
along with 3 QC urine samples. The urine samples were thawed at room temperature (20 
± 3°C) for no longer than 20 min. During preparation, the samples were kept on dry ice to 





µL of each defrosted urine sample was added to 200 µL of phosphate buffer in an 
eppendorf tube. Phosphate buffer (pH 7.4) was prepared by weighing 28.85 g Na2HPO4, 
5.25 g NaH2PO4, 1 mM TSP and 3 mM NaN3 into a 1 L volumetric flask. 200 mL of D2O 
was added before the volume was adjusted to 1 L of water. The eppendorf tubes were 
inverted to mix and the samples were centrifuged at 16,000 × g for 5 min. 550 µL of the 
resulting supernatant was pipetted into a labeled standard 5 mM NMR tube and the lid 
securely closed. Samples were inverted so that the urine settled against the lid and then 
frozen at -80°C prior to NMR spectroscopy. 
 
4.2.8 NMR analysis 
Acquisition of 1H NMR spectra of urine were obtained on a Bruker DRX600 
spectrometer (Rheinstetten, Germany), operating at 600.13 MHz observation frequency. 
One-dimensional (1D) NMR spectra of urine samples were acquired using a solvent pre-
saturation pulse sequence (relaxation decay-90º-acquisition). Water resonance was 
eliminated by applying a secondary radio frequency irradiation during the relaxation 
delay of 3.04s. Typically, 64 scans were accumulated over a spectral width of 12,019 Hz 
into 64K data points with an acquisition time of 2.04 s. The 1H NMR spectra were 
processed using XWINNMR software (Bruker Biospin) and referenced to TSP (δ 0.0 
ppm).  
 
4.2.9 NMR spectral data preprocessing 
The 1H NMR spectra of urine samples over the range δ 0-10.0 were phase corrected, 





Matlab software (version 7, The Mathworks Inc., MA, USA) by Dr. Rachel Cavill, Dr. 
Tim Ebbels and Dr. Hector Keun. Probabilistic quotient normalization (PQN) was 
applied to partially remove concentration differences between urine samples [294]. 
Spectra were subsequently data reduced into 207 regions corresponding to 0.04 ppm 
intervals across the chemical shift range of δ 0.24-9.96 ppm and the signal integral in 
each region was computed. The region of δ 4.40-6.28 ppm was deleted to remove any 
effects of variability in the suppression of the water resonance and any cross relaxation 
effects on the urea signal. In addition, spectral regions corresponding to the citrate 
resonances (δ 2.48-2.56 and 2.64-2.72 ppm) were co-added to remove any variation in 
chemical shifts. The assignments of endogenous urinary metabolites in 1H NMR urine 
spectra were made with reference to published literature data [295,296] and by the use of 
Chenomx NMR suite (version 5.1, Chenomx Inc., Alberta, Canada). 
 
4.2.10 Chemometric data analysis.   
Both normalized datasets obtained from GC/TOFMS and NMR analysis were exported to 
SIMCA-P+ (version 12.0, Umetrics, Umeå, Sweden) to perform PCA individually where 
grouping trends and outliers in the data were observed. Prior to PCA analysis, 
GC/TOFMS and NMR data were unit-variance and pareto-scaled, respectively. DModX 
plot was calculated to check for any outliers. Observations with a DModX twice as large 
as the DModX critical values (threshold 99.5%) and outside the Hotelling T2 (0.95) 
ellipse were considered as outliers and excluded from further data analysis. After initial 





independent models were built and utilized to identify marker metabolites that accounted 
for the differentiation of BC and non-BC cohorts.  
 
4.2.11 Model validation 
To investigate model predictability and over-fitting of data in the PLS-DA model, 
permutation tests with 100 iterations were carried out using SIMCA-P software. This 
permutation tests compared the goodness of fit of the original model with the goodness of 
fit of several models based on data where the order of the Y-observations were randomly 
permuted, while the X-matrix was kept intact [297,298]. The results of the permutation 
tests were visualized using a two-dimensional (2-D) scatter plot called validation plot. 
The validation plot displays the correlation coefficient between the original Y and the 
permuted Y versus the cumulative R2 and Q2. The criteria for model validity are as 
follows: (1) All the Q2 values on the permuted data set are lower than the Q2 value on the 
actual data set. If this is not the case, it means that the model is capable of overfitting 
data. (2) The regression line in validation plot (line joining the actual Q2 point to the 
centroid of the cluster of permuted Q2 values) has a negative value of intercept on the y-
axis [298]. Receiver operating characteristic (ROC) analysis using the cross-validated 
predicted Y (predicted class) values was further performed to verify the robustness of the 
PLS-DA model in discriminating the BC and non-BC cohorts. The sensitivity and 
specificity trade-offs were summarized for each variable using the area under the ROC 






4.3 Results and discussion 
Obtaining an accurate and sensitive noninvasive diagnosis of human BC remains a 
challenging problem in our healthcare system. Application of urinary metabonomics for 
diagnosis of BC is theoretically plausible since pathogenesis of BC may result in 
dynamic yet discernible changes in the molecular environment of the bladder. Therefore, 
metabolic profiling of human urine for BC diagnosis is a logical clinical approach. While 
this idea may appear intuitive, it is somewhat surprising that the rationale of using urinary 
metabolic profiling as a mean to diagnose human BC has not been elaborately 
investigated. In this chapter, we investigated the use of GC/TOFMS and NMR-based 
urinary metabolic profiling in diagnosing BC patients. 
 
4.3.1 GC/TOFMS metabolic profiling.  
Representative GC/TOFMS chromatograms acquired using BC and non-BC urine 
samples analyses are shown in Figure 17A. Our GC/TOFMS-based urinary metabolic 
profiling method demonstrated RT deviation of less than 2 sec in overall analysis. Final 
data table comprised of 398 variables (chromatographic peaks) which were detected 





Figure 17. (A) Overlay of typical GC/TOFMS chromatograms of urine samples and (B) OPLS-DA scores plots obtained from 
the urine analysis of bladder cancer (BC) and non-BC subjects (H) subjects. (C) Validation plot obtained from 100 permutation 









4.3.1.1 Validation of analytical performance 
In this study, we adopted the concept of biological QCs reported by Gika et al. [299] 
wherein PCA was used to check the validity of the data in metabonomic analysis. PCA 
performed on all the samples revealed that the QC samples were tightly clustered in PCA 
scores plot (Figure 1, Appendix III). The observed close clustering of QC samples 
validated the robustness of our metabolic profiling platform with regards to parameters 
such as sample derivatization, stability of the detector response, accuracy of sample 
injection and RT precision. In parallel to using QC samples for qualifying the overall 
performance of the method, variations in the levels of marker metabolites were further 
cross-validated using the same metabolites observed in the QC samples. The %RSD of 
marker metabolites ranged from 3.0 to 33.4% with a median RSD of 6.7%. These marker 
metabolites were selected post-OPLS-DA. 
 
4.3.1.2 Urinary metabonomics of human BC   
PCA scores and DModX plots revealed that two observations belonging to non-BC 
cohort were severe outliers and were excluded from further chemometric data analysis. 
PCA was followed by a supervised analysis technique such as partial least squares 
discriminant analysis PLS-DA or OPLS-DA that aided the screening of marker 
metabolites responsible for class separation by removing systematic variation unrelated to 
pathological status [274,275]. The PLS-DA model obtained from urine sample analysis 
contained three latent variables, showing performance statistics of R2X = 0.360, R2Y = 





calculated based on twenty-four BC and forty-nine non-BC urine samples subsequent to 
PLS-DA analysis. The OPLS-DA model contained four latent variables, showing the 
performance statistics of R2X = 0.420, R2Y = 0.912 and Q2 (cumulative) = 0.245. Clear 
biochemical distinction between the BC and non-BC cohorts was evident in the OPLS-
DA model (Figure 17B). The OPLS-DA was able to correctly classify the urine samples 
into BC and non-BC groups, and it accurately predicted all BC patients and non-BC 
subjects showing 100% sensitivity and specificity. While urine cytology offered 100% 
specificity, its sensitivity was only 33% in detecting BC.  
 
Since the number of females patients in the BC cohort was lower compared to non-BC 
subjects, it was possible that our observed difference in metabolic phenotypes might be 
related to gender-based differences. Therefore, an independent OPLS-DA was performed 
solely based on 20 BC and 28 non-BC male subjects. Performance statistics and marker 
metabolites identified using the OPLS-DA model (two latent variables R2X = 0.379, R2Y 
= 0.862 and Q2 (cumulative) = 0.257) were similar to the OPLS-DA performed on the 
complete data set. Moreover, no significance changes were observed in separation trends 
in the OPLS-DA scores plots (Figure 3, Appendix III). These results further confirmed 
that observed differences in metabolic profiles were not related to gender-based 
differences. 
 
4.3.1.2.1 Classification of bladder tumors 
In addition to accurate diagnosis, classification of bladder tumors is critical for patient 





challenge [300]. Therefore, the feasibility of using urinary metabonomics for 
classification of bladder tumors was evaluated preliminarily in the current study. 
Interestingly, clustering of BC patients according to the stage and grade of the tumors 
was observed within BC group in the OPLS-DA scores plot (Figure 18A). Therefore, 
separate PCA and PLS-DA models were constructed to examine the classification of BC 
patients according to the stage and grade of bladder tumors. Clear clustering was 
observed in PCA scores plot related to stage and grade of BC. PLS-DA model 
demonstrated clear clustering of BC patients according to the stage and grade of the 
tumors (R2X = 0.675, R2Y = 0.945 and Q2 (cumulative) = 0.311; Figure 18B). PLS-DA 
revealed larger separation between papillary noninvasive (Ta) and infiltrative tumors 
compared to the grades of these tumors. While further validation needs to be performed 
using a larger patient cohort, our preliminary findings in current study illuminated the 
potential of urinary metabonomics in the classification of bladder tumors. Focusing on 
the direct correlation of metabolic components and pathological status, this approach will 
ultimately allow extraction of biological events at the interface of cancer pathology and 






Figure 18. (A) OPLS-DA scores plot showing clustering of bladder cancer (BC) samples 
according to classification of tumors (B) Scores plot obtained from PLS-DA analysis of 4 


















































4.3.1.3 Selection of marker metabolites. 
Analysis of OPLS-DA loadings and VIPs indicated several discriminatory metabolites 
that differentiated BC and non-BC urine samples. Totally, 32 metabolites were selected 
based on the criteria of VIP value greater than one. Unpaired t-test and Welch’s t-test 
were employed to select metabolites that dominated the separation between BC and non-
BC groups. Fifteen marker metabolites were selected and illustrated in Table 8. Identities 
of some of the marker metabolites were confirmed by analyzing standard compounds 
using the same analytical conditions adopted for the urinary metabolic profiling.  
 
4.3.1.4 Model validation.   
While performance statistics of multivariate model provided information about its 
validity, there was a possibility that each model was being developed by chance 
correlation. Therefore, goodness of fit (R2 and Q2) of original PLS-DA model and cluster 
of 100 Y-permutated models were visualized using a validation plot (Figure 17C). The 
validation plot strongly indicated that the original model was valid as Q2 regression line 
has a negative intercept and all permuted R2 values to the left were lower than the 
original point to the right. In addition, area under ROC curve (Figure 17D) of the PLS-
DA model calculated using cross validated Y-predicted values resulted in a value of 0.90 
confirming validity of the model. Results obtained from both permutation tests and ROC 
analysis of the PLS-DA model confirmed that our supervised chemometric model was 
valid and the separation of BC and non-BC subjects was not due to chance correlation. 





that the perturbations of the biomarkers were due to biological differences and not by 
chance based on analytical variations.  
 
Table 8. Marker metabolites differentiating bladder cancer (BC) and non-BC subjects  





1668.5 Senecioic acid 66 0.39 <0.0005 <0.005 10.5 
1895.9 2-Butenedioic acid  70 0.37 <0.01 <0.005 5.7 
1794.3 Ribonic acid 73 0.54 <0.005 <0.05 6.7 
1623.4 2,5-Furandicarboxylic acid 76 0.28 <0.005 <0.05 5.2 
2740.3 Melibiose 73 1.70 <0.0005 <0.005 33.4 
1533.2 Sumiki's acid 74 0.22 <0.05 <0.01 3.0 
2457.3 Uridinee 85 1.81 <0.05 <0.005 23.2 
1830.9 2-Propenoic acid 70 0.79 <0.05 <0.05 6.0 
1281 Glycerole 90 0.75 <0.05 <0.07 10.3 
2064.6 Gluconic acid 81 0.65 <0.05 <0.1 17.6 
1254.4 Valerate 71 0.72 <0.05 <0.1 5.3 
1912.9 Fructosee 91 0.67 <0.05 <0.1 28.1 
1218.8 L-valinee 75 1.52 <0.07 <0.05 17.6 
1834.4 Citric acide 95 0.77 <0.07 <0.07 8.6 
1762.5 Ribitole 91 0.74 <0.05 <0.1 3.0 
aRI: Retention Index.bSimilarity index (S.I) shows percentage match between the mass 
spectra of identified compounds compared to the standard library spectrum .cValue less 
than 1 indicates higher concentrations in non-BC urine samples compared to BC and 
values greater than 1 indicate higher concentrations in BC compared to non-BC. 
dVariation of marker metabolite concentrations in QC samples expressed as relative 





4.3.1.5 Evaluation of RT alignment software 
For the processing of 106 files, MetAlign required a processing time of 10 h 30 min 
while MZmine took 21 h 20 min for complete generation of datasets. The processing time 
of Calibration feature and Statistical Compare was not compared as they could not be 
operated on the same computer system. The OPLS-DA scores plots obtained from RT 
aligned dataset are shown in Figure 19. For TagFinder, despite using a Java memory 
space of 32 Gb, only thirty-two of the urine sample files could be imported into the 
workspace. Several trials were performed to import different sample files. The import of 
only thirty-two unique files in each trial run suggested the possible limitation of the 
software’s import function. Considering the wide variance of metabolites among different 
samples, validation by OPLS-DA prediction modeling was not performed for data 
generated by TagFinder. Performance statistics of the OPLS-DA models and prediction 
accuracy (percentage) constructed using the other four RT alignment software packages 
are listed in Table 9. Generally, higher Q2 indicates better predictability of the model and 
Q2 values above 0.2 are commonly observed and considered acceptable in clinical 
metabonomics [301,302].  Calibration feature, Statistical Compare and MetAlign 
demonstrated Q2 of 0.3, 0.436 and 0.439, respectively, and thus were considered as 
acceptable prediction models. The number of latent variables and R2 values of these three 
models did not show any likelihood of being over-fitted. For MZmine, the Q2 of 0.185 
suggested that the prediction model was relatively poor in terms of prediction 
performance. This poor result was in contrast to its good RT alignment performance in 
the standard metabolite experiment. In addition, there was a poor correlation between the 





samples for all the software (Table 9). This observation could be due to the fact that not 
all the functions related to each software were utilized in this study. For example, 
MZmine provided other processing options like peak deconvolution and normalization 
which were not utilized in the current study. These options were not adopted to ensure 
consistency in comparing with other software. In this study, all processing options and 
settings were kept consistent with the standard metabolite method. 
  




R2X R2Y Q2 
Prediction accuracy (%) 
BC Non-BC 
MetAlign 0.316 0.993 0.439 50 100 
MZmine 0.233 0.980 0.185 75 70 
Calibration Feature 0.416 0.887 0.300 75 80 





Figure 19. OPLS-DA score plots obtained from the RT aligned data tested with external prediction set of four BC and ten non-BC 






4.3.1.5.1 Evaluation on user-friendliness of external software 
Each external software (MetAlign, MZmine and TagFinder) evaluated in this study 
provided varying performance and ease of use. All three software supported the import of 
NetCDF (.cdf) file formats, which are generated by most of the GC/MS instruments, thus 
reducing the need for additional tools for file conversion. In this study, MetAlign 
required the shortest processing time for the 106 files, and was almost twice as fast as 
MZmine. MZmine offered the ability to distribute the computation workload to increase 
the processing speed and thus multiple processor system was utilized for our operation of 
MZmine [244]. For first-time users, MetAlign is a suitable choice as it displays an easy-
to-use interface, in which the processes are listed as sequences to guide the user. To allow 
graphical viewing of the aligned peaks, MetAlign provides an additional application, 
GM2MS, which can convert the .csv output to .cdf file. Graphical viewing of the aligned 
peaks will enable the visualization of individual peak shifting by the alignment algorithm. 
This will provide a clearer indication on how well the algorithm aligned the peaks. 
However, despite several attempts using different input files from different samples, both 
low and high concentration samples showed the same peaks with exactly the same 
intensities. This suggested that GM2MS is probably only applicable for LC/MS data 
currently. Both MetAlign and TagFinder offer a direct total processing function, allowing 
automated complete processing of chromatographic peaks if the parameters are optimized 
and confirmed. As for MZmine, it provides an advantage of graphical visualization of the 
chromatograms, which can be used for optimizing parameter settings. For the processing 
of 106 files of approximately 100 Mb each, MZmine requires a Java memory of 20 Gb to 
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complete all the steps listed in methods section 3.2.3.7 (CHAPTER 3) Details of the 
comparison on the user-friendliness of the software packages are listed in Table 10. 
 
Table 10. Comparison on user-friendliness of the three publicly available software 
 MetAlign MZmine TagFinder 
 
Processing time  10 h 30 min 21 h 20 min NA 










.smp (PEG files) 


























No Yes No 
Ability to export 
intermediate results 
Yes Yes No 
 
4.3.2 NMR metabolic profiling 
The representative 1H-NMR 600-MHz spectra acquired using BC and non-BC urine 
samples are shown in Figure 20. From visual inspection of these spectra, it was difficult 
to locate NMR spectral regions which were consistently present or absent in BC 
compared to the non-BC group. Therefore, chemometric data analysis was carried out on 
PQN normalized and binned data obtained from NMR analysis in the same fashion as the 
GC/TOFMS data analysis. Similarly, QC samples were also utilized to validate the 
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overall analytical performance. For PCA analysis, the data were reduced to principal 
components, that described maximum variation within the data. PCA scores revealed that 
three observations belonging to BC group and one observations belonging to non-BC 
groups as severe outliers as their DModX values were more than twice the critical value. 
All the other observations were below the DModX critical value. Upon further 
investigation, we confirmed that three BC samples being identified as outliers were 
possibly due to gross haematuria in two patients and improper collection of urine sample 
after intravenous urogram (IVU) in the another patient. Subsequent to removal of the 
outliers, OPLS-DA model was calculated based on sixteen BC and thirty-two non-BC 
urine samples. The OPLS-DA model contained two latent variables, showing the 
performance statistics of R2X = 0.210, R2Y = 0.561 and Q2 (cumulative) = 0.222. 
Although there was some overlap between the two sample classes, clear separation trend 
between the two groups was evident in the OPLS-DA model (Figure 21). Loadings, 
regression coefficients and VIPs revealed chemical shift regions that separated the two 
classes. The observed changes in endogenous metabolites in urine samples are 
summarized in Table 11. Urinary concentrations of lactate, lysine, glutamic acid, 
pyruvate, phenylacetate, O-acetylcarnitine and unidentified metabolites (δ 2.04 and 2.12 
ppm) were higher in BC patients. In non-BC subjects, urinary concentrations of citrate, 
creatinine, malonate, trimethylamine N-oxide (TMAO), glycolate, hippurate, unknown 





Figure 20. Representative normalized 1H-NMR 600-MHz spectra of urine samples 
obtained from (A) BC and (B) non-BC subjects. 3-HB, 3-hydroxybutyrate; Lac, lactate; 
Ala, alanine; Lys, lysine; Pyr, pyruvate; Cit, citrate; Crt, creatinine; TMAO, 
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Figure 21. OPLS-DA scores plot showing classification of (A) BC and non-BC and (B) 









































Table 11. Marker metabolites differentiating bladder cancer (BC) and non-BC subjects 
Metabolites δ1H BC non-BC p-value 
Lactate 1.32 ↑ ↓ < 0.01 
Lysine 1.72 ↑ ↓ < 0.05 
 1.87    
 1.91    
 3.02    
Glutamic acid 2.28 ↑ ↓ < 0.01 
Pyruvate 2.36 ↑ ↓ > 0.05 
Citrate 2.54 ↓ ↑ < 0.05 
 2.74    
Creatinine 3.04 ↓ ↑ < 0.05 
 4.04    
Malonate 3.18 ↓ ↑ > 0.05 
 5.69    
Trimethylamine N-oxide 3.25 ↓ ↑ > 0.05 
Glycolate 3.94 ↓ ↑ < 0.01 
Hippurate 3.96 ↓ ↑ < 0.05 
 7.54    
 7.63    
 7.82    
 8.52    
 3.24    
Phenylacetate 7.36 ↑ ↓ < 0.01 
 7.42    
O-Acetylcarnitine 2.12 ↑ ↓ < 0.01 
Unknown metabolites 2.04 ↑ ↓  
 2.12 ↑ ↓  
 3.44 ↓ ↑  
 3.68 ↓ ↑  
 3.76 ↓ ↑  
 4.20 ↓ ↑  




4.3.3 GC/TOFMS and NMR comparison 
Sample preparation for urine analysis using GC/TOFMS was relatively time consuming 
and involved several steps compared to that of NMR. Moreover, sample analysis 
throughput was significantly higher for NMR in comparison to GC/TOFMS (~15 mins 
and ~35 mins, respectively). However, assignment of putative metabolite identities in 
GC/TOFMS analysis was complete in fraction of time required for NMR data due to 
availability of EI spectral libraries. Fully automated NMR spectral assignment was 
attempted with Chenomx custom library built using a set of commonly found metabolites 
in urine detected by NMR. However, automatic assignment yielded overfitted data. 
Therefore, NMR assignments required considerable amount of manual interpretation for 
assignment confirmation. NMR spectral assignment yielded approximately one fourth of 
metabolites identified by GC/TOFMS (approximately, 40 and 200, respectively). The 4-
fold difference in the number of metabolites identified by GC/TOFMS and NMR datasets 
can be attributed to both fundamental differences in the two technologies and their 
associated libraries. A portion of urine metabolites in NMR spectra remained unassigned 
due to spectral overlap and Chenomx metabolite library limitation. In contrast, the gas 
chromatographic separation prior to MS detection and deconvolution of peaks simplified 
compound identification in GC/TOFMS data analysis. While there are challenges 
associated with RT variations, good RT precision with RT deviation less than 2 sec was 
observed in our study. However, RT shifts observed between different batches of samples 
may be inevitable due to changes in column performance [286]. Several RT alignment 
software packages were investigated in our study for automatic RT alignment. However, 
none of them were found to be as accurate as manual processing with regards to RT 
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alignment (Section 4.3.1.5, page no. 111). On the other hand, NMR is relatively robust in 
terms of reproducibility. While chromatography coupled NMR instruments are also 
commercially available such as LC-NMR [61], these instruments are not standard 
laboratory equipments. In the absence of access to specialize LC-NMR instrument, one 
can conduct two-dimensional experiments to aid in compound assignment. However, this 
approach requires significant investment in both instrument time and data analysis time 
[303]. Metabolites such as citric acid, glycine, glutamine, creatine, succinate, sugars and 
amino acids were detected by both the analytical platforms. However, several metabolites 
were uniquely detected only by GC/TOFMS (e.g. fatty acids such as heptadecanoic acid 
and fatty alcohols such as decanol) and NMR (such as hypoxanthine, histidine and 
guanidoacetate). 
 
Particularly in urinary metabolic profiling of BC patients, GC/TOFMS showed some 
advantages compared to that of NMR. Outliers detected in NMR data correlated to 
hematuria in patients. Since, hematuria is a common symptom for BC [33,304,305], it 
may pose some interference in identifying BC patient from non-BC subjects with 
hematuria. Although, performance statistics of OPLS-DA models obtained from both the 
analytical platforms were comparable, some overlap between BC and non-BC groups was 
observed the in OPLS-DA scores plot obtained from NMR analysis (Figure 21). 
Moreover, there was no trend or clustering related to grade and stage of BC patients as 
observed in NMR analysis. In contrast, clear clustering of BC patients according to stage 
and grade of tumors could be observed in OPLS-DA scores plots (Figure 18) obtained 
from GC/TOFMS analysis. Several reasons can be attributed this observation. Firstly, the 
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number of metabolites detected by NMR was relatively lower, therefore marker 
metabolites related to stage and grade of bladder tumors may not be detected by NMR. 
Secondly, it is possible that some the markers related to stage and grade of BC could be 
masked by the high concentration metabolites. From Table 8 and Table 11, it is observed 
that except for citric acid, marker metabolites identified by both the analytical 
technologies were distinct. Upon checking the common metabolites (lactate, glutamic 
acid, creatinine, malonate, phenylacetate and glycerol) detected by GC/TOFMS and 
NMR the up- or down-regulation of metabolites correlated among the two techniques. 
 
4.4 Conclusions 
In conclusion, our findings clearly demonstrated the potential of urine metabonomics to 
discriminate BC patients from non-BC individuals. This study indicated that urinary 
metabolic profiling using GC/TOFMS or NMR in conjunction with chemometric data 
analysis may be explored to detect human BC.  In addition, GC/TOFMS-based urinary 
metabonomics platform may aid in classification of bladder tumors. 
 
In the metabonomics analysis, it is paramount to detect as many metabolites as possible 
to increase the coverage of metabolome. Application of novel technologies such as 
GC×GC/TOFMS in urinary metabolic profiling need to be investigated. Therefore, 
metabolic profiling using GC×GC/TOFMS for in vitro and clinical samples is 
investigated additionally.  
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CHAPTER 5 : Application of GC×GC/TOFMS for in vitro and clinical 
characterization of BC 
 
5.1 Introduction  
Comprehensive two dimensional gas chromatography time-of-flight mass spectrometry 
(GC×GC/TOFMS) is a maturing technique noted for its ability to analyze complex 
mixtures and has been successfully applied in metabolomic investigations [301,306-309]. 
GC×GC/TOFMS is superior in terms of chromatographic peak resolution when 
compared to conventional gas chromatographic techniques [286,301,308]. In a GC×GC 
system, analytes eluting from the first column, over a defined time window are focused 
and released (via a process termed modulation) onto a second column where further 
separation is achieved. Typically, a non polar column is selected as the first column and a 
relatively polar column as the second column [301,308]. This configuration achieves 
orthogonality of retention on the two columns and allows greater resolution of 
metabolites in complex matrices. Additionally, the fast spectral acquisition rate (up to 
500 Hz) of TOFMS enables deconvolution of the mass spectra of closely eluting peaks if 
the spectra are sufficiently distinct. The ability to deconvolute the mass spectra robustly 
and accurately is paramount in the analysis of biological matrices. The principles and 
instrumentation of comprehensive two-dimensional gas chromatography are presented in 
greater details in the review papers by Cortes et al. and Ong et al. [310,311]. Application 
of GC×GC/TOFMS in the urinary metabolic profiling of BC would further enhance the 
metabolic space and enable the discovery of novel biomarkers. In this chapter, the 
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application of GC×GC/TOFMS was investigated for the in vitro characterization and 
urinary metabolic profiling of BC. 
 
5.1.1 In vitro characterization of BC 
While clinical cancer metabonomics appear to be a direct approach to discover 
biomarkers related to cancer biology, many confounding factors such as age, gender, diet, 
gut microbiome, pathology, and pharmacological interventions may complicate the 
analysis and mask the important cancer-derived metabolic fluxes.  Recently, profiling of 
extracellular metabolites has been recognized as a complementary tool for the 
physiological characterization of microorganisms and cells [312-314]. The strategy of 
analyzing the phenotypes of cells or tissues by profiling the metabolites that they excrete 
or fail to take up from their surroundings is defined as metabolic footprinting or 
exometabolomics [312]. On the other hand, analyzing intracellular metabolites is 
commonly referred to metabolic fingerprinting [315]. Metabolic footprinting presents 
several advantages compared to metabolic fingerprinting. As the intracellular metabolism 
is dynamic and the turnover rate of most metabolites is extremely fast, ranging from 
milliseconds to minutes, metabolic fingerprinting demands a rapid quenching of cellular 
metabolism followed by an effective separation of intra- and extracellular metabolites 
[316]. These experimental requirements impose technical difficulties and may result in 
misinterpretation of the metabolic fluxes. Secondly, there are several biochemical 
processes that are specifically related to the extracellular media, such as the degradation 
of complex substrates, and these can be assessed only by measuring the degradation 




Hence, metabolic footprinting may provide complementary information on the 
perturbations of metabolites that can be used to interpret the in vivo metabolomic 
observations. The aim of this study was to apply GC×GC/TOFMS-based metabolomics 
for the metabolic footprinting of a pair of immortalized human uroepithelial cells, 
nontumorigenic HUC-1 and tumorigenic HUC T-2. As these cells share the same 
genome, their differential metabolic phenotypes are related to the transformation of the 
normal urothelial cells to the tumorigenic cells via exposure to polycyclic hydrocarbon 
chemical carcinogen, 3-methylcholanthrene (MCA).  Since the exposure to polycyclic 
hydrocarbon from tobacco smoke has been linked to the development of several cancers 
including BC; the in vitro biomarkers arising from the metabolic footprinting of HUC-1 
and HUC T-2 may facilitate the mechanistic understanding of the carcinogenesis of BC.  
 
5.1.2 Urinary metabonomics of BC 
In the CHAPTER 4, the application of GC/TOFMS and NMR for the noninvasive 
diagnosis of BC was presented. Based on the results, it was inferred that gas 
chromatography based metabonomics platform holds the potential to diagnose BC and at 
the same time provides information on the classification of bladder tumors. In 
comparison to GC/TOFMS, GC×GC/TOFMS offers several advantages [301,309,318]. 
We therefore extended GC/TOFMS urinary metabonomic analysis of BC to 
GC×GC/TOFMS analysis. In the second part of this chapter, GC×GC/TOFMS was 
applied to examine its potential in clinical diagnosis of human BC.  
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5.1.3 Aims of current study 
The main aim of this chapter was to explore GC×GC/TOFMS in in vitro and clinical 
characterization of BC.  The specific objectives of this chapter are as shown below.  
• Application of GC×GC/TOFMS-based metabolic footprinting to characterize the 
in vitro molecular changes associated with BC using nontumorigenic and 
tumorigenic human urothelial cells. 
• Application of GC×GC/TOFMS in urinary metabolic profiling of BC. 
• Evaluation of the advantages and drawbacks of GC×GC/TOFMS as compared to 
single-dimension GC/MS and NMR in the global profiling of urinary metabolites. 
 
5.2 Experimental 
5.2.1 Chemicals  
MSTFA with 1 % TMCS and MOX reagent were purchased from Pierce (Rockford, 
IL,USA). Alkane standard mixture (C10 to C40), and sodium sulfate (anhydrous) were 
obtained from Sigma-Aldrich (St. Louis MO, USA). SV-HUC-1 (CRL-9520) and MC-
SV-HUC T-2 (CRL-9519) cells were obtained from American Type Culture Collection 
(ATCC) (Manassas, VA, USA). Ham’s F-12 nutrient mixture powder, 2mM L-glutamine, 
50 units penicillin/50 µg streptomycin per mL were purchased from Invitrogen 




5.2.2 In vitro characterization of BC 
5.2.2.1 Cell culture of urothelial cells  
Both HUC-1 and HUC T-2 cells were cultured on 24 well plates at 1 × 105 cell density 
per well in 1 mL of Ham’s F-12 media (10 % FBS, 2 mM  L-glutamine, 50 units 
penicillin/50 µg streptomycin per mL) and incubated at 37°C in the presence of 5% CO2. 
After 24 h, the media in each plate was removed and replaced with 1 mL of fresh media. 
Each sample was incubated further for 24 h. The media obtained from HUC-1 and HUC 
T-2 cells were subsequently harvested and snapped frozen using liquid nitrogen. Three 
replicates of Ham’s F-12 media without cells which were used as controls and treated in 
the same way as HUC-1 and HUC T-2 cell culture media samples. All the samples were 
stored at -80oC until further analysis.  
 
5.2.2.2 Monitoring cell proliferation 
1x104 each of the HUC-1 and HUC T-2 cells were plated separately in quadruplicates in 
a 96-well plate and incubated at 37°C with 5% CO2 for 24 and 48 h. CellTiter 96® 
AQueous One Solution Cell Proliferation Assay (Promega, USA) was used to measure 
the viability of HUC-1 and HUC T-2 after 24 and 48 h. Briefly, 20 µL of the CellTiter 
96® AQueous One Solution Reagent was added to each well containing 100 µL of culture 
medium and incubated in the dark at 37°C for 2 h. The absorbance of each well was 
measured at 490 nm using GENios Pro™ microplate reader (Tecan, Switzerland). To 
confirm the cell proliferation rate, 1x105 cells/well were plated into a 6 well plate and the 
cell number per well was enumerated after 24 and 48 h using a haemocytometer. 
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5.2.3 Urinary metabolic profiling 
The overall workflow of metabolic profiling approach utilized in this study is similar to 
the workflow used for GC/TOFMS-based metabonomic analysis (CHAPTER 4, Figure 
15). 
 
5.2.3.1 Clinical population 
The clinicopathological data of BC and non-BC groups are summarized in Table 12.  
 
Table 12. Summary of clinicopathogical characteristics of bladder cancer (BC) patients 
and non-BC subjects.  
Characteristics BC Patients Non-BC controls 
No. of subjects 38 61 
Age (mean/SD) 68.3 ± 10.9 60.5 ± 12.7 
Gender   
Male 
 
32 (84.2 %) 36 (59.0 %) 
Female 6 (15.8 %) 23 (41.0 %) 
Cancer stage and gradea   
PUNLMP 4 (10.5 %)  
Ta-LG 9 (23.7 %)  
Ta-HG 4 (10.5 %)  
T1-LG 1 (2.6 %)  
T1-HG 9 (23.7 %)  
CIS/T1-HG 4 (10.5 %) 
 
 
Others 7 (18.4 %)  
Citizenship  
Chinese 28 (73.7 %) 46 (75.4 %) 
Indian 6 (15.8 %) 11 (18.0 %) 
Othersb 4 (10.5 %) 4 (6.6 %) 
Smoking habit   
Non smokers 
 
12 (31.6%) 31 (50.8%) 
Ex-smokers 12 (31.6%) 4 (6.6 %) 
Smokers 10 (26.3 %) 8 (13.1 %) 
Information not available 4 (10.5 %) 18 (29.5 %) 
aTumors were classified according World Health Organization (WHO)/International Society of Urological 
Pathology (ISUP) classification criteria. Low grade and high grade are represented as LG and HG 
respectively.  bOther citizenships include Caucasian and Malaysian. Two non-BC patient samples which 




5.2.4 Sample preparation for GC×GC/TOFMS analysis 
Sample preparation of both cell culture media and urine samples are described in this 
section. All the culture media samples were thawed at room temperature (23 ± 3°C). 
Subsequently, 1.7 mL of methanol was added to 200 µL of each media sample. The 
mixture was vortex-mixed at high speed for 5 min, centrifuged subsequently for 10 min 
at 10000 × g at 4°C.  A 1.5 mL of each supernatant was then carefully separated and 
evaporated to dryness at 40°C under a gentle stream of nitrogen. 100 µL of toluene (dried 
over anhydrous sodium sulfate) was added to each dry residue, mixed for 1 min and dried 
again at 50oC under nitrogen. The dried metabolic extract was derivatized first with 50 
µL of methoxyamine (20 mg/mL) for 2 h at 60°C. Subsequently, 100 µL of MSTFA with 
1 % TCMS was added to the mixture and heated for 1 h at 60°C to form the TMS 
derivatives. TMS derivatives were cooled and 100 μL of supernatant was transferred into 
GC vial and subjected to GC×GC/TOFMS analysis. HUC-1, HUC T-2 and control 
samples were randomized to avoid analytical biasness.  
 
All the urine samples were prepared according to the sample preparation protocol 
described previously (CHAPTER 4, Section 4.2.3). Briefly, 200 µL of each urine samples 
was subjected to urea depletion using 100 U of urease enzyme. Subsequently, each urine 
sample was extracted using methanol, dried and subjected to methoximation followed by 





5.2.5 GC×GC/TOFMS analysis. 
A Pegasus 4D GC×GC/TOFMS (LecoCorp., St. Joseph, MI, USA) was utilized for the 
analysis. The instrument was equipped with an Agilent 7890 GC and Pegasus IV TOFMS 
(LecoCorp., St. Joseph, MI, USA) featuring a dual-stage, quad-jet thermal consumable 
free modulator (CFM) and an independently temperature-controlled secondary oven. 
CFM is a recently introduced modulator where the nitrogen gas is chilled by passing it 
through a coil immersed in a dewar of silicone oil. The silicone oil is chilled by the cold 
probe from a closed-loop immersion cooler (FTS, Stone Ridge, NY, USA) which was set 
at the temperature of -80°C. Helium was used as the carrier gas at 1.5 mL/min in 
corrected constant flow mode and the injector split ratio was set to 1:20. A 30 m × 250 
µm (i.d.) × 0.25 µm DB-1 (Agilent J&W Scientific, Folsom, CA)  and a 1.5 m × 100 µm 
(i.d.) × 0.100 µm Rxi®-17 (Restek Corp., Bellefonte, PA, USA) fused silica capillary 
columns were used as the primary and secondary columns, respectively. 
 
5.2.5.1 Cell culture media analysis 
Primary oven temperature was programmed at 70°C for 0.2 min, increased at 10°C/min 
to 270°C where it was held for 5 min. Secondary oven temperature was always 
maintained at 10°C higher than the primary oven temperature. The thermal modulator 
was set to 45°C higher relative to the primary oven. A modulation time of 2 s with hot 
pulse of 0.6 s was used. The injector, transfer line and ion source temperatures were 
maintained at 220, 200 and 250oC, respectively, throughout each analysis. Injector split 
ratio was set to 1:20. The MS was operated in EI mode (70 eV) at the detector voltage of 
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1650 V. Data acquisition was performed in the full scan mode from m/z 40 to 600 with an 
acquisition rate of 100 Hz. 
 
5.2.5.2 Urine samples analysis 
Primary oven temperature was programmed at 70°C for 0.2 min, increased at 10°C/min 
to 270°C where it was held for 7.5 min. Secondary oven temperature was always 
maintained at 10°C higher than the primary oven temperature. The thermal modulator 
was set to 20°C higher relative to the primary oven. A modulation time of 3.5 sec with 
hot pulse of 0.8 sec was used. The injector, transfer line and ion source temperatures were 
maintained at 220, 200 and 250oC, respectively, throughout each analysis. Injector split 
ratio was set to 1:50. The MS was operated in EI mode (70 eV) at the detector voltage of 
1600 V. Data acquisition was performed in the full scan mode from m/z 40 to 600 with an 
acquisition rate of 100 Hz. 
 
5.2.6 Data preprocessing 
Each chromatogram obtained from GC×GC/TOFMS analysis of either cell culture 
supernatants or urine samples were processed for baseline correction, smoothing, noise 
reduction, deconvolution, library matching and area calculation using the ChromaTOF 
software (version 4.21, LecoCorp.). Area of each peak was calculated using the unique 
mass of each derivatized metabolite. Only peaks with signal to noise ratio S/N greater 
than 100 and 200 for media and urine samples were utilized, respectively, for further 
analysis. All GC×GC/TOFMS detected peaks were identified by comparing both the MS 
spectra and the RI with those available in the NIST mass spectral library (Wiley registry) 
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and our in-house spectral library. Subsequently, the Statistical Compare feature of 
ChromaTOF software was utilized to generate data table in which all the peak 
information from different chromatograms were aligned. Statistical Compare utilized a 
mass spectral match criterion of 60% when aligning the multi-dimensional peak data 
comprising sample names, metabolites, RT, mass and integrated peak area. Quantitation 
mass for each peak in the data table was selected from the unique mass that was common 
to all matching peaks within the retention window (2 times of peak width). Subsequently, 
this unique mass was used to calculate the peak areas from each chromatogram. 
Similarly, the best quality peak from matching peaks was then selected whose name was 
used as the analyte name in the data table. 
 
The resulting data table comprised observations (samples and controls) and variables 
(peak intensities) aligned according to their RT and unique mass pair as identifiers. The 
data table was exported as a .csv file and was processed subsequently using in-house 
Matlab (Mathworks, Natick, MA, USA) scripts to retain only observations (sample 
identities) and variables (area values) while removing other details which were not 
necessary for the chemometric analysis. In addition, peaks which were not present in at 
least 50% of the samples were removed from the data table. Total area normalization was 
performed to correct minor variations due to sample preparation and analysis.  
 
5.2.6.1 Chemometric data analysis 
Normalized data obtained from media and urine analyses were exported to SIMCA-P 
(version 12.0, Umetrics, Umeå, Sweden) to perform PCA where grouping trends and 
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outliers were observed. Prior to PCA analysis, GC×GC/TOFMS data was mean-centered 
and unit variance-scaled. DModX plot was calculated to check for any outliers. After 
initial overview of the GC×GC/TOFMS data using PCA, the data were subjected to PLS-
DA where a model was built and utilized to identify marker metabolites that accounted 
for the differentiation of BC from non-BC phenotypes. The chemical identities of the 
marker metabolites were further confirmed by cross-referencing with the Golm 
metabolite library [319] and the HMDB database [320]. In addition, metabolic pathway 
interpretation of marker metabolites was performed using the KEGG database [321]. 
Complete data analysis workflow is shown in Figure 22. 
 
5.2.6.1.1 External validation 
To evaluate the predictive ability of the OPLS-DA model for new samples, an external 
sample set containing seven BC patients and ten non-BC subjects was used. The clinical 










5.3 Results and discussion 
5.3.1 GC×GC/TOFMS analysis of media and urine samples 
Representative GC×GC/TOFMS chromatograms obtained from the analysis of cell 
culture supernatant of urothelial cells and a urine sample are shown in Figure 23. 
GC×GC/TOFMS analysis showed increased peak capacity, improved analyte 
detectability, and enhanced resolution. Visual inspection of chromatograms to identify 
major difference between the two sample groups was performed using several strategies 
proposed by Shellie et al. [309]. The derivatized metabolites were not only separated 
chromatographically, but also via deconvolution of the mass spectra. The MS spectra of 
most of the TMS derivatives were dominated by 73 and 147 mass ions while the 
characteristic ions of each metabolite were low in abundance. This resulted in poor 
accuracies in deconvolution and peak area integration of co-eluting peaks [322] . 
Therefore, the background TMS ions (m/z 73, and 147) were specified in the data 
processing method of the ChromaTOF software for two purposes. Firstly, the software 
performed two levels of peak identification when comparing the peak MS spectra with 
library spectra, one with the specified masses and one without the masses. Both matches 
must pass the threshold for assigning the compound name. Secondly, while selecting a 
mass for peak area integration, the specified TMS derivative masses were given lower 
preference by using higher S/N thresholds. When derivative masses were specified in the 
data processing method, we observed that the analyte names were more accurately 




Figure 23. Typical GC×GC/TOFMS total ion chromatograms (TICs) represented as 









5.3.2 Data preprocessing  
Subsequent to deconvolution, an average of 450 and 930 derivatized compounds were 
detected in each chromatogram in media and urine respectively. Although, a large 
number of analytes were detected, a number of them belonged to artifacts derivatizing 
reagent or column bleeding. One key advantage of GC×GC/TOFMS was that the artifacts 
were chromatographically separated from the metabolites due to the second dimension 
separation. To consistently remove these artifacts from all the chromatograms, the 
classification feature of ChromaTOF software was utilized where chromatographic 
regions belonging to artifacts were demarcated. Such artifacts or chromatographic noise, 
if not removed, would significantly disturb the subsequent chemometric data analysis 
[308].  
 
Subsequent to the removal of artifacts, peak information belonging to different 
chromatograms was aligned in a data table. Due to the varied number of peaks and 
inconsistencies in assignment of compound name, aligning peaks in a suitable matrix 
format was particularly challenging. A few strategies had been reported to address this 
challenge [301,309,323]. However, these strategies typically required manual data 
processing in conjunction with existing instrument software [309] or development of new 
software [323]. This challenge was suitably addressed in our study by using the Statistical 
Compare feature of the ChromaTOF software. Although, Statistical Compare accurately 
aligned a large percentage of data, in few instances, we observed that some of the 
analytes were represented multiple times in the data table. However, these peaks could be 
identified easily because of the similar analyte names and assigned quantitation masses. 
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Multiply-represented peaks were counter-checked in the raw data, suitably corrected and 
finally, only a single analyte name was retained in the data table for each metabolite. 
Subsequent to alignment of peak information, the final data table comprised 286 collated 
from the analysis of HUC-1 and HUC T-2 cells. On the other hand, 533 peaks were 
collated from the analysis of BC and non-BC urine analysis. Results obtained from the 
analysis of cell culture and urine samples are presented in details in the following 
sections.  
 
5.3.3 In vitro characterization of BC 
Cancer and normal cell derived from different sources, may have differences in their 
metabolic phenotypes unrelated to tumorigenicity of the cells but rather reflective of their 
inherent genetic differences. Therefore to compare the metabolic profiles of normal and 
tumor cells, it is important to use cells derived from the same origin. The HUC-1 and 
HUC T-2 cells obtained from ATCC were originally produced by immortalizing 
uroepithelial cells with the SV-40 virus to give HUC-1 cells which were further treated 
with a chemical carcinogen, 3-methylcholanthrene (MCA), to produce HUC T-2 cells. 
HUC-1 is nontumorigenic and has a balanced chromosome composition, while HUC T-2 
is tumorigenic and aneuploid. As the rate at which cells proliferate will affect the quantity 
of metabolic products, the growth rates of both cell lines were determined using the MTS 
assay. As shown in Figure 24A, the proliferation rates of both cells lines after 24 and 48 h 
were similar (p > 0.05). Therefore any differences observed in the metabolic footprints 
were possibly related to metabolic perturbations. To further confirm our observation we 
enumerated the cells at 24 and 48 h of culture. As shown in Figure 24B, the cell numbers 
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were not statistically significant (p > 0.3) at both time points. These data corroborated 
with our earlier findings and confirmed that both cell lines were proliferating at similar 
rates.  
 















































5.3.3.1 Chemometric data analysis.  
Chemometric data analysis was performed to generate interpretable models for the 
complex inter-correlation of cell culture data [324]. PCA data were reduced to 2 principal 
components that described maximum variation within the data. PCA scores revealed 
moderate outliers belonging to the respective HUC-1 and HUC T-2 groups as these 
observations were lying outside the 95% confidence ellipse (Hotelling T2). While 
DModX values of these two observations were below the critical value, they were 
excluded from further chemometric data analysis. Clear grouping trends of HUC-1 and 
HUC T-2 was observed in the PCA scores plot with minor overlap. Performance statistics 
of PCA model showed R2X = 0.325 and Q2 (cumulative) = 0.118. PCA was followed by 
PLS-DA that aided our identification of a list of potential biomarkers which were 
statistically significant between the two cell types [274,275]. The PLS-DA model 
calculated based on 22 observations contained three latent variables, showing the 
performance statistics of R2X = 0.418, R2Y = 0.977 and Q2 (cumulative) = 0.852 (Figure 
25). Loadings, regression coefficients and variable importance plots (VIPs) revealed 
variables (metabolites) that separated the two classes. Totally, 81 metabolites showed a 
VIP > 1 suggesting that the overall metabolic profiles of the two cell lines were distinctly 
different. Using a VIP cut-off of 1.5 and p-value (Welch t-test) less than 0.05, 20 
metabolites were identified as significantly different between two groups. These marker 




Figure 25. PLS-DA scores plots obtained from the analysis of culture supernatant 
analysis of nontumorigenic (HUC-1) and tumorigenic (HUC T-2) cells 
 
 
5.3.3.2 Metabolic pathway evaluation.  
Both KEGG and HMDB databases were explored to connect the differential metabolites 
observed to metabolic pathways. As shown in Table 13, metabolic perturbations were 
mainly detected in the area of propanoate metabolism and other pathways related to 
energy metabolism. A number of interesting observations could be inferred from the 
metabolic fluxes. Firstly, glycine was found to be at higher concentrations while 3-
phosphoglyceric acid at lower concentrations in cancer cell media compared to that of 
normal cells. Glycine is formed from the glycolytic intermediate 3-phosphoglycerate and 




















serine. Increased glycine coupled to elevated 3-phosphoglycerate suggested possible 
upregulation of hypoxia-inducible factor-1(HIF-1) signaling pathway. Higher expression 
of HIF-1 correlates to the upregulation of HIF-1 signalling pathway observed clinically in 
BC patients [325,326]. HIF-1 is also upregulated in several cancer cell types, resulting in 
the increased expression of proteins involved in a range of metabolic pathways and 
increased rate of glycolysis [45]. Increased glycolysis was evident in our study based on 
the higher amount (~4 fold, p<0.0005) of glucose consumption observed in cancer HUC 
T-2 cells as compared to normal HUC-1 cells. However, increased glucose consumption 
could also be due to increased expression of glucose transporters and Type II hexokinase 
which are commonly observed in cancer cells [327,328]. In addition, higher consumption 
of 1-phenyl-ethylamine and gluconic acid/galactitol in cancer cells might suggest the 
upregulated pentose phosphate pathway in BC cells as compared to their non-malignant 
counterpart. Recently, higher pentose phosphate pathway activity was also observed 
when the metabolic phenotypes of a breast cancer cell line were compared with the non-




Table 13. Marker metabolites identified from metabolic footprinting of HUC-1 and HUC 
T-2 cells 





1. Malic acidc,d  1487 1.6 < 0.000005 84.1 
2. 1-amino-cyclopropane-1-carboxylic acidd   1356 -1.4 < 0.00005 65.7 
3. 3-Methyl-2-oxo-butanoic acidc  1205 1.8 < 0.00005 70.1 
4. Propanoic acid derivative 1379 1.6 < 0.0001 - 
5. Glycerol-2-phosphatec,d  1650 -1.5 < 0.0005 84.5 
6. D-Glucose c,d   1924 -4.2 < 0.0005 88 
7. 3-Phosphoglyceric acid c,d   1810 -1.6 < 0.0005 72.5 
8. Sugar alcohol 1845 -5.0 < 0.0005 - 
9. Unknown  1699 -4.2 < 0.0005 - 
10. Glucuronic acidc  2011 -3.8 < 0.001 70.0 
11. Mannosec,d   1883 1.4 < 0.001 84.0 
12. Sorbosec,d   1873 -3.6 < 0.001 89.0 
13. Glycinec,d   1309 1.3 < 0.005 88.0 
14. Erythrosec,d   1461 -2.0 < 0.005 74.8 
15. 1-phenyl-ethylamine  1366 -1.4 < 0.00005 68.8 
16. Malonic acid ester 1719 1.3 < 0.01 66.2 
17. Benzyl alcohol  1129 -3.1 < 0.01 90.2 
18. Myo-inositolc,d   2088 -1.2 < 0.05 80.9 
19. Gluconic acid c,d   1993 -3.1 < 0.05 75.6 
20. Long chain fatty acid derivative 1149 1.4 < 0.05 - 
aPositive value indicates higher concentrations in cancer (HUC T-2) and negative values 
indicate higher concentrations in normal (HUC-1) cell culture supernatants. bSimilarity 
index (S.I.) shows percentage match between the mass spectra of identified compounds 
compared to the standard library spectrum. cRetention Index (RI) matched with HMDB 
database, dRI matched with Golms database  
 
5.3.4 Urinary metabonomics of BC 
Analytical performance was validated using PCA on QC samples using the similar 
strategies utilized for validation of GC/TOFMS analysis (CHAPTER 4, Section 4.3.1.1). 
Close clustering of QC samples was observed in PCA scores plot suggesting analytical 
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precision with regards to several parameters including modulation cycle and RT and 
sample preparation precision.  
 
We used the normalized data set with 99 observations (BC and non-BC samples) and 533 
variables (peak areas) as an input for PCA. All variables were mean-centred and UV-
scaled. Three samples belonging to non-BC group were identified as outliers from the 
PCA scores plot and DModX plot. The outliers were excluded from further data analysis. 
PCA scores plot revealed grouping trend of BC and non-BC observations. Subsequently, 
the data was subjected to PLS-DA and OPLS-DA to build predictive models and to 
identify potential biomarkers associated with BC. The PLS-DA model contained three 
latent variables, showing the performance statistics of R2X = 0.256, R2Y = 0.818 and 
Q2Y (cumulative) = 0.426. The OPLS-DA model contained four latent variables, 
showing the performance statistics of R2X = 0.278, R2Y = 0.904 and Q2Y (cumulative) = 
0.398. The X-score plot of t1 and t2 of the OPLS-DA model (Figure 26A) demonstrated 
accurate classification of BC patients and non-BC subjects with 100% sensitivity and 
specificity. While urine cytology offered 100% specificity, its sensitivity was determined 




Figure 26. (A) OPLS-DA scores plot obtained from the GC×GC/TOFMS based urine analysis of bladder cancer (BC) and non-BC (H) 
subjects. (B) Validation plot obtained from 100 permutation tests. (C) Receiver operating characteristic (ROC) calculated using cross 
validated Y-predicted values of PLS-DA model and (D) T-predicted scatter plot of OPLS-DA model obtained from prediction of 
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5.3.4.1 Selection of marker metabolites 
OPLS-DA loadings and VIPs indicated several discriminatory metabolites that 
differentiated BC and non-BC phenotypes. Totally, 83 discriminatory variables had a VIP 
value greater than one. Unpaired t test and Welch’s t test were employed to select 
metabolites that dominated the separation between the BC and non-BC groups (Table 
14). 
 
5.3.4.2 Model validation 
The OPLS-DA model was validated using permutation tests and ROC analysis of the 
cross validated Y-predicted values. The validation plot (Figure 26B) strongly indicated 
that the original PLS-DA model was valid as Q2 regression showed a negative intercept 
and R2 values of permuted models were lower than the R2 value of the original PLS-DA 
model. In addition, area under the ROC curve using cross validated Y-predicted values 
resulted in a value of 0.88, confirming the validity of the model.  
 
5.3.4.3 External validation 
The OPLS-DA model correctly predicted the entire non-BC subjects (10 out of 10) and 5 
out of 7 BC patient urine samples showing the sensitivity and specificity of 71% and 




Table 14. Differentiating marker metabolites between bladder cancer (BC) and non-BC 
subjects by GC×GCTOFMS based urinary metabonomic profiling.  
S.No. R.Ia Metabolite Identity Fold Changeb  t-test Welch t-test 
1 1055.9 Lactic acid 1.7 <0.05 <0.05 
2 1065.1 Hydroxybutyric acid 1.2 <0.05 <0.05 
3 1111.9 3,4-Dihydroxyphenylpyruvate 1.4 <0.05 <0.05 
4 1130.1 Unknown  1.3 <0.01 <0.01 
5 1139.8 p-Cresol 1.7 <0.005 <0.01 
6 1162.7 2-Aminoisobutyric acid 1.5 <0.01 <0.01 
7 1186.7 2-Pentadecanol 1.7 <0.005 <0.01 
8 1213.6 Unknown 2.5 <0.005 <0.05 
9 1240.3 Erythro-Pentonic acid 2.1 <0.05 <0.05 
10 1267 Ethylmalonic acid 1.6 <0.05 <0.05 
11 1368.9 2,3,4,5-Tetrahydroxypentanoic 
acid-1,4-lactone 
1.7 <0.05 <0.05 
12 1386.8 2-Hydroxymalonic acid 1.7 <0.05 <0.05 
13 1435.1 Pinene 0.9 <0.2 <0.1 
14 1450.4 Itaconic acid  1.8 <0.00005 <0.0005 
15 1495.2 Adipic acid 1.4 <0.05 <0.1 
16 1520 Levulinic acid enol  0.4 <0.01 <0.005 
17 1530.2 3-Methyladipic acid 1.4 0.02 0.04 
18 1544.8 Erythritol 1.2 <0.05 <0.01 
19 1545 2-Hydroxyglutaric acid 0.7 <0.01 <0.01 
20 1565.1 Unknown 1.7 <0.005 <0.01 
21 1580 Sebacic acid 0.7 <0.05 <0.05 
22 1600 Ethyl tartrate 0.4 <0.05 <0.01 
23 1605.9 Anthranilic acid 1.7 <0.001 <0.005 
24 1692 3-Hydroxysebacic acid 2.2 <0.005 <0.01 
25 1708.5 Cyclopentane-1,2-diamine 1.8 <0.00005 <0.0005 
26 1708.7 4-Methoxycinnamic acid 1.6 <0.0005 <0.005 
27 1756.9 Sugar (Unknown) 0.4 <0.05 <0.05 
28 1882.8 Vanillylmandelic acid 1.3 <0.05 <0.05 
29 1905.7 Gluconic acid 0.5 <0.05 <0.05 
30 1912.1 Coumaric acid derivative 1.4 <0.01 <0.05 
31 1929.4 Talonic acid 1.3 <0.01 <0.05 
32 1988.2 Gluconic acid  1.3 <0.05 <0.05 
33 2006.6 Gluconic acid derivative 2.0 <0.05 <0.1 
34 2120.2 Heptadecanoic acid 1.3 <0.05 <0.05 
35 2447.9 Pseudo uridine  1.6 <0.1 <0.1 
36 1382.8 Dihydroxyacetone 0.7 <0.05 <0.05 
37 1680.0 N-acetyl-anthranilic acid 1.9 <0.0005 <0.005 
38 1627.5 2,5-Furandicarboxylic acid 0.5 <0.1 <0.05 
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39 1905.7 2-Butanedioic acid 0.6 <0.1 <0.05 
40 2798.9 Melibiose 1.3 <0.1 <0.1 
41 1745.8 Ribitol 0.6 <0.1 <0.05 
42 1535.4 Sumiki's acid 0.6 <0.2 <0.2 
43 2401.6 Uridine 1.2 <0.1 <0.1 
44 1805.7 Ribonic acid 0.5 <0.1 <0.05 
45 1288.0 Glycerol 0.7 <0.1 <0.05 
46 1841.0 Citric acid 0.8 <0.05 <0.05 
aRI: Retention Index. bValue less than 1 indicates higher concentrations in non-BC urine 
samples compared to BC and values greater than 1 indicate higher concentrations in BC 
compared to non-BC.  
 
5.3.4.4 Metabolic pathway evaluation.  
The OPLS-DA model revealed several marker metabolites related to BC (Table 14). 
Anthranilic acid and N-acetyl-anthranilic acid, both products of tryptophan metabolism 
were found in higher concentrations in BC patient urine. Several studies have indicated 
that tryptophan and its urinary metabolites are factors in urinary bladder carcinogenesis 
[330]. Since, most of the primary aromatic amino metabolites, structurally similar to 
known environmental human bladder carcinogens, are derived from tryptophan and are 
present in human urine, it was hypothesized that BC could result from a metabolic 
alteration manifested by an increased urinary concentration of certain tryptophan 
metabolites [330,331]. As some of the aromatic amines are oxidized by the process of N-
hydroxylation, similar processes might be involved in the oxidation of anthranilic acid 
giving rise to the corresponding hydroxylamine derivatives. These hydroxylamine 
derivatives are at present hypothetical, but by analogy with other aryl hydroxylamines, 
they might be carcinogenic. However, exact mechanism of tryptophan metabolites 




Interestingly, p-cresol, vanillylmandelic acid and 3,4-dihydroxyphenylpyruvate 
belonging to the tyrosine metabolic pathway were found to be present at higher 
concentrations in BC patient urine samples. p-Cresol is formed endogenously from 
metabolism of tyrosine by gut microflora [332]. Recently, it was shown that cresols are 
tumor promoters in rodents [333]. Altered tryptophan and tyrosine metabolism highlights 
that microbial metabolism of amino acids in gut microflora plays a significant role in the 
pathogenesis of BC. Lawrie et al. showed that saccharin which increases protein and 
amino acid substrate, when administered orally in rats resulted in the changes in 
metabolism of amino acids by the gut flora, leading to an increased formation of co-
carcinogens, cresol and indican derived from tyrosine and tryptophan metabolism, 
respectively [334]. This earlier finding is of interest since alteration of both tyrosine and 
tryptophan metabolism was also observed through urinary metabonomic analysis. 
Recently, vanillylmandelic acid is gaining increasing attention due to its potential to 
diagnose pheochromocytoma [335] and paraganglioma of the bladder [336]. Elevated 
vanillylmandelic acid in urine of BC patients was also consistent with the higher level of 
the metabolite in urine of patients with paraganglioma of the bladder [336,337]. It was 
observed that concentration of vanillylmandelic acid returns to normal in one year after 
complete removal of the tumor in paraganglioma patients [338]. 
 
From Table 14, it can be observed that metabolites of dicarboxylic acids namely 3-
hydroxysebacic acid, 3-methyladipic acid, adipic acid and sebacic acid were also 
significantly different in BC patients suggesting altered peroxisomal metabolism. The 
importance of peroxisomes in the metabolism of dicarboxylic acids has been 
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demonstrated in patients with Zellweger syndrome as urinary excretion of adipic acid, 
suberic acid and sebacic acid increases in these patients who have a complete lack of 
liver peroxisomes [339]. Similarly, 4-methoxycinnamic acid and coumaric acid both 
hydroxyl derivatives of cinnamic acid were found to be at higher levels in BC patient 
urine. In addition, the urinary levels of uridine and pseudouridine, endogenous 
metabolites for the synthesis of RNA, were found to be higher in BC compared to non-
BC urine reflecting the higher energetic state of the tumor. Furthermore, 2-
aminoisobutyric acid, catabolite of both DNA and RNA was found to be significantly 
higher in BC urine. In a large cohort study involving 192 BC patients, it was showed that 
pseudouridine and 2-aminoisobutyric acid were higher in BC patients and may be 
diagnostic for tumors in the upper urinary tract and in follow-up patients with bladder 
tumors [340]. High inter-subject variation in both metabolites was observed in the study. 
In addition, it was also noted that concentrations of pseudouridine and 2-aminoisobutyric 
acid increased only in some subgroup of BC patients. It is also important to emphasize 
that urinary 2-aminoisobutyric acid contributes to the graduation of malignancy, but is 
not valuable as a general screening procedure due to its high inter-subject variability 
[341].  
 
Profiling of these marker metabolites demonstrated the additional capability of 
metabonomics in the biochemical characterization of BC such as understanding the 
metabolic pathways involved in tumorogenesis. In addition, marker metabolites identified 
in our study and correlated with marker metabolites reported in earlier literatures. This 
demonstrated the strength of metabonomic analysis in capturing global metabolic 
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perturbations that were previously observed through several independent studies.  It can 
also be inferred that the increased predictive ability of the metabonomic platform could 
be a result of the synergetic predictive ability of each marker metabolite which 
individually may lack desirable sensitivity and specificity in detecting BC.  
 
5.3.4.5  Comparison of 1D versus 2D GC/TOFMS analysis 
In this section, a comparison between 1D GC/TOFMS and GC×GC/TOFMS analytical 
platforms in urinary metabolic profiling of BC is made to summarize the advantages and 
limitations of each analytical platform. Application of GC×GC/TOFMS for urinary 
metabolic profiling of BC offered several advantages. Firstly, the predictive ability of the 
OPLS-DA model based on GC/TOFMS analysis (Q2= 0.245) was significantly improved 
compared to that of model based on GC×GC/TOFMS data (Q2= 0.398). Secondly, 46 
marker metabolites were detected using GC×GC/TOFMS compared to 15 marker 
metabolites detected by GC/TOFMS. In addition, approximately 2 fold increase in the 
peak capacity and 5 to 7 fold increase in sensitivity were observed in GC×GC analysis 
compared to 1D GC analysis. It is also worth noting that artifact peaks arising from 
column bleed and derivatizing reagent were chromatographically separated in two 
dimensional GC analyses thereby enabling the automatic removal of these artifact peaks 
based on classification rules prior to chemometric data analysis. The number of 
modulation cycles in which a particular peak appears could be visualized using the sub-
peak display (Figure 27). In contrast, the identification of artifact peaks in GC/TOFMS 
demanded experience, knowledge and manual intervention. Although some of the artifact 
peaks were removed manually in GC/TOFMS analysis, it is likely that a large number of 
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artifact peaks could be still present in GC/TOFMS data. Effective removal of artifact 
peaks in GC×GC/TOFMS could possibly explain the increased predictive ability of its 
OPLS-DA model. Another contributing factor for increased predictive ability could be 
the increased sensitivity achieved by GC×GC/TOFMS which enabled detection of low 
abundant metabolites. It is important to note that analytical purity was significantly 
enhanced in addition to the increased sensitivity. Analytical purity refers to a combined 
feature of both chromatographic resolution and mass spectral deconvolution power. If the 
mass spectrum of a peak can be completely resolved (either chromatographically or by 
deconvolution) the analytical purity value equals zero. On the other hand, the value 
increases with amount of overlap in the mass spectra of the co-eluting compounds. As 
noted by Welthagen et al. [342], a compound peak may co-elute with other compounds 
yet it can be still pure if its spectrum contains unique features relative to co-eluting 
compounds. Therefore, it is more likely to achieve good analytical purity if the 
chromatographic resolution is enhanced as in the case of GC×GC/TOFMS. As expected, 
a larger number of peaks with lower analytical purity values (less than one) were detected 
in our GC×GC/TOFMS analysis. To perform a direct comparison between one and two 
dimensional GC, we used the QC samples. In QC samples, 84% of the peaks had an 
analytical purity value less than one in GC×GC/TOFMS analysis. In contrast, only 33% 
of the peaks had analytical purity value less than one when GC/TOFMS was used. For 
example, as shown in Figure 28A, adipic acid and malic acid co-eluted in GC/TOFMS 
analysis causing poor analytical purity. However, the same compounds peaks were 




Figure 27. Surface plot displaying sub-peaks obtained from GC×GC/TOFMS analysis of cell culture media sample. Artifact peaks are 






Figure 28. (A) GC/TOFMS chromatogram showing co-elution of adipic acid and malic 




Although, two dimensional GC offered several advantages, few limitations were noted. 
Since short and narrow bore columns are commonly used as second dimension columns 
in GC×GC analysis, column overloading was commonly observed [343]. Overloading of 
the secondary column was encountered in urine analysis when GC×GC/TOFMS was 
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adopted in our study. Therefore, the split ratio was increased to 50 to avoid column 
overloading by allowing less amount of derivatized sample to pass through the column. 
Due to cryogenic focussing in GC×GC/TOFMS analysis, the sensitive detection of more 
number of peaks could still be achieved compared to GC/TOFMS despite the increased 
split ratio. However, the increase in split ratio might have compromised the detection of 
some low abundant metabolites. Another issue that has not been thoroughly investigated 
so far is RT shift in GC×GC/TOFMS analysis. In our observation, RT shift in 
GC×GC/TOFMS analysis is minimal (less than 2 peak widths) up to 200 analyses. It is 
also worth noting that although GC×GC offered increased resolution of peaks, co-elution 
of some metabolites remains inevitable due to the complex nature of biological matrices.   
 
In summary, the advantages of GC×GC/TOFMS are (1) increased chromatographic 
resolution without compromising analytical run time (2) higher sensitivity through 
cryogenic focusing, (3) improved spectral match due to increased analytical purity of 
peaks and (4) larger coverage of metabolic space through detection of low abundant 
metabolites.  
 
5.4 Conclusions  
In this chapter, GC×GC/TOFMS was demonstrated as a powerful tool for analyzing in 
vitro cell media and complex urine samples. Application of GC×GC offered several 
pertinent advantages when compared to GC/MS analysis, improved identification of 




Results from our GC×GC/TOFMS metabolic footprinting study indicated that it was 
possible to discriminate in vitro metabolic profiles in relation to tumorigenic and 
nontumorigenic uroepithelial cell types. A number of metabolic pathways related to 
energy metabolism were found to be perturbed in cancer cells. The unique in vitro 
metabolic profiles generated by GC×GC-TOFMS revealed metabolic perturbations in BC 
that in turn facilitated our understanding of the biochemistry of BC.  
 
Application of GC×GC/TOFMS in urinary metabolic profiling of BC validated the 
results obtained from GC/TOFMS analysis and confirmed its applicability in 
distinguishing BC patients from non-BC controls. In addition, application of 
GC×GC/TOFMS aided increased predictive power of OPLS-DA model and identification 





CHAPTER 6 : Conclusions  
In this thesis, we investigated the application of metabonomic platform in diagnosing 
human BC using urine samples. Additionally, marker metabolites associated with the BC 
phenotype were also identified. 
  
Analyses using analytical platforms, NMR and GC/MS, suggested that urinary metabolic 
signatures of BC were distinct and different from controls. GC/MS method validation 
showed good precision and stability for diverse chemical classes of compounds. In 
addition, we evaluated alignment accuracies of various peak alignment algorithms 
(MetAlign, MZmine, StatisticalCompare, Calibration and TagFinder) in alignment of 
metabolite peaks and standard compounds. Among peak alignment algorithms evaluated, 
calibration feature showed superior performance. The key advantages of using calibration 
feature in peak alignment include (1) circumvention of external software packages and 
(2) greater flexibility to modify and optimize parameters compared to other peak 
alignment algorithms. For instance, different criteria such as spectral match threshold, 
quantitation mass and RT deviation window can be set individually for each metabolite. 
 
Compared to NMR, GC/MS showed several advantages in the metabolic profiling of 
urine samples. NMR spectral assignment yielded approximately one fourth of metabolites 
identified by GC/TOFMS (approximately, 40 and 150, respectively). The 4-fold 
difference in the number of metabolites identified by GC/TOFMS and NMR datasets can 
be attributed to both fundamental differences in the two technologies and their associated 
libraries. Outliers detected in NMR metabonomic analysis correlated to hematuria in 
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patients. Since, hematuria is a common symptom for BC; it may pose some interference 
in identifying BC patient from non-BC subjects with hematuria. Compared to NMR, GC-
based urinary metabolic profiling also showed greater advantage in marker metabolite 
identification and classification of bladder tumors. Particularly, GC coupled to TOFMS 
offered several additional advantages over GC coupled to quadrupole MS which included 
reduced analysis time and higher accuracies in peak deconvolution. Mainly, the 
metabolic space covered was larger when GC/TOFMS was used. However, it is 
important to note that similar to other analytical platforms, metabolic space covered by 
GC analytical platform is limited. In particular, due to requirement of derivatization, 
some chemical classes of metabolites may not be detected by GC/MS.  
 
Urinary metabolic profiles can be altered due to age, gender, diet, race and smoking 
habits. Among these factors, age was possibly not a confounding factor in our study 
since, both BC and non-BC groups had similar age characteristics. As there was no 
restriction on diet and smoking habit of the subjects in the current study, either of these 
factors could be confounding if one particular group uniformly shared the similar 
characteristic. Upon investigating the clinical metadata, there was not one characteristic 
that was present consistently in one group compared to other. Moreover, we 
demonstrated that it was possible to differentiate BC patients and non-BC subjects in the 
presence of background variation. If highly selected populations with as many matched 
pathophysiological parameters as possible were recruited in our study, it would possibly 
aid the profiling of biomarkers of BC by removing major sources of variations. However, 
to find clinical utility, a diagnostic assay should have high sensitivity, selectivity and 
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robustness to test an unknown population even in the presence of background variations. 
Therefore, strength of our current study design was that it did not over emphasize the 
diagnostic accuracy of the OPLS-DA model by studying a highly selective clinical 
population. 
 
Application of GC×GC/TOFMS increased the number of metabolites detected and 
improved both peak resolution and peak purity significantly. One major advantage of 
GC×GC/TOFMS is that complete chromatographic resolution of metabolic peaks is no 
longer mandatory. Urinary metabolic profiling using GC×GC/TOFMS combined with 
chemometric data analysis led to the discovery of a number of important marker 
metabolites related to BC. GC×GC/TOFMS metabonomic platform showed 100 % 
specificity and 71 % sensitivity. In contrast, 100% specificity and 46 % sensitivity was 
observed using cytology. In addition, classification of BC patients according to the stage 
and grade of the tumors was also possible using metabonomic analysis. These findings 
are of crucial importance in terms of diagnosing BC. To the best of our knowledge, this is 
the first study that demonstrated the feasibility of GC-based metabolic profiling for the 
diagnosis of human BC and classification of bladder tumors. Results from our 
GC×GC/TOFMS metabolic footprinting study indicated that it was possible to 
discriminate in vitro metabolic profiles in relation to tumorigenic and nontumorigenic 
uroepithelial cell types. The unique in vitro metabolic profiles generated by GC×GC-
TOFMS revealed metabolic perturbations in BC that in turn facilitated our understanding 
of the biochemistry of BC. In summary, an elucidation of the association between global 
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metabolic profiles and BC could open new avenues in the diagnosis and surveillance of 
the disease.  
6.1 Future directions 
Based on the current study, urinary metabonomics of BC patients has opened up a vast 
area for future investigations. The following areas are worth investigating based on 
observations made during current study. 
 
6.1.1 Validation of biomarkers of BC 
To verify and validate the findings of current study, further research should attempt to 
perform metabonomic analysis on a larger cohort of BC patients. The biomarker 
identified via metabonomics needs to be sensitive and specific for BC detection. Hence, it 
is necessary to validate the identified biomarkers. Urine samples obtained from patients 
suffering from other urological cancers such as prostate should also be included in the 
validation of BC biomarkers to evaluate their specificity. Urine sample from BC patients 
at different stages of cancer should be included to evaluate the sensitivity of the 
biomarkers in classification of bladder tumors.  
 
6.1.2 Markers related to stage and grade of bladder tumors 
In the clinical management of BC, characterization of bladder tumors is extremely 
important since treatment strategies vary with respective to the stage and grade of tumors. 
Particularly, clinical managements of superficial and noninvasive tumors are distinct. 
Transurethral tumor resection and intravesical BCG are generally recommended in 
superficial BC [24], while radical cystectomy is generally advocated in invasive tumors 
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[25]. In this thesis, the classification of BC patients according to stage and grade of 
tumors using metabonomics approach was demonstrated preliminarily. Metabolic 
profiling of different tumor types in a larger cohort study will provide insights into the 
molecular mechanisms of BC progression.  
 
6.1.3 Monitoring marker metabolites in followup patients 
In this study, we have demonstrated that urinary metabonomics can aid in the diagnosis 
of BC. BC is characterized by frequent recurrences that can progress to more invasive 
disease. The recurrence rates of BC are as high as 50-70%, therefore, life-long close 
surveillance is needed [17]. It is worth examining more closely whether urinary 
metabonomics would allow prediction of some aspect of cancer recurrence in the bladder 
and thereby, provide a proof-of-principle for its application in the clinical surveillance of 
human BC. Urine samples collected from BC patients prior and after tumour resection 
can be subjected to urinary metabonomic analysis to identify differences in metabolic 
profiles of BC recurrent and non-recurrent phenotypes. In addition, marker metabolites 






6.1.4 Investigation of metabolic differences related to age, race and smoking habit 
Endogenous metabolites in biofluids and tissues in humans can be altered due to number 
of pathophysiological conditions. Metabolic profiles can be altered due to age, sex, diet, 
race and smoking habits. Differences in metabolic profiles based on genders were 
observed in the thesis. Similarly, potential differences in metabolic profiles in relation to 
smoking habits need to be evaluated. Investigation of metabolic profiles related to 
smoking is particularly important with respect to BC since smoking is identified as its 
leading cause of BC. The results will facilitate the understanding the effects of tobacco 
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Table 1. List of keywords used to profile publications in PubMed and Web of Science (WOS) 








Transcriptomics transcriptomics OR “transcriptional profiling” 
Metabonomics metabolomics OR metabonomics OR "metabolic profiling" OR "metabolic fingerprinting" 
OR "metabolic footprinting" 
Preclinical and clinical 
metabonomics  
(((((((((metabolomics OR metabonomics OR "metabolic profiling" OR "metabolic 
fingerprinting" OR "metabolic footprinting") NOT (plant)) NOT (bacteria)) NOT (algae)) 
NOT (fungal)) NOT (yeast)) NOT (worm)) NOT (food) NOT (ecology) NOT (environment)) 
NOT metalloproteome) 
WOS Preclinical and clinical 
metabonomics  
Topic=((metabolomics OR metabonomics OR "Metabolic profiling" OR "Metabolic 
fingerprinting" OR "Metabolic footprinting") NOT plant NOT fungal NOT yeast NOT algae 
NOT metalloproteome) 
Refined by: [excluding] Subject Areas=( PLANT SCIENCES ) AND [excluding] Subject 
Areas=( MICROBIOLOGY ) AND [excluding] Subject Areas=( MARINE & 
FRESHWATER BIOLOGY ) AND [excluding] Subject Areas=( FISHERIES ) AND 
[excluding] Subject Areas=( FORESTRY ) AND [excluding] Subject Areas=( 
ENVIRONMENTAL SCIENCES ) AND [excluding] Subject Areas=( HORTICULTURE ) 
AND [excluding] Subject Areas=( SOIL SCIENCE ) AND [excluding] Subject Areas=( 
ECOLOGY ) AND [excluding] Subject Areas=( AGRICULTURE, MULTIDISCIPLINARY 
) AND [excluding] Subject Areas=( FOOD SCIENCE & TECHNOLOGY ) AND 
[excluding] Subject Areas=( AGRICULTURE, DAIRY & ANIMAL SCIENCE ) AND 
[excluding] Subject Areas=( VETERINARY SCIENCES ) AND [excluding] Subject 
Areas=( AGRICULTURAL ECONOMICS & POLICY ) AND [excluding] Subject Areas=( 
AGRICULTURAL ENGINEERING ) 
PubMed NMR  (((((((((metabolomics OR metabonomics OR "metabolic profiling" OR "metabolic 
fingerprinting" OR "metabolic footprinting") NOT (plant)) NOT (bacteria)) NOT (algae)) 
NOT (fungal)) NOT (yeast)) NOT (worm)) NOT (food) NOT (ecology) NOT (environment)) 
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NOT metalloproteome) AND ("nuclear magnetic resonance") 
WOS NMR  Publications obtained by using keywords for collating ‘Preclinical and clinical 
metabonomics’ studies were further refined by: "nuclear magnetic resonance"  
PubMed GC/MS  (((((((((metabolomics OR metabonomics OR "metabolic profiling" OR "metabolic 
fingerprinting" OR "metabolic footprinting") NOT (plant)) NOT (bacteria)) NOT (algae)) 
NOT (fungal)) NOT (yeast)) NOT (worm)) NOT (food) NOT (ecology) NOT (environment)) 
NOT metalloproteome) AND ("gas chromatography" AND "mass spectrometry") 
WOS GC/MS  Publications obtained by using keywords for collating ‘Preclinical and clinical 
metabonomics’ studies were further refined by: "gas chromatography" AND "mass 
spectrometry" 
PubMed LC/MS  (((((((((metabolomics or metabonomics or "metabolic profiling" or "metabolic 
fingerprinting" or "metabolic footprinting") NOT (plant)) NOT (bacteria)) NOT (algae)) 
NOT (fungal)) NOT (yeast)) NOT (worm)) NOT (food) NOT (ecology) NOT (environment)) 
NOT metalloproteome) AND ("liquid chromatography" AND "mass spectrometry") 
WOS LC/MS  Publications obtained by using keywords for collating ‘Preclinical and clinical 
metabonomics’ studies were further refined by: "liquid chromatography" AND "mass 
spectrometry" 
PubMed Other analytical platforms  (((((((((metabolomics or metabonomics or "metabolic profiling" or "metabolic 
fingerprinting" or "metabolic footprinting") NOT (plant)) NOT (bacteria)) NOT (algae)) 
NOT (fungal)) NOT (yeast)) NOT (worm)) NOT (food) NOT (ecology) NOT (environment)) 
NOT metalloproteome) AND (("capillary electrophoresis" AND "mass spectrometry") OR 
("direct infusion" AND "mass spectrometry") OR ("fourier transform infrared 
spectroscopy")) 
WOS Other analytical platforms  Publications obtained by using keywords for collating ‘Preclinical and clinical 
metabonomics’ studies were further refined by: ("capillary electrophoresis" AND "mass 
spectrometry") OR ("direct infusion" AND "mass spectrometry") OR ("fourier transform 
infrared spectroscopy") 
PubMed Blood  (((((((((metabolomics or metabonomics or "metabolic profiling" or "metabolic 
fingerprinting" or "metabolic footprinting") NOT (plant)) NOT (bacteria)) NOT (algae)) 
NOT (fungal)) NOT (yeast)) NOT (worm)) NOT (food) NOT (ecology) NOT (environment)) 
NOT metalloproteome) AND (blood OR serum OR plasma) 
WOS Blood  Publications obtained by using keywords for collating ‘Preclinical and clinical 
metabonomics’ studies were further refined by: (blood OR serum OR plasma) 
 204 
  
PubMed Urine  (((((((((metabolomics or metabonomics or "metabolic profiling" or "metabolic 
fingerprinting" or "metabolic footprinting") NOT (plant)) NOT (bacteria)) NOT (algae)) 
NOT (fungal)) NOT (yeast)) NOT (worm)) NOT (food) NOT (ecology) NOT (environment)) 
NOT metalloproteome) AND (urine) 
WOS Urine  Publications obtained by using keywords for collating ‘Preclinical and clinical 
metabonomics’ studies were further refined by: urine 
PubMed CSF  (((((((((metabolomics or metabonomics or "metabolic profiling" or "metabolic 
fingerprinting" or "metabolic footprinting") NOT (plant)) NOT (bacteria)) NOT (algae)) 
NOT (fungal)) NOT (yeast)) NOT (worm)) NOT (food) NOT (ecology) NOT (environment)) 
NOT metalloproteome) AND ("cerebrospinal fluid") 
WOS  Publications obtained by using keywords for collating ‘Preclinical and clinical 
metabonomics’ studies were further refined by: "cerebrospinal fluid" 
PubMed Saliva  (((((((((metabolomics or metabonomics or "metabolic profiling" or "metabolic 
fingerprinting" or "metabolic footprinting") NOT (plant)) NOT (bacteria)) NOT (algae)) 
NOT (fungal)) NOT (yeast)) NOT (worm)) NOT (food) NOT (ecology) NOT (environment)) 
NOT metalloproteome) AND (saliva) 
WOS Saliva  Publications obtained by using keywords for collating ‘Preclinical and clinical 
metabonomics’ studies were further refined by: saliva 
PubMed Amniotic fluid (((((((((metabolomics or metabonomics or "metabolic profiling" or "metabolic 
fingerprinting" or "metabolic footprinting") NOT (plant)) NOT (bacteria)) NOT (algae)) 
NOT (fungal)) NOT (yeast)) NOT (worm)) NOT (food) NOT (ecology) NOT (environment)) 
NOT metalloproteome) AND ("amniotic fluid") 
WOS Amniotic fluid  Publications obtained by using keywords for collating ‘Preclinical and clinical 
metabonomics’ studies were further refined by: "amniotic fluid" 
PubMed Tissue  (((((((((metabolomics or metabonomics or "metabolic profiling" or "metabolic 
fingerprinting" or "metabolic footprinting") NOT (plant)) NOT (bacteria)) NOT (algae)) 
NOT (fungal)) NOT (yeast)) NOT (worm)) NOT (food) NOT (ecology) NOT (environment)) 
NOT metalloproteome) AND (tissue OR biopsy) 
WOS Tissue  Publications obtained by using keywords for collating ‘Preclinical and clinical 
metabonomics’ studies were further refined by: (tissue OR biopsy) 
PubMed Clinical Publications obtained by using keywords for collating ‘Preclinical and clinical 
metabonomics’ studies were further refined by: Human checkbox; NOT "cells" 
WOS Clinical Publications obtained by using keywords for collating ‘Preclinical and clinical 
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metabonomics’ studies were further refined by: (human OR "homo sapiens" OR clinical OR 
patient OR man); then by: NOT "cells" 
PubMed Animal  Publications obtained by using keywords for collating ‘Preclinical and clinical 
metabonomics’ studies were further refined by: Animal checkbox 
WOS Animal  Publications obtained by using keywords for collating ‘Preclinical and clinical 
metabonomics’ studies were further refined by: (animal OR rat OR mice OR rabbit OR dog 
OR primate) 
PubMed In vitro  (((((((((metabolomics or metabonomics or "metabolic profiling" or "metabolic 
fingerprinting" or "metabolic footprinting") NOT (plant)) NOT (bacteria)) NOT (algae)) 
NOT (fungal)) NOT (yeast)) NOT (worm)) NOT (food) NOT (ecology) NOT (environment)) 
NOT metalloproteome) AND ("In vitro" OR "cell culture") 
WOS In vitro Topic=((metabolomics OR metabonomics OR "Metabolic profiling" OR "Metabolic 
fingerprinting" OR "Metabolic footprinting") NOT plant NOT fungal NOT yeast NOT algae 
NOT metalloproteome) AND ("In vitro" OR "cell culture") 

























 Further refine by year 
for each “omic” 
technology 
Refine to fit exclusion criteria:  
Articles published as conference proceedings, 
reprints, meeting abstracts, corrections and additions 
were excluded from the analysis using Boolean 
search operator ‘NOT’ 
 
Search databases based on 
keywords for different “omic” 
technologies 
Studies related to each ‘omic’ technology published from 
1985-2009 were collated using various keywords  for 
genomics, transcriptomics, proteomics and metabonomics 
specified in Table 1, Appendix I. 
Genomics Proteomics Transcriptomics  Metabonomics 
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Search databases based on keywords: Metabolomics OR 
metabonomics OR metabolic profiling OR metabolic fingerprinting 
OR metabolic footprinting 
Metabonomics studies published from 1995-2009 were collated 
using various keywords specified in Table 1, Appendix I. 
 
Refine to fit exclusion criteria:  
1. Studies involving non-mammals, plants, microorganisms, 
agriculture, environmental monitoring and food science 
2. Articles published as conference proceedings, reprints,  
meeting abstracts, corrections and additions  
 
Further refine by 
year 
Further refine by countries and regions: United 
States of America (USA) and Canada, Europe, 
Middle East, Asia Pacific, South America 
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Figure 3. Flowchart illustrating methodology employed to determine metabonomics trend with regards to analytical platform, 





















Further refined by year 
Further refine by analytical 
methods: NMR, GC/MS, 
LC/MS, Others 
Further refine by nature of study: 
clinical, animal or in vitro studies 
 
Further refine by sample: blood, 
urine, cerebrospinal fluid (CSF), 
saliva, tissue samples, amniotic 
fluid 
 
Search databases based on keywords: Metabolomics OR 
metabonomics OR metabolic profiling OR metabolic fingerprinting 
OR metabolic footprinting 
Refine to fit inclusion criteria using various keywords  related to 
analytical platforms specified in Table 1, Appendix I: Studies 
published from 1995-2009 
Refine to fit exclusion criteria:  
1. Studies involving non-mammals, plants, microorganisms, 
agriculture, environmental monitoring and food science 
2. Articles published as conference proceedings, reprints,  




Figure 4. Graphs showing the number of preclinical and clinical metabonomic-based publications each year, on (A) normal scale and 
on (B) log scale. Graphs showing number of metabonomic-based studies published by authors in each (C) geographical region, and 
























































































Table 2. Key metabonomic-based research institutions in each geographical region 
Region Research institutions No. of publicationsa 
USA & Canada University of California, Davis 60 
Purdue University 35 
Duke University 34 
Europe Imperial College London 163 
Cambridge University 58 
University of Manchester  47 
Asia Pacific  
 
The Chinese Academy of Sciences  81 
Shanghai Jiao Tong University 29 
Zhejiang University 15 
Keio University 15 





Table 3. Collated marker metabolites reported in different cancers 




Kidney Liver Lymphoma Oral Oesophageal Ovarian Prostate Stomach 
1 2- hydroxy-
butyric acid  00008    
1 (+) 
     1 (+)  
1 (+) 
   
2 Acetate 
 00042    
1 (-) 
   1 (+)  
1 (-) 
     
3 Betaine 
 00043      
2 (-) 





    
2 (+ in 
urine; - in 
tissue)   
1 (+) 
 
       
5 Aceto-
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6 Carnitine 
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compared 








   








2 (1+, 1-; 
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10 Cytidine 
 00089    
1 (+) 
   
1 (+) 
       
11 Dimethyl-
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1 (-) 
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46 Urea 
 00294    
1 (-) 
   
1 (-) 





    
2 (+ in 
tissue; - in 
serum)   
2 (+) 
 








       
1 (+) 
   
49 3-hydroxy-
butyric acid 00357    
1 (+) 




   
50 Beta-D-
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53 Cysteine 
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2 (+) 
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hate (GMP) 01397    
1 (+) 
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1 (+) 
   
1 (-) 





    
1 (+) 
 
   
1 (+) 
 
       
70 Benzoic 
acid 
 01870    
1 (-) 
       
1 (-) 
   
71 Phosphoric 




   
72 1-methyl-
inosine 
(m1I) 02721    
1 (+) 
 
   
2 (+) 
 





    
1 (+) 
 
   
2 (+) 
 












   
1 (+) 
 




cytidine 05923    
1 (+) 





    
2 (1+, 1-; 
both in 
tissue) b  
1 (-) 
 




    
4 (+) 




             
79 Choline 
containing 
















80 Lipids - 3 (+) 1 (+) 5 (+) 1 (-)  5 (+) 2 (-)      1 (+) 
81 N-
acetylglyco






       
82 Phosphoch






   
1 (+) 













      










































    
1 (-) 
 
        
(+) refers to elevated levels in cancer compared to normal subjects.(-) refers to decreased levels in cancer compared to 
normal subjects.a DLBCL: Diffuse large B-cell lymphoma; FL: Follicular lymphoma.b Metabolites which have conflicting 
change of direction observed in the same type of sample and same cancer. 
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Table 4. Pathways and respective metabolites perturbed in different cancers 
Pathway Cancers involved Metabolites involved 
Alanine Metabolism Colorectal; Kidney; Liver Alanine; Pyruvate 
Ammonia Recycling 
 
Brain; Breast; Colorectal; 
Kidney; Liver; Ovarian 
Glycine; Asparagine; Aspartate; 
Glutamine; Glutamate; Histidine; 
Pyruvate 
Arginine and Proline 
Metabolism 
Brain; Colorectal; Kidney; 
Ovarian 
Creatine; Fumarate; Arginine; 
Aspartate; Proline; Urea 




Colorectal Aspartate; Uracil 
Bile Acid Biosynthesis Brain; Breast; Cervical; 
Colorectal; Kidney; Liver 
Cholestrol; Glycine; Taurine 
Cysteine Metabolism Colorectal Cysteine; Pyruvate 
Galactose Metabolism Colorectal; Kidney; Liver Glucose; Glycerol; Myo-inositol 
Gluconeogenesis Colorectal; Kidney; Liver Beta-D-Glucose; Glucose; Lactate; 
Pyruvate 
Glucose-Alanine Cycle Colorectal; Kidney; Liver Glucose; Alanine; Pyruvate 
Glutamate Metabolism Colorectal; Kidney; Ovarian GABA; Glutathione; Glutamine; 
Succinate 
Glutathione Metabolism Brain; Colorectal; Ovarian Glutathione; Glycine; Cysteine 
Glycerolipid Metabolism Colorectal Glycerol; Hexadecanoic acid  
Glycine, Serine and 
Threonine Metabolism 
Brain; Cervical; Colorectal; 
Kidney; Liver; Ovarian 
Creatine; Glycine; Cysteine; 
Threonine; Pyruvate 
 
Glycolysis Colorectal; Kidney; Liver Beta-D-glucose; Glucose; Pyruvate 
Methionine Metabolism 
 
Brain; Breast; Cervical; 
Colorectal; Kidney; Liver; 
Ovarian 















Breast; Prostate Choline; Ethanoloamine 
Purine Metabolism Colorectal; Liver; Ovarian Adenosine; Hypoxanthine; Inosine; 
Glutamine 
Pyrimidine Metabolism Colorectal; Liver; Ovarian Cytidine; Glutamine; Uracil; 
Uridine 
Pyruvate Metabolism Colorectal; Kidney; Liver; 
Ovarian 
Acetate; Lactate; Malate; Pyruvate 
Taurine and Hypotaurine 
Metabolism 
Colorectal Cysteine; Taurine 
TCA Cycle Colorectal; Kidney; Liver; 
Ovarian 
Citrate; Fumarate; Malate; 
Pyruvate; Succinate 
Transcription/Translation Brain; Breast; Colorectal; 
Head & Neck; Kidney; 
Liver; Ovarian 
Alanine, Arginine, Asparagine; 
Aspartate; Cysteine; Glutamine; 
Glutamate; Histidine; Isoleucine; 
Leucine; Lysine; Phenylalanine; 
Proline; Threonine; Tyrptophan; 
Tyrosine; Valine 
Tyrosine Metabolism Colorectal; Liver Acetoacetate; Fumarate; Tyrosine 
Urea Cycle Brain; Breast; Colorectal; 
Kidney; Liver; Ovarian 
Fumarate; Alanine; Arginine; 
Aspartate; Glutamine; Glutamate; 
Pyruvate; Urea 
Valine, Leucine and 
Isoleucine Degradation 







Figure 1. Parameter settings for MetAlign 
 
 









Table 1. Precision and stability of amino acids in human urine (analyzed as TMS derivatives) 
 
  Variation (%RSD) 








(n=5) (n=4) (n=5) (n=5) 
      
Amino acids      
 L-Alanine 5.90 3.04 0.72 0.96 
 Glycine 4.32 4.86 1.11 4.41 
 Glycyl-L-leucine 11.83 12.07 8.84 8.85 
 Hydroxyproline 14.11 12.49 1.73 2.54 
 L-Glutamine 3.55 12.98 10.64 5.87 
 L-Isoleucine# 10.12 4.59 8.19 52.04 
 L-Serine 4.42 2.29 0.35 1.80 
 L-Threonine 4.33 2.66 0.62 0.75 
 L-Valine 5.58 4.03 2.84 1.44 
 Norvaline 6.94 6.96 0.52 1.06 
 Phenylalanine# 4.37 4.48 3.24 16.30 
 Tyrosin 10.44 5.15 7.73 5.96 
      
#Freeze thaw stability of compounds of which %RSD >15. 
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Table 2. Precision and stability of organic acids in human urine (analyzed as TMS derivatives) 
 
  Variation (%RSD) 













Organic acids      
 2,2-Dimethylbutanoic acid 9.87 2.83 0.78 2.01 
 2,5-Furandicarboxylic acid 13.84 8.47 6.28 0.28 
 2-Ethylhydracrylic acid 7.59 10.86 6.06 10.41 
 2-Hydroxy-3-methylbutyric acid 9.70 4.78 0.00 3.49 
 2-Methylglutaric acid 4.48 1.02 6.92 1.29 
 3-(3-hydroxyphenyl)-3-hydroxypropanoic acid 14.43 4.26 2.02 4.56 
 4-Deoxythreonic acid 3.76 1.15 0.93 1.09 
 4-Hydroxycyclohexylcarboxylic acid 8.43 9.81 2.31 10.09 
 5-Hydroxyhexanoic acid* 10.07 15.54 12.85 12.16 
 Acetic acid 7.45 2.11 3.67 4.12 
 Acetopyruvic acid 3.99 5.98 5.83 2.23 
 Aconitic acid 4.86 7.27 4.54 1.91 
 Acrylic acid 8.93 10.25 2.54 7.78 
 Adipic acid 8.05 5.97 10.10 1.24 
 Arabinonic acid 13.34 14.49 12.59 4.22 
 Atrolactic acid 6.24 13.62 7.97 53.06 
 Butanoic acid 10.22 11.08 7.09 7.75 
 Butyric acid 7.32 11.95 6.85 13.53 
 Citraconic acid 9.70 3.50 0.00 3.49 
 Citric acid 6.14 4.18 0.52 0.25 
 D-Gluconic acid 7.52 4.45 1.06 0.72 
 Erythronic acid 4.52 0.78 0.41 0.88 
 Fumaric acid 8.48 2.43 3.31 1.09 
 Hydroxyglutaric acid 12.78 9.17 6.52 5.77 
 Indoleacetic acid 9.04 5.53 0.42 2.49 
 Isobutyric acid 10.33 1.50 2.54 3.70 
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 Isocitric acid 8.59 4.86 1.40 1.25 
 Malic acid 3.02 4.87 1.26 1.90 
 Malonic acid  11.57 4.65 2.05 13.17 
 Methylsuccinic acid* 4.32 15.19 4.08 6.57 
 Mevalonic acid 7.04 3.26 0.06 4.62 
 Monoethyl malonic acid 11.57 4.65 2.05 13.17 
 Oxalic acid 6.67 10.91 11.90 13.71 
 Pimelic acid 13.62 12.27 0.29 13.08 
 Propionic acid 2.87 3.92 0.29 1.42 
 Pyruvic acid 14.89 7.42 2.92 6.67 
 Ribonic acid 14.32 8.44 13.45 3.59 
 Sebacic acid 8.27 11.40 7.30 6.23 
 Succinic acid 5.48 6.59 5.93 4.67 
 Shikimic acid 3.88 2.86 1.63 5.03 
 Tartaric acid 6.69 3.08 1.08 0.03 
 Valeric acid 12.56 11.94 4.51 11.05 
      
* Interday variation of compounds of which %RSD >15. 
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 Table 3. Precision and stability of sugars and sugar alcohols in human urine (analyzed as TMS derivatives) 
 
  Variation (%RSD) 













      
Sugars and 
sugar alcohols      
 alpha-D-Galactopyranose 5.66 1.54 0.13 3.20 
 alpha-D-Glucopyranose 8.83 6.46 9.57 3.54 
 alpha-DL-Arabinopyranose 8.07 10.21 10.89 12.97 
 alpha-D-Xylopyranose 7.59 2.94 1.39 3.13 
 alpha-L-Galactofuranoside* 3.88 15.76 0.81 6.54 
 alpha-L-Galactopyranose 11.60 10.65 3.26 0.65 
 Arabinofuranose 6.55 9.21 6.75 6.03 
 L-Arabinose 14.65 4.24 1.44 4.26 
 beta-D-Galactofuranose 13.75 9.56 8.04 9.74 
 beta-DL-Lyxopyranose 6.88 2.16 5.43 2.84 
 D-Fructose 14.81 10.76 0.47 4.90 
 D-Galactose 6.79 3.19 2.14 1.12 
 D-Glucose 2.90 2.06 1.82 2.88 
 D-Glucuronic acid 9.40 14.98 10.60 3.26 
 D-Mannose 5.86 2.04 1.88 2.99 
 Galactaric acid 3.15 3.10 1.16 1.33 
 Galactitol 7.68 3.11 3.88 0.84 
 Glucitol 5.75 5.13 0.51 1.84 
 Iso-Erythritol 3.64 2.10 0.01 2.21 
 L-Fucose 8.99 4.10 0.15 1.24 
 Lyxopyranoside 12.75 25.31 8.12 0.19 
 Myoinositol 9.01 11.90 4.39 0.54 
 Ribitol 4.77 1.34 0.49 1.60 
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 Scyllo-inositol 4.08 3.03 1.18 4.66 
 Talose 10.92 10.24 10.09 5.52 
 Xylopyranoside 13.47 9.50 0.41 3.62 
 1,5-Gluconolactone 7.17 11.59 5.07 10.21 
 Erythrose 7.58 3.22 2.17 2.93 
 Gulose 7.55 1.26 1.08 2.09 
 Maltose 8.75 5.20 9.41 2.87 
 Melibiose 8.56 1.93 4.17 1.22 
 Xylulose  12.04 5.29 0.96 1.96 
* Interday variation of compounds of which %RSD >15. 
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Table 4. Precision and stability of fatty acids, aromatics and glycerols in human urine (analyzed as TMS derivatives) 
 
  Variation (%RSD) 













      
Fatty acids      
 2-Pentenoic acid## 3.22 4.00 34.42 1.38 
 4-Pentenoic acid 8.45 3.40 1.00 2.87 
 Stearic acid 10.97 6.19 0.04 9.63 
      
Aromatics      
 Hydroxyphenyllactic acid 6.54 2.84 4.10 4.69 
 Tyramine 8.08 12.44 2.79 12.01 
 Benzeneacetic acid 13.20 2.27 1.72 4.97 
 Phenylacetic acid 7.39 2.45 3.48 6.29 
Glycerols      
 2-Methylpropantriol 14.16 1.60 3.09 0.10 
 Glycerol 10.58 3.04 0.79 1.50 
      




Table 5. Precision and stability of endogenous compounds in human urine (analyzed as TMS derivatives) 
 
  Variation (%RSD) 













      
Other chemical classes     
 1,2,3-Butanetriol 10.12 4.54 8.19 0.23 
 1,2-Propanediol 14.33 15.04 1.62 12.87 
 1,4-Dioxane*,### 7.30 66.36 2.02 8.14 
 1H-Pyrido[3,4-b]indol-1-one 4.66 5.02 1.41 2.03 
 1-Pentene 5.14 6.32 5.21 2.19 
 Vaniethylene glycol  9.96 7.24 8.13 11.11 
 2,3,4-tri-O-acetyl-D-xylono-1,5-lactone*,# 14.59 15.89 9.21 19.88 
 2-Methyl-1,4-butanediol 10.32 7.27 8.40 9.48 
 2-Thiazolidinone 7.02 7.73 1.86 1.08 
 3-Hydroxyhippuric acid 3.93 5.72 1.84 1.79 
 3-Methyl-2-butanone 13.53 13.78 0.59 1.45 
 3-Methylvalerate  7.64 1.81 2.62 4.51 
 4-Methyl-2-pentenal 11.18 13.89 0.85 10.54 
 5-Hydroxy-N-Valeric acid 7.47 5.36 1.49 7.15 
 Acetone 10.21 1.83 2.60 1.70 
 Boric acid  6.34 10.80 0.20 4.30 
 Bromo succinate 2.89 1.10 0.57 1.15 
 Butane 13.86 7.78 1.98 8.37 
 Cadaverine 3.81 4.03 2.64 4.69 
 Cinnamoylaminoethanoate 8.52 3.06 0.72 1.22 
 Creatinine 10.36 13.84 1.48 6.35 
 D-Erythro-pentopyranose 5.73 4.56 1.27 0.20 
 D-Glucitol a 8.51 15.83 0.05 4.88 
 D-Glucofuranuronic acid* 6.67 15.56 7.74 5.72 
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 Ethanamine 12.83 13.78 14.00 1.37 
 Ethanediamide 4.54 1.17 1.93 0.53 
 Galacturonic acid 8.01 10.59 3.66 6.59 
 Glucuronic lactone 5.48 5.15 0.12 2.12 
 Hippuric acid 2.58 1.29 0.20 1.00 
 L-Altrose 5.86 3.30 1.88 2.99 
 Levulinic acid  4.70 2.98 6.60 0.51 
 Mannoonic acid 6.16 0.57 0.06 3.22 
 N,N-Dimethylguanidine 13.70 1.52 4.16 2.49 
 N-Acetylputrescine 6.46 10.15 1.38 4.00 
 Phosphoric acid 6.27 6.96 1.34 8.77 
 Piperidine-2-carboxylic acid 7.45 10.31 1.81 4.94 
 Pyrrolidin-2-carbonsaeureamide 10.22 4.42 7.09 8.11 
 Tetradecanamide 6.77 7.00 3.77 7.68 
 Tryptophan 7.87 7.27 1.36 3.09 
 Uracil 7.47 4.80 6.54 13.47 
 Uridine 11.09 15.60 4.14 9.36 
 UN-1 9.87 4.76 4.71 6.31 
 UN-2 12.85 5.35 7.87 1.07 
 UN-3 ## 6.76 7.45 21.94 6.33 
 UN-4 12.14 10.01 14.96 1.17 
 UN-5 15.58 18.23 0.15 0.10 
 UN-6 13.93 12.58 8.19 9.02 
 Urea* 11.68 23.28 3.61 1.31 
 Xylitol 5.33 2.27 0.16 3.48 
* Interday variation,## auto sampler stability and #freeze thaw stability of compounds of which %RSD >15. 
UN: Unknown compound (Similarity index of the compound <70% with NIST, Wiley libraries). 






Figure 1. PCA scores plot showing clustering of quality control (QC) samples (red solid 
diamond).  
 
Figure 2. PLS-DA scores plots obtained from the urine analysis of bladder cancer (BC) 





































Figure 3. OPLS-DA scores plots obtained from the urine analysis of male bladder cancer 
(BC) and male non-BC subjects (H) subjects. (A) Identifiers colored according to BC or 





Table 1. Clinicopathogical characteristics of bladder cancer (BC) patients and non-BC 
subjects utilized for external validation of the OPLS-DA model. 
Characteristics BC Patients Non-BC controls 
No. of subjects 7 10 
Age (mean/SD) 63.6 ± 16.4 58.4 ± 12.1 
Gender   
Male 
 
7 (100 %) 7 (70.0 %) 
Female 0 (0 %) 3 (30.0 %) 
Cancer stage and grade a   
PUNLMP 0 (0 %)  
Ta-LG 4 (57.1 %)  
Ta-HG 1 (14.3 %)  
T1-LG 0 (0 %)  
T1-HG 2 (28.6 %)  
CIS/T1-HG 0 (0 %) 
 
 
Others 0 (0 %)  
Citizenship   
Chinese 4 (57.1 %) 9 (90.0 %) 
Indian 1 (14.3 %) 1 (10.0 %) 
Othersb 2 (28.6 %) 0 (0 %) 
Smoking habit   
Non smokers 
 
2 (28.6%) 4 (40.0%) 
Ex-smokers 2 (28.6%) 1 (10.0 %) 
Smokers 2 (28.6 %) 1 (10.0 %) 
Information not available 1 (14.3 %) 4 (40.0 %) 
aTumors were classified according World Health Organization (WHO)/International 
Society of Urological Pathology (ISUP) classification criteria. Low grade and high grade 
are represented as LG and HG respectively.  bOther races include Caucasian and 
Malaysian. 
